Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 16, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Title of 12(b) Security | Common stock, $0.01 par value per share | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 90-1002689 | ||
Entity Address, Address Line One | 1151 Maplewood Drive, | ||
Document Annual Report | true | ||
Entity Address, City or Town | Itasca | ||
Entity Address, State or Province | IL | ||
Entity Address, Postal Zip Code | 60143 | ||
Trading Symbol | KN | ||
Security Exchange Name | NYSE | ||
Document Transition Report | false | ||
City Area Code | 630 | ||
Document Period End Date | Dec. 31, 2023 | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Current Fiscal Year End Date | --12-31 | ||
Local Phone Number | 250-5100 | ||
Entity File Number | 001-36102 | ||
Entity Registrant Name | Knowles Corporation | ||
Entity Central Index Key | 0001587523 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | false | ||
Entity Public Float | $ 1,610,000,000 | ||
Entity Common Stock, Shares Outstanding | 89,629,865 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Document Type | 10-K | ||
Amendment Flag | false |
Cover
Cover | 12 Months Ended |
Dec. 31, 2023 | |
Cover [Abstract] | |
Entity Interactive Data Current | Yes |
Document Financial Statement Error Correction [Flag] | false |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Auditor [Line Items] | |
Auditor Name | PricewaterhouseCoopers LLP |
Auditor Location | Chicago, Illinois |
Auditor Firm ID | 238 |
CONSOLIDATED STATEMENTS OF EARN
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Income Statement [Abstract] | ||||
Revenues | $ 707.6 | $ 764.7 | $ 868.1 | |
Cost of goods sold | 435.5 | 455.7 | 508.6 | |
Restructuring charges - cost of goods sold | (1.3) | 32.2 | 0 | |
Gross Profit, Total | 283.4 | 276.3 | 359.5 | |
Research and development expenses | 78.5 | 81.7 | 92.8 | |
Selling and administrative expenses | 150.3 | 128.9 | 146.4 | |
Total impairment charges | 0 | 470.9 | 4 | |
Restructuring charges | 3.5 | 9.6 | 0.5 | |
Operating expenses | 232.3 | 691.1 | 243.7 | |
Operating earnings (loss) | 51.1 | (414.8) | 115.8 | |
Interest expense, net | 5.4 | 3.9 | 14.2 | |
Other expense (income), net | 0.7 | (0.5) | (3) | |
(Benefit from) provision for income taxes | (27.4) | 11.9 | (45.6) | |
Earnings (loss) from continuing operations | 72.4 | (430.1) | 150.2 | |
Earnings (loss) from discontinued operations, net | 0 | 0 | 0.2 | |
Net earnings (loss) | $ 72.4 | $ (430.1) | $ 150.4 | |
Earnings per share: | ||||
Income (Loss) from Continuing Operations, Per Basic Share | $ 0.80 | $ (4.69) | $ 1.63 | |
Income (Loss) from Continuing Operations, Per Diluted Share | 0.79 | (4.69) | 1.59 | |
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share | 0 | 0 | 0 | |
Earnings Per Share, Basic | 0.80 | (4.69) | 1.63 | |
Earnings Per Share, Diluted | $ 0.79 | $ (4.69) | $ 1.59 | |
Weighted-average common shares outstanding: | ||||
Basic (in shares) | [1] | 90,900,000 | 91,700,000 | 92,300,000 |
Diluted (in shares) | [1] | 91,600,000 | 91,700,000 | 94,700,000 |
(Loss) earnings before income taxes | [2] | $ 45 | $ (418.2) | $ 104.6 |
Gain (Loss) on Disposition of Property Plant Equipment | $ (10) | $ 0.5 | $ 0 | |
[1] Years Ended December 31, 2023 2022 2021 Revenues $ 707.6 $ 764.7 $ 868.1 Cost of goods sold 435.5 455.7 508.6 (Gain) loss on sale of fixed assets (10.0) 0.5 — Restructuring charges - cost of goods sold (1.3) 32.2 — Gross profit 283.4 276.3 359.5 Research and development expenses 78.5 81.7 92.8 Selling and administrative expenses 150.3 128.9 146.4 Impairment charges — 470.9 4.0 Restructuring charges 3.5 9.6 0.5 Operating expenses 232.3 691.1 243.7 Operating earnings (loss) 51.1 (414.8) 115.8 Interest expense, net 5.4 3.9 14.2 Other expense (income), net 0.7 (0.5) (3.0) Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations 72.4 (430.1) 150.2 Earnings from discontinued operations, net — — 0.2 Net earnings (loss) $ 72.4 $ (430.1) $ 150.4 Earnings (loss) per share from continuing operations: Basic $ 0.80 $ (4.69) $ 1.63 Diluted $ 0.79 $ (4.69) $ 1.59 Earnings per share from discontinued operations: Basic $ — $ — $ — Diluted $ — $ — $ — Net earnings (loss) per share: Basic $ 0.80 $ (4.69) $ 1.63 Diluted $ 0.79 $ (4.69) $ 1.59 Weighted-average common shares outstanding: Basic 90.9 91.7 92.3 Diluted 91.6 91.7 94.7 Years Ended December 31, (in millions) 2023 2022 2021 Revenues: Precision Devices $ 221.4 $ 242.9 $ 201.1 MedTech & Specialty Audio 230.0 229.9 231.3 Consumer MEMS Microphones 256.2 291.9 435.7 Total revenues $ 707.6 $ 764.7 $ 868.1 Earnings (loss) from continuing operations before interest and income taxes: Precision Devices $ 25.0 $ 56.1 $ 43.7 MedTech & Specialty Audio 85.2 84.6 77.0 Consumer MEMS Microphones 13.6 (504.5) 60.0 Total segments 123.8 (363.8) 180.7 Corporate expense / other 73.4 50.5 61.9 Interest expense, net 5.4 3.9 14.2 Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Depreciation and amortization: Precision Devices $ 15.8 $ 13.8 $ 13.3 MedTech & Specialty Audio 8.2 8.1 6.3 Consumer MEMS Microphones 20.3 29.5 39.9 Corporate 2.2 2.5 3.0 Total $ 46.5 $ 53.9 $ 62.5 Capital expenditures: Precision Devices $ 7.6 $ 7.4 $ 5.6 MedTech & Specialty Audio 4.6 7.3 11.6 Consumer MEMS Microphones 4.7 17.2 29.2 Corporate — 0.2 2.2 Total $ 16.9 $ 32.1 $ 48.6 Research and development: Precision Devices $ 13.8 $ 12.3 $ 10.5 MedTech & Specialty Audio 18.2 16.9 16.1 Consumer MEMS Microphones 46.1 52.4 65.7 Corporate 0.4 0.1 0.5 Total $ 78.5 $ 81.7 $ 92.8 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | |||
Net earnings (loss) | $ 72.4 | $ (430.1) | $ 150.4 |
Other comprehensive (loss) earnings, net of tax | |||
Foreign currency translation | (6.1) | (23.2) | (3.6) |
Employee benefit plans: | |||
Actuarial (losses) gains and prior service costs arising during period | (0.4) | 0.3 | 4.3 |
Amortization or settlement of actuarial losses and prior service costs | 0.5 | 0.5 | 0.7 |
Net change in employee benefit plans | 0.1 | 0.8 | 5 |
Changes in fair value of cash flow hedges: | |||
Unrealized net gains (losses) arising during period | (3.9) | (2.8) | 0.3 |
Net losses (gains) reclassified into earnings | 2.2 | 3.5 | (1.6) |
Total cash flow hedges | (1.7) | 0.7 | (1.3) |
Other comprehensive (loss) earnings, net of tax | (7.7) | (21.7) | 0.1 |
Comprehensive earnings (loss) | $ 64.7 | $ (451.8) | $ 150.5 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 87.3 | $ 48.2 |
Accounts Receivable, after Allowance for Credit Loss, Current | 135.3 | 134.7 |
Inventories, net | 196.4 | 169.5 |
Prepaid and other current assets | 9.8 | 10 |
Total current assets | 428.8 | 362.4 |
Property, plant, and equipment, net | 175.4 | 161.8 |
Goodwill | 540.7 | 471 |
Intangible assets, net | 189.4 | 85.1 |
Operating Lease, Right-of-Use Asset | 13.1 | 12.6 |
Other assets and deferred charges | 115.4 | 91 |
Total assets | 1,462.8 | 1,183.9 |
Current liabilities: | ||
Long-term Debt, Current Maturities | 47.1 | 0 |
Accounts payable | 51.3 | 41.4 |
Accrued compensation and employee benefits | 33 | 26.9 |
Operating Lease, Liability, Current | 5.1 | 8.4 |
Other accrued expenses | 25 | 19.9 |
Federal and other taxes on income | 3.1 | 2.5 |
Total current liabilities | 164.6 | 99.1 |
Long-term debt | 224.1 | 45 |
Deferred Income Tax Liabilities, Net | 0.7 | 0.9 |
Operating Lease, Liability, Noncurrent | 8.2 | 7.2 |
Long-term operating lease liabilities | 31.1 | 38.8 |
Commitments and contingencies (Note 15) | ||
Stockholders' equity: | ||
Preferred Stock, Value, Issued | 0 | 0 |
Common Stock, Value, Issued | 1 | 1 |
Treasury Stock, Common, Value | (151.2) | (103.3) |
Additional paid-in capital | 1,689.9 | 1,665.5 |
Accumulated deficit | (375.8) | (448.2) |
Accumulated other comprehensive loss | (129.8) | (122.1) |
Total stockholders' equity | 1,034.1 | 992.9 |
Total equity | 1,034.1 | 992.9 |
Total liabilities and stockholders' equity | $ 1,462.8 | $ 1,183.9 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | |
Common stock, shares authorized (in shares) | 400,000,000 | |
Common stock, shares issued (in shares) | 97,297,703 | 96,431,604 |
Common Stock, Shares, Outstanding | 89,092,871 | 91,078,376 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | |||
Allowance for doubtful accounts receivable | $ 0.2 | $ 1.1 | $ 0.2 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 | |
Preferred stock, shares issued (in shares) | 0 | 0 | |
Common stock, par value (in dollars per share) | $ 0.01 | ||
Common stock, shares authorized (in shares) | 400,000,000 | ||
Common stock, shares issued (in shares) | 97,297,703 | 96,431,604 | |
Common Stock, Shares, Outstanding | 89,092,871 | 91,078,376 | |
Treasury Stock, Common, Shares | 8,204,832 | 5,353,228 |
CONSOLIDATED STATEMENT OF STOCK
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions | Total | Amount | Treasury Stock, Common | Treasury Stock, Common Convertible Notes Due Twenty Twenty One [Member] Convertible Debt | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] Convertible Notes Due Twenty Twenty One [Member] Convertible Debt | Retained Earnings [Member] | AOCI Attributable to Parent [Member] |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Treasury Stock, Common, Shares | (1,078,363) | |||||||
Common stock, shares issued (in shares) | 92,689,912 | |||||||
Balance at Dec. 31, 2020 | $ 1,303.5 | $ 0.9 | $ (16.2) | $ 1,587.8 | $ (168.5) | $ (100.5) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Stock Repurchased During Period, Shares | (2,139,413) | |||||||
Stock Repurchased During Period, Value | 44.5 | $ 44.5 | ||||||
Net earnings (loss) | 150.4 | 150.4 | ||||||
Other Comprehensive Income (Loss), Net of Tax | 0.1 | 0.1 | ||||||
Exercise of convertible note hedges | 32.1 | 32.1 | ||||||
Stock Issued During Period, Shares, New Issues | 1,540,314 | |||||||
Exercise of stock options | 25.6 | $ 0.1 | 25.5 | |||||
Stock Issued During Period, Value, Conversion of Convertible Securities | 0 | $ 5.9 | ||||||
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | (5.9) | |||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 363,579 | |||||||
Shares received from convertible note hedges | (363,601) | |||||||
Exercise of convertible note hedges | 0 | $ 7.6 | $ 7.6 | |||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings | 882,552 | |||||||
Balance at Dec. 31, 2021 | 1,459.5 | $ 1 | $ (62.4) | 1,639.4 | (18.1) | (100.4) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | (7.7) | (7.7) | ||||||
Treasury Stock, Common, Shares | (3,217,798) | |||||||
Common stock, shares issued (in shares) | 95,112,778 | |||||||
Stock Repurchased During Period, Shares | (2,339,045) | |||||||
Stock Repurchased During Period, Value | 44 | $ 44 | ||||||
Net earnings (loss) | (430.1) | (430.1) | ||||||
Other Comprehensive Income (Loss), Net of Tax | (21.7) | (21.7) | ||||||
Exercise of convertible note hedges | 28.6 | 28.6 | ||||||
Stock Issued During Period, Shares, New Issues | 643,911 | |||||||
Exercise of stock options | 7.5 | $ 0 | 7.5 | |||||
Shares Issued During Period, Value, Exercise of Warrants | 0 | $ 3.1 | ||||||
Shares Issued During Period, Shares, Exercise of Warrants | 203,615 | |||||||
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature | 3.1 | |||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings | 674,915 | |||||||
Balance at Dec. 31, 2022 | 992.9 | $ 1 | $ (103.3) | 1,665.5 | (448.2) | (122.1) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ (6.9) | (6.9) | ||||||
Treasury Stock, Common, Shares | 5,353,228 | (5,353,228) | ||||||
Common stock, shares issued (in shares) | 96,431,604 | 96,431,604 | ||||||
Stock Repurchased During Period, Shares | (2,851,604) | |||||||
Stock Repurchased During Period, Value | $ 47.5 | $ 47.5 | ||||||
Net earnings (loss) | 72.4 | 72.4 | ||||||
Other Comprehensive Income (Loss), Net of Tax | (7.7) | (7.7) | ||||||
Excise Tax on Repurchased Shares | 0.4 | 0.4 | ||||||
Exercise of convertible note hedges | 29 | 29 | ||||||
Stock Issued During Period, Shares, New Issues | 195,170 | |||||||
Exercise of stock options | 1.6 | $ 0 | 1.6 | |||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings | 670,929 | |||||||
Balance at Dec. 31, 2023 | 1,034.1 | $ 1 | $ (151.2) | 1,689.9 | $ (375.8) | $ (129.8) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings | $ (6.2) | $ (6.2) | ||||||
Treasury Stock, Common, Shares | 8,204,832 | (8,204,832) | ||||||
Common stock, shares issued (in shares) | 97,297,703 | 97,297,703 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Activities | |||
Net earnings (loss) | $ 72.4 | $ (430.1) | $ 150.4 |
Adjustments to reconcile net earnings (loss) to cash from operating activities: | |||
Depreciation and amortization | 46.5 | 53.9 | 62.5 |
Stock-based compensation | 29 | 28.6 | 32.1 |
Total impairment charges | 0 | 470.9 | 4 |
Restructuring Costs | (1.8) | 13.5 | 0 |
Non-cash interest expense and amortization of debt issuance costs | 2 | 0.7 | 8 |
Deferred income taxes | (40.3) | 1.6 | (61.2) |
Gain (Loss) on Disposition of Property Plant Equipment | (10) | 0.5 | 0 |
Other, net | (0.9) | (5.9) | 0 |
Changes in assets and liabilities (excluding effects of foreign exchange): | |||
Receivables, net | 12.7 | 11.1 | (12.3) |
Inventories, net | 11.5 | (22.8) | (20.7) |
Prepaid and other current assets | (0.4) | 2 | (2.9) |
Accounts payable | 6.2 | (41.2) | 17.2 |
Accrued compensation and employee benefits | 4 | (15) | 11.9 |
Other accrued expenses | (2) | (0.3) | 1.8 |
Accrued taxes | (0.4) | 1.3 | (1.1) |
Other non-current assets and non-current liabilities | (5.8) | 17.5 | (7.6) |
Net cash provided by operating activities | 122.7 | 86.3 | 182.1 |
Investing Activities | |||
Acquisitions of business (net of cash acquired) | (136.9) | (0.7) | (78.5) |
Payments to Acquire Assets, Investing Activities | (0.3) | 0 | 0 |
Additions to property, plant, and equipment | (16.9) | (32.1) | (48.6) |
Proceeds from the sale of property, plant, and equipment | 12.5 | 0.1 | 0.6 |
Payments for (Proceeds from) Investments | (0.4) | (0.4) | (3.5) |
Proceeds from Sale of Short-term Investments | 0.4 | 0.4 | 0.4 |
Net cash used in investing activities | (141.6) | (32.7) | (129.6) |
Financing Activities | |||
Borrowings under revolving credit facility | 150 | 23 | 70 |
Payments under revolving credit facility | (35) | (48) | 0 |
Debt instrument, face amount | 0 | 0 | 172.5 |
Payments for Repurchase of Common Stock | (47.5) | (44) | (44.5) |
Tax on stock option exercises and restricted and performance stock unit vesting | (6.2) | (6.9) | (7.7) |
Proceeds from exercise of stock-based awards | 1.6 | 7.5 | 25.6 |
Payments of debt issuance costs | (2.2) | 0 | 0 |
Payments of finance lease obligations | (2.5) | (4.8) | (2.3) |
Net cash provided by (used in) financing activities | 58.2 | (73.2) | (131.4) |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | (0.2) | (1.1) | 0 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total | 39.1 | (20.7) | (78.9) |
Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations | 87.3 | 48.2 | 68.9 |
Supplemental information - cash paid during the year for: | |||
Income taxes | 10.6 | 6.2 | 16.1 |
Interest | $ 5.4 | $ 3.6 | $ 7.4 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Summary of Significant Accounting Policies | 1. Summary of Significant Accounting Policies Background - Knowles Corporation (NYSE:KN) is a market leader and global provider high performance capacitors and radio frequency ("RF") products, balanced armature speakers, advanced micro-acoustic microphones, and audio solutions, serving the medtech, defense, electric vehicle, industrial, communications, and consumer electronics markets. The Company uses its leading position in SiSonic TM micro-electro-mechanical systems ("MEMS") microphones and strong capabilities in audio processing technologies to optimize audio systems and improve the user experience across consumer applications. Knowles is also a leader in hearing health acoustics, high performance capacitors, and RF solutions for a diverse set of markets. The Company's focus on the customer, combined with its unique technology, proprietary manufacturing techniques, and global operational expertise, enable the Company to deliver innovative solutions across multiple applications. References to "Knowles," "the Company," "we," "our," and "us" refer to Knowles Corporation and its consolidated subsidiaries. On November 1, 2023, we completed the acquisition of Cornell Dubilier ("CD"), a manufacturer of film, electrolytic, and mica capacitors used in medtech, military, and industrial electrification applications. On May 3, 2021, the Company acquired all of the outstanding shares of common stock of Integrated Microwave Corporation ("IMC"), a manufacturer of RF filters. Both acquisitions were integrated into the Precision Devices segment. See Note 3. Acquisitions for additional information related to these transactions. On February 24, 2020, the Company announced that its Board of Directors had authorized a share repurchase program of up to $100 million of the Company's common stock. On April 28, 2022, we announced that our Board of Directors had increased the authorization by up to $150 million in additional aggregate value. The timing and amount of any shares repurchased will be determined by the Company based on its evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. The Company is not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. The actual timing, number, and share price of shares repurchased will depend on a number of factors, including the market price of the Company’s common stock, general market and economic conditions, and applicable legal requirements. Any shares repurchased will be held as treasury stock. During the years ended December 31, 2023, 2022, and 2021, we repurchased 2,851,604, 2,339,045, and 2,139,413 shares of common stock, respectively, for a total of $47.5 million, $44.0 million, and $44.5 million, respectively. Financial Statement Presentation - The Consolidated Financial Statements included in this Annual Report on Form 10-K are presented in conformity with U.S. generally accepted accounting principles ("U.S. GAAP"). Use of Estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and disclosures. These estimates may be adjusted due to changes in future economic, industry, or customer financial conditions, as well as changes in technology or demand. Estimates are used in accounting for, among other items, inventory reserves, restructuring reserves, warranty reserves, pension and post-retirement plans, stock-based compensation, useful lives for depreciation and amortization of long-lived assets, future cash flows associated with impairment testing for goodwill, indefinite-lived intangible assets and other long-lived assets, deferred tax assets, uncertain income tax positions, changes in tax laws, and contingencies. Management uses historical experience and all available information to make these estimates. Actual results may ultimately differ from estimates, although management does not believe such differences would materially affect the financial statements in any individual year. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the Consolidated Financial Statements in the period that they are determined. Cash and Cash Equivalents - Cash and cash equivalents include cash on hand, demand deposits, and temporary cash investments with original maturities less than three months. Allowance for Doubtful Accounts – The Company maintains allowances for estimated losses as a result of customers' inability to make required payments. Management evaluates the aging of the accounts receivable balances, the financial condition of its customers, historical trends, relevant forecasts, and the time outstanding of specific balances to estimate the amount of accounts receivable that may not be collected in the future and records the appropriate provision. Inventories – Inventories are stated at the lower of cost or net realizable value, determined on the first-in, first-out ("FIFO") basis. The value of inventory may decline as a result of surplus inventory, price reductions, or technological obsolescence. It is the Company’s policy to carry reserves against the carrying value of inventory when items have no future demand (obsolete inventory) and additionally, where inventory items on hand have demand, yet have insufficient forecasted activity to consume the entire stock within a reasonable period. The Company recognizes reserves against the carrying value of such at-risk inventory items after considering the nature of the risk and any mitigating factors. Property, Plant, and Equipment - Property, plant, and equipment includes the historic cost of land, buildings, equipment, and significant improvements to existing plant and equipment or, in the case of acquisitions, a fair market value appraisal of such assets completed at the time of acquisition. Property, plant, and equipment also includes the cost of purchased software. Expenditures for maintenance, repairs, and minor renewals are expensed as incurred. When property or equipment is sold or otherwise disposed of, the related cost and accumulated depreciation is removed from the respective accounts, and the gain or loss realized on disposition is reflected in earnings. The Company historically depreciates its assets on a straight-line basis over their estimated useful lives as follows: buildings and improvements 5 to 31.5 years; machinery and equipment 1.5 to 7 years; furniture and fixtures 2 to 5 years; vehicles 3 to 5 years; and software 3 to 5 years. Leases - The Company determines whether an arrangement is a lease at contract inception. Lease liabilities and right-of-use assets are recognized on the lease commencement date based on the net present value of fixed lease payments over the lease term. The Company includes options to extend or terminate a lease within the lease term when it is reasonably certain the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. Lease liabilities represent an obligation to make lease payments arising from a lease while right-of-use assets represent a right to use an underlying asset during the lease term. Right-of-use assets include prepaid fixed lease payments and exclude lease incentives. As the Company's leases do not have a readily determinable implicit rate, the Company uses its incremental borrowing rate to determine the present value of fixed lease payments based on information available at the lease commencement date. Fixed lease expense for operating leases and right-of-use asset amortization for finance leases are generally recognized on a straight-line basis over the lease term. Variable lease payments, such as payments based on an index rate or usage, are expensed as incurred and excluded from lease liabilities and right-of-use assets. The Company combines lease components and nonlease components such as maintenance into a single lease component, which results in the capitalization of all fixed payments within lease liabilities and right-of-use assets. Derivative Instruments - The Company uses derivative financial instruments to hedge its exposure to foreign currency exchange rate risk. The Company does not enter into derivative financial instruments for speculative purposes and does not have a material portfolio of derivative financial instruments. Derivative financial instruments used for hedging purposes must be designated and effective as a hedge of the identified risk exposure at inception of the contract. The Company recognizes all derivatives as either assets or liabilities on the Consolidated Balance Sheets and measures those instruments at fair value. For derivatives designated as cash flow hedges, the effective portion of changes in the fair value of the derivatives is recorded as a component of other comprehensive earnings and subsequently recognized in net earnings when the hedged items impact earnings. Goodwill and Indefinite-Lived Intangible Assets - Goodwill represents the excess of purchase consideration over the fair value of the net assets of businesses acquired. Goodwill and certain other intangible assets deemed to have indefinite lives are not amortized. Instead, goodwill and indefinite-lived intangible assets are tested for impairment at least annually, or more frequently if there are events or circumstances indicating the carrying value of individual reporting units or assets may exceed their respective fair values on a more likely than not basis. The Company performs its annual impairment assessment in the fourth quarter of each year on October 1. Recoverability of goodwill is measured at the reporting unit level. The Company has three reporting units - Precision Devices ("PD"), MedTech & Specialty Audio ("MSA"), and Consumer MEMS Microphones ("CMM.") The goodwill balances associated with PD, MSA, and CMM were $132.8 million, $137.7 million, and $270.2 million, respectively, as of December 31, 2023. As discussed in Note 18. Segment Information, in the fourth quarter of 2022, the Company determined that each of its three operating segments represents a single reportable segment (compared to the two reportable segments disclosed previously). The Company had no change in its reporting units as a result of the change in its reportable segments. The impairment assessment compares the fair value of each reporting unit to its carrying value. Impairment is measured as the amount by which the carrying value of a reporting unit exceeds its fair value. Fair value is estimated using a discounted cash flow model that includes the Company’s market participant assumptions, forecasted future cash flows based on historical performance and future estimated results, determinations of appropriate discount rates, and other assumptions which are considered reasonable and inherent in the discounted cash flow analysis. Significant assumptions used in the model included forecasted revenue and terminal growth rates, profit margins, income tax rates, capital expenditures, working capital requirements, and the Company's weighted average cost of capital. These assumptions require significant judgment and actual results may differ from estimated amounts. For the impairment testing conducted as of October 1, 2023, the fair value of the PD and MSA reporting units exceeded their carrying values by at least 180% and the fair value of the CMM reporting unit exceeded its carrying value by approximately 7%. The CMM reporting unit recorded goodwill impairment charges totaling $470.9 million for the year ended December 31, 2022 (see Note 4. Impairment Charges). No goodwill impairment charges were recorded for any reporting unit for the years ended December 31, 2023 or 2021. Potential circumstances that could have a negative effect on the fair value of our reporting units include, but are not limited to, lower than forecasted revenue and terminal growth rates, decreased profit margins, higher income taxes, increased capital expenditures, higher working capital requirements, and changes in the weighted average cost of capital. A reduction in the estimated fair value of the reporting units including due to the potential sale or restructuring of the CMM business, could trigger an impairment in the future. The Company cannot predict the occurrence of certain events or changes in circumstances that might adversely affect the carrying value of goodwill and intangible assets. In testing its indefinite-lived trademarks for impairment, the Company uses a relief from royalty method to calculate and compare the fair value of the intangible asset to its carrying value. This method estimates the fair value of trademarks by calculating the present value of royalty income that could hypothetically be earned by licensing the trademark to a third party. Any excess of carrying value over the estimated fair value is recognized as an impairment loss. No impairment of indefinite-lived trademarks was indicated for the years ended December 31, 2023, 2022, or 2021. See Note 7. Goodwill and Other Intangible Assets for additional information on goodwill and indefinite-lived intangible assets. Other Intangible and Long-Lived Assets - Other intangible assets with determinable lives consist primarily of customer relationships, developed technology, and trademarks, which are amortized over estimated useful lives typically ranging from 5 to 15 years. Long-lived assets and intangible assets with determinable lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an indicator of impairment exists for any grouping of assets, an estimate of undiscounted future cash flows is produced and compared to its carrying value. If an asset is determined to be impaired, the loss is measured by the excess of the carrying amount of the asset over its fair value as determined by an estimate of discounted future cash flows. The Company recorded impairment charges for its long-lived assets of $4.0 million during the year ended December 31, 2021. There were no impairments of long-lived assets recorded during the years ended December 31, 2023 and 2022. See Note 4. Impairment Charges for additional details. Other Assets and Deferred Charges - Investments in mutual funds of $6.2 million and $5.0 million are included in Other assets and deferred charges as of December 31, 2023 and 2022, respectively. These investments are carried at fair value based on quoted prices for identical assets in active markets, resulting in classification within Level 1 of the fair value hierarchy. Gains and losses related to the investments are recorded within the Consolidated Statements of Earnings as a component of Other (income) expense, net. Other assets and deferred charges also include non-current deferred tax assets. Foreign Currency - Assets and liabilities of non-U.S. subsidiaries, where the functional currency is not the U.S. dollar, are translated into U.S. dollars at year-end exchange rates. Revenue and expense items are translated using weighted-average exchange rates. Foreign currency translation gains and losses are included as a component of Accumulated other comprehensive loss. Assets and liabilities of an entity that are denominated in currencies other than an entity’s functional currency are re-measured into the functional currency using end of period exchange rates or historical rates where applicable to certain balances. Gains and losses related to these re-measurements are recorded within the Consolidated Statements of Earnings as a component of Other (income) expense, net. Revenue Recognition - Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The majority of the Company’s revenue is generated through the manufacture and sale of a broad range of specialized products and components. For product and component sales, each good sold to a customer typically represents a distinct performance obligation. The Company’s performance obligation to provide goods to a customer is typically satisfied at a point in time upon completion of the shipping process as indicated by the terms of the contract, at which point control is transferred to the customer and revenue is recognized. The Company has no significant arrangements with multiple performance obligations. Remaining performance obligations consist of the aggregate amount of the total transaction price that is unsatisfied or partially satisfied. As of December 31, 2023 and 2022, our total remaining performance obligations were immaterial. The Company recognizes sales-based royalty revenue under third-party license agreements as the related sales are made by licensees. The terms of a contract or historical business practice can give rise to variable consideration, including customer discounts, rebates, and returns. The Company estimates variable consideration using either the expected value or most likely amount method. We include amounts in the transaction price to the extent it is probable that a significant reversal of revenue will not occur in a subsequent reporting period. Our estimates of variable consideration are based on all reasonably available information (historical, current, and forecasted). Rebates are recognized over the contract period based on expected revenue levels. Sales discounts and rebates totaled $4.8 million, $4.4 million, and $5.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Returns and allowances totaled $4.3 million, $7.1 million, and $4.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. The Company accounts for shipping and handling activities that occur after control of the related good transfers to the customer as fulfillment activities rather than evaluating such activities as performance obligations. As a result, all shipping and handling costs related to contracts with customers are recognized in the Cost of goods sold line on the Consolidated Statements of Earnings. Additionally, the Company applies the practical expedient allowing incremental costs of obtaining a contract to be expensed as incurred if the amortization period of the resulting asset would have been less than one year. These costs primarily consist of sales commissions and the Company has no such significant costs exceeding the one year limit for applying the practical expedient. Receivables, net from contracts with customers were $129.2 million and $125.7 million as of December 31, 2023 and 2022, respectively. See Note 18. Segment Information for disclosures regarding the disaggregation of revenues. Stock-Based Compensation – The principal awards issued under the stock-based compensation plans include stock options, restricted stock units ("RSUs"), and performance share units ("PSUs"). The cost for such awards is measured at the grant date based on the fair value of the award. The value of the portion of the award that is expected to ultimately vest is generally recognized as expense on a straight-line basis, generally over the explicit service period and is included in Cost of goods sold, Research and development expenses, and Selling and administrative expenses in the Consolidated Statements of Earnings, depending on the functional area of the underlying employees. At the time of grant, the Company estimates forfeitures, based on historical experience, in order to estimate the portion of the award that will ultimately vest. The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted to employees. The fair value of each RSU granted is equal to the share price at the date of the grant. The fair value of each PSU is determined using a Monte Carlo simulation. The cost related to PSUs with performance conditions is recognized based on the expected attainment of performance targets. Changes in estimates for performance conditions that impact the number of shares expected to vest are recognized prospectively through cumulative adjustments. The cost for PSUs is recognized regardless of the expected attainment of market conditions as the grant date fair value considers the range of possible stock price and total shareholder return outcomes. See Note 14. Equity Incentive Program for additional information related to the Company’s stock-based compensation. Income Taxes - The Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset and liability method. Under this method, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The Company offsets and presents deferred tax liabilities and assets, as well as any related valuation allowance, as a single non-current amount on the Consolidated Balance Sheets on a jurisdictional basis. The Company's policy is to release income tax effects from accumulated other comprehensive loss in the period the underlying item expires. The Company establishes valuation allowances for its deferred tax assets if, based on all available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such assessments, significant weight is given to evidence that can be objectively verified. The assessment of the need for a valuation allowance requires considerable judgment on the part of management with respect to the benefits that could be realized from future taxable income, as well as other positive and negative factors. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. The Company recognizes tax benefits from uncertain tax positions only if it believes that it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. Adjustments are made to these reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on the Company's financial condition and operating results. The provision for income taxes includes the effects of any reserves that are believed to be appropriate, as well as the related net interest and penalties. Research and Development Costs – Research and development costs, including qualifying engineering costs, are expensed when incurred. Non-cash Investing Activities - Purchases of property, plant, and equipment included in accounts payable were $1.1 million at both December 31, 2023 and 2022, and $5.4 million at December 31, 2021. These non-cash amounts are not reflected as Capital expenditures within investing activities of the Consolidated Statements of Cash Flows for the respective periods. The Company completed an asset acquisition in 2023 for a total purchase price of approximately $2.0 million, including contingent consideration with an estimated fair value of $1.7 million. This non-cash amount is not reflected in “Acquisition of asset” within Investing Activities on the Consolidated Statements of Cash Flows for the year ended December 31, 2023. See also Note 7. Goodwill and Other Intangible Assets. Recently Issued Accounting Standards |
Disposed and Discontinued Opera
Disposed and Discontinued Operations (Notes) | 12 Months Ended |
Dec. 31, 2023 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Disposal Groups, Including Discontinued Operations, Disclosure | 2. Disposed and Discontinued Operations Management and the Board of Directors periodically conduct strategic reviews of the Company's businesses. On July 7, 2016, the Company completed the sale of its speaker and receiver product line (“Speaker and Receiver Product Line”) for $45.0 million in cash, less purchase price adjustments for a net amount received of $40.6 million. In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations, the results of operations and financial positions of the Speaker and Receiver Product Line have been reclassified to discontinued operations for all periods presented as these disposals represent strategic shifts that had a major effect on the Company's results of operations. During the year ended December 31, 2021, the Company recorded tax benefits for refunds of $0.2 million received during 2021 related to the Speaker and Receiver Product Line. |
Property, Plant and Equipment,
Property, Plant and Equipment, net | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment, net | 6. Property, Plant, and Equipment, net The following table details the major components of property, plant, and equipment, net: (in millions) December 31, 2023 December 31, 2022 Land $ 14.3 $ 12.5 Buildings and improvements 122.5 114.6 Machinery, equipment, and other 518.2 531.2 Subtotal 655.0 658.3 Less accumulated depreciation (479.6) (496.5) Total $ 175.4 $ 161.8 |
Intangible Assets, Goodwill and
Intangible Assets, Goodwill and Other | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets Disclosure [Text Block] | 7. Goodwill and Other Intangible Assets The changes in the carrying value of goodwill by reportable segment for the years ended December 31, 2023 and 2022 are as follows: (in millions) Precision Devices MedTech & Specialty Audio Consumer MEMS Microphones Total Balance at January 1, 2022 $ 62.5 $ 137.7 $ 741.1 $ 941.3 Impairment charges (1) — — (470.9) (470.9) Purchase price adjustment 0.7 — — 0.7 Foreign currency translation — — (0.1) (0.1) Balance at December 31, 2022 63.2 137.7 270.1 471.0 Acquisition 69.6 — — 69.6 Foreign currency translation — — 0.1 0.1 Balance at December 31, 2023 $ 132.8 $ 137.7 $ 270.2 $ 540.7 (1) During the year ended December 31, 2022 the Company recorded total goodwill impairment charges of $470.9 million. See Note 4. Impairment Charges for more information. The gross carrying value and accumulated amortization for each major class of intangible assets are as follows: December 31, 2023 December 31, 2022 (in millions) Gross Carrying Accumulated Gross Carrying Accumulated Amortized intangible assets: Trademarks $ 16.0 $ 1.2 $ 2.0 $ 0.8 Customer relationships 121.1 16.0 36.4 10.3 Developed technology 64.5 27.4 45.4 20.1 Other 2.4 2.0 2.4 1.9 Total 204.0 46.6 86.2 33.1 Unamortized intangible assets: Trademarks 32.0 32.0 Total intangible assets, net $ 189.4 $ 85.1 In connection with the acquisition of CD in 2023, the Company recognized customer relationships of $82.7 million, developed technology of $19.1 million, and trademarks of $14.0 million. See also Note 3. Acquisitions. The Company completed an asset acquisition in 2023. In connection with this acquisition, the Company recognized customer relationships with a fair value of approximately $2.0 million, reflecting cash paid of $0.3 million and contingent consideration with an estimated fair value of $1.7 million. These customer relationships have an estimated useful life of 7 years. As of December 31, 2023, the weighted average remaining useful lives for the amortizable intangible assets are: trademarks at 13.8 years, customer relationships at 9.1 years, developed technology at 6.5 years, and other at 7.3 years. The weighted average remaining useful life in total for all amortizable intangible assets was 8.9 years as of December 31, 2023. Total amortization expense for the years ended December 31, 2023, 2022, and 2021 was $13.5 million, $12.2 million, and $15.9 million, respectively. Amortization expense for the next five years and thereafter, based on current definite-lived intangible balances, is estimated to be as follows: (in millions) 2024 $ 23.1 2025 22.5 2026 16.6 2027 16.6 2028 15.8 2029 and thereafter 62.8 Total $ 157.4 |
Leases, Codification Topic 842
Leases, Codification Topic 842 | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases of Lessee Disclosure [Text Block] | 8. Leases The Company has leases for manufacturing, sales, support, and engineering facilities, certain manufacturing and office equipment, and vehicles. The majority of the leases have remaining terms of 1 to 7 years, some of which include options to extend the leases for up to 6 years, and some of which include options to terminate the leases within 1 year. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company subleases certain facilities to third parties. The following table details the components of lease cost: Years Ended December 31, (in millions) 2023 2022 2021 Operating lease cost (1) $ 7.9 $ 8.2 $ 9.9 Finance lease cost: Amortization of right-of-use assets 2.3 2.3 2.3 Interest on lease liabilities 0.2 0.3 0.4 Sublease income (3.3) (3.5) (3.0) Total lease cost $ 7.1 $ 7.3 $ 9.6 (1) Includes short-term and variable lease costs, which were immaterial. The components of lease cost other than Interest on lease liabilities are presented within the Cost of goods sold, Research and development expenses, and Selling and administrative expenses lines on the Consolidated Statements of Earnings based on the use of the underlying assets. Interest on lease liabilities is presented within the Interest expense, net line on the Consolidated Statements of Earnings. The following table presents supplemental balance sheet information related to finance leases: (in millions) Balance Sheet Line December 31, 2023 December 31, 2022 Finance lease right-of-use assets Property, plant, and equipment, net $ 3.4 $ 5.3 Current finance lease liabilities Other accrued expenses $ 1.6 $ 2.5 Long-term finance lease liabilities Other liabilities 0.6 1.4 Total finance lease liabilities $ 2.2 $ 3.9 The following table presents supplemental cash flow information related to leases: Years Ended December 31, (in millions) 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.1 $ 12.4 $ 10.2 Operating cash flows from finance leases 0.2 0.3 0.4 Financing cash flows from finance leases 2.5 4.8 2.3 Lease liabilities arising from obtaining right-of-use assets: (2) Operating leases $ 2.6 $ 2.0 $ 6.5 Finance leases 0.7 0.4 0.3 (2) Does not include operating lease liabilities of $3.4 million and finance lease liabilities of $0.1 million obtained in the acquisition of CD. See Note 3. Acquisitions for more information. The following table details weighted-average remaining lease terms and discount rates: December 31, 2023 December 31, 2022 Weighted-average remaining lease term (in years): Operating leases 3.3 2.5 Finance leases 2.5 2.2 Weighted-average discount rate: Operating leases 5.0 % 3.4 % Finance leases 5.6 % 5.3 % The following table details maturities of lease liabilities as of December 31, 2023: (in millions) Operating Leases Finance Leases 2024 $ 5.5 $ 1.6 2025 3.3 0.4 2026 2.4 0.2 2027 2.1 0.1 2028 1.0 — 2029 and thereafter 0.2 — Total lease payments 14.5 2.3 Less interest (1.2) (0.1) Present value of lease liabilities $ 13.3 $ 2.2 |
Accrued Expenses and Other Liab
Accrued Expenses and Other Liabilities | 12 Months Ended |
Dec. 31, 2023 | |
Accrued Liabilities and Other Liabilities [Abstract] | |
Accrued Expenses and Other Liabilities | 9. Other Accrued Expenses and Other Liabilities The following table details the major components of other accrued expenses: (in millions) December 31, 2023 December 31, 2022 Restructuring and exit costs $ 8.5 $ 4.0 Sales volume rebates 3.6 4.0 Accrued taxes other than income taxes 2.4 1.8 Accrued insurance 2.0 1.6 Current finance lease liabilities 1.6 2.5 Current hedging liability 0.7 0.8 Warranty 0.7 0.4 Other 5.5 4.8 Total $ 25.0 $ 19.9 The following table details the major components of other liabilities: (in millions) December 31, 2023 December 31, 2022 Deferred compensation, including defined benefit plans $ 13.6 $ 12.9 Restructuring and exit costs 10.7 18.7 Unrecognized tax benefits 2.3 2.5 Unearned/deferred revenue 1.7 2.5 Long-term finance lease liabilities 0.6 1.4 Long-term hedging liability 0.4 — Other 1.8 0.8 Total $ 31.1 $ 38.8 Warranty Accruals Estimated warranty program claims are provided for at the time of sale. Amounts provided for are based on historical costs and adjusted for new claims. The changes in the carrying amount of product warranties were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Beginning balance, January 1 $ 0.4 $ 0.5 $ 0.4 Provision for warranties 0.5 0.6 1.0 Settlements made (0.4) (0.5) (0.9) Other adjustments, including currency translation (1) 0.2 (0.2) — Ending balance, December 31 $ 0.7 $ 0.4 $ 0.5 |
Restructuring and Related Activ
Restructuring and Related Activities | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Activities | 10. Restructuring and Related Activities Restructuring and related activities are designed to better align the Company's operations with current market conditions through targeted facility consolidations, headcount reductions, and other measures to further optimize operations. During the year ended December 31, 2023, the Company recorded restructuring charges within the PD segment of $2.5 million for severance pay and benefits related to headcount reductions and for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations. The Company also recorded $1.4 million for severance pay and benefits related to headcount reductions within the Consumer MEMS Microphones segment and $0.8 million for Corporate charges during the year ended December 31, 2023. During the year ended December 31, 2023, the Company recorded gains of $1.0 million for the sale of certain machinery and equipment that was previously written off through restructuring charges within the Consumer MEMS Microphones segment. The Company also recorded a $1.5 million reversal of restructuring charges within the Consumer MEMS Microphones segment as a result of changes in estimates. The Company recorded a $1.3 million credit for the aforementioned restructuring charges within Gross profit and the remaining $3.5 million of expense within Operating expenses for the year ended December 31, 2023. During the year ended December 31, 2022, the Company restructured its MEMS microphones product line through two restructuring programs, which are included within the CMM segment. These actions resulted in the settlement of supplier obligations, non-cash fixed asset write-offs, and severance pay. During the year ended December 31, 2022, the Company recorded restructuring charges of $39.0 million related to this action, including $21.1 million for the settlement of supplier obligations, $13.5 million in fixed asset write-off costs, and $4.4 million in severance pay and benefits. In addition, during the year ended December 31, 2022, the Company recorded restructuring charges of $2.2 million for severance pay and benefits to rationalize the Intelligent Audio product line workforce, which is included within the CMM segment, and $0.6 million for other costs. The Company recognized $32.2 million of the aforementioned restructuring charges within Gross profit and the remaining $9.6 million within Operating expenses for year ended December 31, 2022. During the year ended December 31, 2021, the Company recorded restructuring charges within Operating expenses of $0.5 million. These charges were primarily for actions associated with the Intelligent Audio product line, which is included within the CMM segment. The following table details restructuring charges incurred by reportable segment for the periods presented: Years Ended December 31, (in millions) 2023 2022 2021 Precision Devices $ 2.5 $ — $ 0.1 MedTech & Specialty Audio — — 0.1 Consumer MEMS Microphones (1.1) 41.2 0.3 Corporate 0.8 0.6 — Total $ 2.2 $ 41.8 $ 0.5 The following table details the Company’s severance and other restructuring accrual activity: (in millions) Severance Pay and Benefits Contract Termination and Other Costs Total Balance at January 1, 2021 $ 1.9 $ 0.7 $ 2.6 Restructuring charges 0.5 — 0.5 Payments (2.0) (0.7) (2.7) Balance at December 31, 2021 0.4 — 0.4 Restructuring charges 6.6 35.2 41.8 Payments (6.2) (1.6) (7.8) Other, including foreign currency (1) 0.1 (11.8) (11.7) Balance at December 31, 2022 0.9 21.8 22.7 Restructuring charges 4.7 (2.5) 2.2 Payments (4.3) (3.1) (7.4) Other, including foreign currency (2) 1.1 0.6 1.7 Balance at December 31, 2023 $ 2.4 $ 16.8 $ 19.2 (1) Other activity during 2022 includes the non-cash disposal of fixed assets of $13.5 million within the MEMS microphones product line. (2) Other activity during 2023 includes $1.1 million of reserves assumed by the Company with the acquisition of CD within the PD segment. The severance and restructuring accruals are recorded in the following line items on the Consolidated Balance Sheets: (in millions) December 31, 2023 December 31, 2022 Other accrued expenses $ 8.5 $ 4.0 Other liabilities 10.7 18.7 Total $ 19.2 $ 22.7 |
Hedging Transactions and Deriva
Hedging Transactions and Derivative Instruments | 12 Months Ended |
Dec. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments and Hedging Activities Disclosure | 11. Hedging Transactions and Derivative Instruments The Company is affected by changes in certain market conditions. These changes in market conditions may adversely impact the Company’s financial performance and are referred to as "market risks." The Company uses derivatives as a risk management tool to mitigate the potential impact of certain market risks, which are primarily foreign currency risk related to ongoing business operations. Cash Flow Hedging The Company uses cash flow hedges to minimize the variability in cash flows of assets, liabilities, or forecasted transactions caused by fluctuations in foreign currency exchange rates. These derivatives, which are designated cash flow hedges, are carried at fair value. The changes in their fair values are recorded to Accumulated Other Comprehensive Income (Loss) ("AOCI") and reclassified in current earnings when the hedge contract matures or becomes ineffective. To manage its exposure to foreign currency exchange rates, the Company has entered into currency deliverable forward contracts. These derivative instruments allow the Company to hedge portions of its forecasted funding needs, which are generally expected to occur within the next twelve months and are denominated in currencies other than the U.S. dollar. The Company maintains a foreign currency cash flow hedging program primarily to reduce the risk that the net U.S. dollar cash inflows and non-U.S. dollar net cash outflows will be adversely affected by changes in foreign currency exchange rates. At December 31, 2023 and 2022, the notional value of the derivatives related to currency forward contracts, principally the Chinese yuan, Malaysian ringgit, Philippine peso, and Japanese yen, was $49.2 million and $68.0 million, respectively. The Company presents the impact of foreign exchange contracts qualifying as cash flow hedges within the Cost of goods sold line on the Consolidated Statements of Earnings, which is the same line used to present the earnings effect of the hedged item. Economic (Non-Designated) Hedging In addition to derivative instruments that are designated and qualify for hedge accounting, the Company also uses certain derivatives as economic hedges of foreign currency risk. Although these derivatives were not designated and/or did not qualify for hedge accounting, they are effectively economic hedges. The changes in fair value of these economic hedges are immediately recognized in earnings. The Company uses foreign currency economic hedges to offset the earnings impact that fluctuations in foreign currency exchange rates have on certain monetary assets and liabilities denominated in non-functional currencies. The Company does not enter into these hedges for speculative reasons. These derivatives are carried at fair value with changes in fair value immediately recognized in earnings within Other (income) expense, net. In addition, these derivative instruments minimize the impact of exchange rate movements on the Company’s balance sheet, as the gains or losses on these derivatives are intended to offset gains and losses from the reduction of the hedged assets and liabilities. At December 31, 2023 and 2022, the notional value of the derivatives related to economic hedging was $111.7 million and $86.3 million, respectively. The notional amounts of the derivative financial instruments do not necessarily represent amounts exchanged by the parties and, therefore, are not a direct measure of our exposure to the financial risks described above. The amounts exchanged are calculated by reference to the notional amounts and by other terms of the derivatives, such as foreign currency exchange rates or other financial indices. The Company does not view the fair values of its derivatives in isolation, but rather in relation to the fair values or cash flows of the underlying hedged transactions or other exposures. Virtually all of our derivatives are straightforward over-the-counter instruments with liquid markets. Fair Value Measurements All derivatives are carried at fair value on the Company’s Consolidated Balance Sheets. ASC 820, Fair Value Measurement, establishes a fair value hierarchy that requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value as follows: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities. Level 3 - Unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company determines the fair values of its derivatives based on standard valuation models or observable market inputs such as quoted market prices or foreign currency exchange rates; therefore, the Company classifies the derivatives within Level 2 of the valuation hierarchy. The fair values of derivative instruments held by the Company are as follows (in millions): Derivative Assets (Liabilities) Hedge Type Contract Type Balance Sheet Line December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments Cash flow hedges Foreign exchange contracts Prepaid and other current assets $ 0.4 $ 1.1 Cash flow hedges Foreign exchange contracts Other assets and deferred charges — 1.3 Cash flow hedges Foreign exchange contracts Other accrued expenses (0.7) (0.8) Cash flow hedges Foreign exchange contracts Other liabilities (0.4) — Derivatives not designated as hedging instruments Economic hedges Foreign exchange contracts Prepaid and other current assets 0.1 0.6 Economic hedges Foreign exchange contracts Other accrued expenses (0.1) — The pre-tax amount of unrealized (loss) gain recognized in accumulated other comprehensive loss on derivatives designated as hedging instruments is as follows (in millions): Years Ended December 31, Hedge Type Contract Type 2023 2022 2021 Cash flow hedges Foreign exchange contracts $ (5.0) $ (3.4) $ 0.5 The table above excludes a tax benefit of $1.1 million and $0.6 million for the years ended December 31, 2023 and 2022, respectively, and tax expense of $0.2 million for the year ended December 31, 2021. The pre-tax impact of derivatives on the Consolidated Statements of Earnings is as follows (in millions): Years Ended December 31, 2023 2022 2021 Hedge Type Contract Type Cost of goods sold Other expense (income), net Cost of goods sold Other expense (income), net Cost of goods sold Other expense (income), net Total amounts per Consolidated Statements of Earnings $ 435.5 $ 0.7 $ 455.7 $ (0.5) $ 508.6 $ (3.0) Effect of derivatives designated as hedging instruments Amount of loss (gain) reclassified from accumulated other comprehensive loss into earnings: Cash flow hedges Foreign exchange contracts 2.7 — 4.5 — (2.1) — Effect of derivatives not designated as hedging instruments Amount of loss (gain) recognized in earnings: Economic hedges Foreign exchange contracts — 3.3 — 1.0 — (1.4) |
Borrowings and Lines of Credit
Borrowings and Lines of Credit | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Borrowings and Lines of Credit | 12. Borrowings Borrowings (net of debt issuance costs, debt discount, and amortization) consist of the following: (in millions) December 31, 2023 December 31, 2022 $400.0 million Revolving Credit Facility $ 160.0 $ 45.0 Seller Note 111.2 — Total 271.2 45.0 Less current maturities of Seller Note 47.1 — Total long-term debt $ 224.1 $ 45.0 Total debt principal payments over the next five years are as follows: (in millions) 2024 $ 50.0 2025 72.9 2026 — 2027 — 2028 160.0 Revolving Credit Facility On February 8, 2023, the Company entered into an Amended and Restated Credit Agreement (the "A&R Credit Agreement") that amends and restates the prior Credit Agreement, dated September 4, 2020, and provides for a senior secured revolving credit facility with borrowings in an aggregate principal amount at any time outstanding not to exceed $400.0 million (the "Credit Facility"). The A&R Credit Agreement, among other things, extends the maturity date of the Credit Facility from January 2, 2024 to February 8, 2028, replaces the London Inter-Bank Offered Rate (“LIBOR”) with the Term Secured Overnight Financing Rate (“Term SOFR”) as a reference rate available for borrowings, amends the minimum Interest Coverage Ratio, and amends certain other financial covenants with which the Company must comply, as described below. On September 25, 2023, the Company amended its A&R Credit Agreement to, among other things, (a) permit the Company in connection with the acquisition of CD, to incur senior priority seller financing indebtedness (the “Seller Note”) in an aggregate principal amount of $122.9 million secured by certain assets (including equity interests) acquired in connection with such acquisition and the capital stock of Cornell Dubilier, LLC (the “Acquisition Assets”), which shall mature two years after the effective date of such Seller Note (the “Seller Note Maturity Date”), (b) extends the requirement to pledge the Acquisition Assets that would otherwise constitute collateral under the Credit Agreement to the date that is 90 days after the Seller Note Maturity Date, and (c) restricts, until the Seller Note Maturity Date, the amount of dispositions and investments from the Company and certain of its subsidiaries into Cornell Dubilier, LLC and the acquired subsidiaries that constitute Acquisition Assets from exceeding $80.0 million in the aggregate. All other terms remain the same as the A&R Credit Agreement dated February 8, 2023. Up to $100.0 million of the Credit Facility will be available in Euro, Pounds Sterling, and other currencies requested by the Company and up to $50.0 million of the Credit Facility will be made available in the form of letters of credit. Undrawn amounts under the Credit Facility accrue a commitment fee at a per annum rate of 0.225% to 0.350%, based on a leverage ratio grid. At any time during the term of the Credit Facility, the Company will be permitted to increase the commitments under the Credit Facility or to establish one or more incremental term loan facilities under the Credit Facility in an aggregate principal amount not to exceed the sum of $200.0 million, plus additional amounts, so long as the senior secured leverage ratio does not exceed 2.00 to 1.00. The A&R Credit Agreement includes requirements, to be tested quarterly, that the Company maintains (i) a minimum ratio of Consolidated EBITDA to consolidated cash interest expense of 3.00 to 1.00, (the "Interest Coverage Ratio"), (ii) a ratio of total indebtedness, minus netted cash in an aggregate amount not to exceed $50.0 million, to Consolidated EBITDA of 3.75 to 1.00 (the "Total Net Leverage Ratio"), and (iii) a maximum ratio of senior net secured indebtedness to Consolidated EBITDA of 3.25 to 1.00 (the "Senior Secured Net Leverage Ratio"). For these ratios, Consolidated EBITDA and consolidated interest expense are calculated using the most recent four consecutive fiscal quarters in a manner defined in the A&R Credit Agreement. At December 31, 2023, the Company was in compliance with these covenants and it expects to remain in compliance with all of its debt covenants over the next twelve months. The interest rates under the A&R Credit Facility will be, at the Borrowers' option (1) (A) in the case of borrowings denominated in U.S. dollars Term SOFR, (B) in the case of borrowings denominated in Sterling, Daily Simple Sonia, or (C) for borrowings denominated in Euro, EURIBOR, in each case, plus the rates per annum determined from time to time based on the total net leverage ratio of the Company as of the end of and for the most recent period of four fiscal quarters for which financial statements have been delivered (the "Applicable Margin"); or (2) in the case of borrowings denominated in U.S. dollars, alternate base rate ("ABR") (as defined in the A&R Credit Agreement) plus the Applicable Margin. The Applicable Margin for Term SOFR, Daily Simple Sonia, or EURIBOR could range from 1.50% to 2.50% while the Applicable Margin for ABR could range from 0.50% to 1.50%. The weighted-average interest rate on the Company's borrowings under the Credit Facility and the 2020 Credit Facility was 6.55%, 3.21%, and 2.25% for the years ended December 31, 2023, 2022, and 2021, respectively. The weighted-average commitment fee on the revolving lines of credit was 0.23% for the years ended December 31, 2023 and 2022 and 0.26% for the years ended December 31, 2021. Seller Note On November 1, 2023, the Company completed the acquisition of CD for a total purchase price of $246.8 million. This acquisition was funded by borrowings on the Revolving Credit Facility and an interest-free note from the seller with aggregate principal payments of $122.9 million (the "Seller Note"). The Seller Note is due and payable in cash with $50.0 million maturing on November 1, 2024 and $72.9 million maturing on November 1, 2025. On the acquisition date, the Company recorded the Seller Note at its present value of $109.9 million by discounting the future principal payments using an imputed rate of interest of approximately 7.1% in accordance with accounting guidance in ASC 835, Interest. The Company recognized imputed interest expense on the Seller Note of approximately $1.3 million for the year ended December 31, 2023. The Seller Note is secured by certain assets (including equity interest) acquired in connection with the acquisition. The Seller Note includes Knowles Capital Holdings, Inc. and Knowles Intermediate PD Holdings, LLC as borrowers, which jointly and severally agree to pay James P. Kaplan, as representative of the sellers of Cornell Dubilier, the principal amount of $122.9 million as described above. The Seller Note is not interest-bearing except at such time as an event of default has occurred, upon which and during the continuance of an event of default, all overdue principal will accrue interest at 2.0% per annum plus the SOFR-based rate otherwise applicable under the Company’s existing credit facility. The Seller Note is subject to customary conditions and events of default and the secured nature of the Seller Note is supported by a Security Agreement. Interest expense and interest income for the years ended December 31, 2023, 2022, and 2021 were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Interest expense $ 7.4 $ 4.3 $ 14.4 Interest income (2.0) (0.4) (0.2) Interest expense, net $ 5.4 $ 3.9 $ 14.2 Warrants In the second quarter of 2016, the Company entered into warrant transactions, whereby the Company sold warrants to acquire shares of the Company's common stock at a strike price of $21.1050 per share (the “Warrants”). The Company received aggregate proceeds of $39.1 million from the sale of the Warrants. The Warrants were separate transactions entered into by the Company, and were not part of the Notes, and were accounted for as part of additional paid-in capital. The Warrants expired during the first quarter of 2022, which resulted in the Company delivering 0.2 million shares of its common stock held in treasury. Settlement of the Warrants resulted in a $3.1 million decrease in treasury stock, which was measured based on the acquisition cost of the delivered shares determined on a first-in, first-out (“FIFO”) basis, offset by an equivalent decrease in additional paid-in capital with no net impact to equity. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 13. Income Taxes The components of earnings (loss) before income taxes and discontinued operations were: Years Ended December 31, (in millions) 2023 2022 2021 Domestic $ (120.4) $ (410.1) $ 15.5 Foreign 165.4 (8.1) 89.1 Total earnings (loss) before income taxes and discontinued operations $ 45.0 $ (418.2) $ 104.6 Income tax (benefit) expense for the years ended December 31, 2023, 2022, and 2021 is comprised of the following: Years Ended December 31, (in millions) 2023 2022 2021 Current: U.S. Federal $ 1.8 $ 1.2 $ 0.4 State and local 0.3 0.6 0.3 Foreign 12.1 5.5 14.8 Total current tax expense $ 14.2 $ 7.3 $ 15.5 Deferred: U.S. Federal $ (39.9) $ 3.0 $ (57.1) State and local (2.5) (0.3) (2.6) Foreign 0.8 1.9 (1.4) Total deferred tax (benefit) expense (41.6) 4.6 (61.1) Total income tax (benefit) expense $ (27.4) $ 11.9 $ (45.6) The reconciliation of income tax (benefit) expense at the U.S. Federal income tax rate to the Company’s actual income tax (benefit) expense was as follows: Years Ended December 31, 2023 2022 2021 Income tax expense (benefit) at U.S. federal statutory income tax rate $ 9.4 $ (87.8) $ 22.0 State and local taxes, net of Federal income tax benefit (2.1) 0.6 0.3 Foreign operations tax effect 4.2 6.4 3.5 Research and experimentation tax credits (2.9) (3.4) (4.0) Valuation allowance (14.4) 0.8 (59.7) Tax incentives (1.7) (1.3) (1.2) Tax contingencies (0.2) (1.1) 0.6 Tax holiday (0.8) (0.4) (10.6) Foreign taxes 0.2 1.1 1.0 Non-deductible and non-taxable interest (1.5) 0.2 (0.2) Stock-based compensation 3.7 1.8 5.1 Impact of intangible property transfers (26.6) — — Other, principally non-tax deductible items 1.6 2.5 1.3 Goodwill impairment — 90.6 — Global low tax and foreign derived intangible income 4.3 0.1 (2.5) Foreign currency adjustments — — (0.7) Prior period items (0.6) 1.8 (0.5) Total income tax (benefit) expense $ (27.4) $ 11.9 $ (45.6) The Company’s effective tax rate has been favorably impacted by three tax holidays – two holidays granted to us by Malaysia, one which would have been effective through December 31, 2026 and the other which expired on July 31, 2021, and a tax holiday granted by China (the “Hi-Tech Rate”). Each of the tax holidays is subject to the Company’s satisfaction of certain conditions. As a result of the rapid decline in current demand for global consumer electronics during 2022, we did not satisfy all of the conditions of our tax holiday in Malaysia that was in effect January 1, 2022. As such, we are not including this tax holiday benefit in our 2023 or 2022 effective tax rate. Our 2021 effective tax rate includes the benefit for the Malaysian tax holidays that were in effect during 2021. The Hi-Tech Rate is a preferential tax rate for high technology enterprises for Chinese tax purposes that is effective for the Company's annual tax filings 2021 through 2023. This benefit is being reflected as a tax holiday in the effective tax rate. We expect to continue to satisfy the conditions for the Hi-Tech Rate. If the Company fails to satisfy such conditions, the Company’s effective tax rate may be adversely impacted. The continuing operations benefit of incentives for the years ending December 31, 2023, 2022, and 2021 is estimated to be $1.1 million, $0.8 million, and $10.7 million, respectively. The continuing operations benefit of tax holidays on a basic per share basis for the years ending December 31, 2023 and 2022 was $0.01. The continuing operations benefit of tax holidays on a basic per share basis for the years ending December 31, 2021 was $0.12. The components of the Company’s deferred tax assets and liabilities included the following: (in millions) December 31, 2023 December 31, 2022 Deferred tax assets: Accrued compensation, principally post-retirement, and other employee benefits $ 13.2 $ 11.0 Accrued expenses 5.2 4.4 Accrued interest 0.4 1.5 Net operating loss and other carryforwards 67.4 68.0 Inventories, principally due to reserves for financial reporting purposes and capitalization for tax purposes 8.2 8.2 Unremitted earnings of non-U.S. subsidiaries 0.7 2.0 Intangible assets, principally due to different tax and financial reporting bases 23.3 6.9 Plant and equipment, principally due to differences in depreciation 10.0 13.8 Total gross deferred tax assets 128.4 115.8 Valuation allowance (25.5) (39.7) Total deferred tax assets $ 102.9 $ 76.1 Deferred tax liabilities: Other liabilities $ (4.0) $ (2.2) Total gross deferred tax liabilities (4.0) (2.2) Net deferred tax asset $ 98.9 $ 73.9 Classified as follows in the Consolidated Balance Sheets: Other assets and deferred charges (non-current deferred tax assets) $ 99.6 $ 74.8 Deferred income taxes (non-current deferred tax liabilities) (0.7) (0.9) Net deferred tax asset $ 98.9 $ 73.9 The Company recorded valuation allowances of $25.5 million and $39.7 million at December 31, 2023 and 2022, respectively, against deferred tax assets from continuing operations as the Company believes it is more likely than not that these assets will not be realized. At December 31, 2023, we recognized an income tax benefit of $15.1 million related to the reversal of the deferred tax asset valuation allowance on our U.S. foreign tax credits and certain U.S. state tax attributes. The Company routinely reviews the future realization of deferred tax assets based on projected future reversal of taxable temporary differences, available tax planning strategies, and projected future taxable income. Management believes that it is more likely than not that the Company will realize the benefits of the remaining deferred tax assets. At December 31, 2023, the Company had $3.8 million of U.S. federal net operating losses that are available, of which $2.1 million will expire in the next 6 to 10 years, and of which $1.7 million will expire in the next 11 to 20 years. There are $3.2 million of domestic State net operating losses that are available between 2027 and 2043. There are $5.2 million of non-U.S. net operating loss carryforwards, of which $0.3 million will expire in the next 5 years; $4.1 million will expire in the next 11 to 20 years; $0.7 million can be carried forward indefinitely; and $0.1 million is a capital loss carried forward indefinitely. The Company has $24.3 million of U.S. federal research and development credits that begin to expire in 2024 and $15.1 million of foreign tax credits that begin to expire in 2027. In addition, the Company has $15.7 million of state credits, of which $2.0 million will expire between 2024 and 2038 if unused, and $13.7 million can be carried forward indefinitely. As of December 31, 2023, the Company has approximately $1.4 billion of undistributed earnings in its foreign subsidiaries. Approximately $0.3 billion of these earnings are no longer considered permanently reinvested. The incremental tax cost to repatriate these earnings to the U.S. is immaterial. The Company has not provided for deferred taxes on approximately $1.1 billion of undistributed earnings from non-U.S. subsidiaries which are indefinitely reinvested in operations. If these earnings were distributed, they would likely not be subject to U.S. federal income tax because they were previously taxed under the Tax Reform Act. We would likely be required to accrue and pay U.S. state and local taxes and withholding taxes payable to various countries. It is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. Unrecognized Tax Benefits The Company records interest and penalties associated with unrecognized tax benefits as a component of income tax expense. During the years ended December 31, 2023, 2022, and 2021, the Company recorded interest expense resulting in insignificant balances. The Company recorded penalty expense during the years ended December 31, 2022, and 2021 resulting in accrued penalties of $0.1 million, and $0.3 million, respectively, which were included in Other liabilities on the Consolidated Balance Sheets. During the year ended December 31, 2023, the Company recorded no penalty expense The Company's tax returns are routinely audited by the tax authorities in the relevant jurisdictions. For tax years before 2020, the Company is no longer subject to U.S. federal income tax examination. For tax years before 2016, the Company’s Malaysian principal subsidiary is no longer subject to examination. Included in the balance of total unrecognized tax benefits at December 31, 2023 are potential benefits of $2.3 million, which if recognized, would affect the effective rate on earnings from continuing operations. Given the Company's current valuation allowance position, no benefit is expected to result from the reversal of any uncertain tax position associated with the acquired attributes. Unrecognized tax benefits at January 1, 2021 $ 10.2 Reductions for tax positions of prior years (0.3) Settlements (0.4) Unrecognized tax benefits at December 31, 2021 $ 9.5 Reductions as a result of a lapse in statute of limitations (1.3) Foreign exchange fluctuations (0.1) Unrecognized tax benefits at December 31, 2022 $ 8.1 Reductions as a result of a lapse in statute of limitations (0.3) Foreign exchange fluctuations 0.2 Unrecognized tax benefits at December 31, 2023 $ 8.0 |
Equity Incentive Program
Equity Incentive Program | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Payment Arrangement | 14. Equity Incentive Program The Company maintains equity compensation plans that provide for the issuance of Knowles stock to directors, executive officers, and other employees. The maximum number of shares available for issuance under the plans is 16.1 million, of which 7.1 million were available for future awards at December 31, 2023. The following table summarizes the stock-based compensation expense recognized by the Company for the periods presented: Years Ended December 31, (in millions) 2023 2022 2021 Pre-tax stock-based compensation expense Cost of goods sold $ 2.1 $ 1.6 $ 1.6 Research and development expenses 5.9 5.6 5.5 Selling and administrative expenses 21.0 21.4 25.0 Total pre-tax stock-based compensation expense 29.0 28.6 32.1 Tax benefit 3.3 4.4 5.1 Total stock-based compensation expense, net of tax $ 25.7 $ 24.2 $ 27.0 Compensation expense for stock-based awards is measured based on the fair value of the awards as of the date the stock-based awards are granted and adjusted to the estimated number of awards that are expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. Compensation costs for stock-based awards are amortized over their service period. Stock Option s and SSARs The fair value of stock options granted by the Company was estimated on the date of grant using a Black-Scholes option-pricing model based on the assumptions shown in the table below. No stock options were granted during the year ended December 31, 2023. Years Ended December 31, 2022 2021 Risk-free interest rate 0.85% 0.06% Dividend yield —% —% Expected life (years) 4.5 4.5 Volatility 34.3% 36.0% Fair value at date of grant $6.29 $6.14 to $6.31 Expected volatilities are based on the historical volatility of the Company’s stock. The risk-free interest rate is based on U.S. government issues with a remaining term equal to the expected life of the stock options. The expected term is the period over which our employees are expected to hold their options. It is based on the simplified method from the SEC’s safe harbor guidelines. The Company does not currently anticipate paying dividends over the expected term. The exercise price per share for the stock options granted by the Company was equal to the closing price of Knowles' stock on the NYSE on the date of the grant. The period during which options granted by the Company were exercisable was fixed by Knowles' Compensation Committee of the Board of Directors at the time of grant. Generally, stock options vest one-third on each of the first three anniversaries of the grant date and expire seven years from the grant date. The following table summarizes the Company's stock-settled stock appreciation right ("SSAR") and stock option activity for the year ended December 31, 2023. SSARs Stock Options Number of Shares Weighted-Average Exercise Price Aggregate Intrinsic Value Weighted-Average Remaining Contractual Term (Years) Number of Shares Weighted-Average Exercise Price Aggregate Intrinsic Value Weighted-Average Remaining Contractual Term (Years) (in millions, except share and per share amounts) Outstanding at December 31, 2022 223,564 $ 23.92 2,703,424 $ 16.28 Exercised — — (536,771) 12.47 Forfeited — — (12,684) 20.97 Expired (223,564) 23.92 (49,613) 19.49 Outstanding at December 31, 2023 — $ — $ — 0.0 2,104,356 $ 17.15 $ 3.3 2.3 Exercisable at December 31, 2023 — $ — $ — 0.0 1,947,845 $ 16.84 $ 3.3 2.0 The aggregate intrinsic value in the table above represents the difference between the Company's closing stock price on December 31, 2023 and the exercise price of each SSAR and stock option, multiplied by the number of in-the-money awards. There was no unrecognized compensation expense related to SSARs at December 31, 2023. Unrecognized compensation expense related to stock options not yet exercisable at December 31, 2023 was $0.4 million. This cost is expected to be recognized over a weighted-average period of 0.8 years. Other information regarding the exercise of SSARs and stock options is listed below: Years Ended December 31, (in millions) 2023 2022 2021 SSARs Aggregate intrinsic value of SSARs exercised $ — $ 0.1 $ 0.1 Stock Options Cash received by Knowles for exercise of stock options $ 1.6 $ 7.5 $ 25.6 Aggregate intrinsic value of stock options exercised 2.9 6.0 6.6 Tax benefit from stock options exercised 0.6 1.2 1.2 RSUs The following table summarizes the Company's RSU activity for the year ended December 31, 2023: Share units Weighted-average grant date fair value Unvested at December 31, 2022 1,880,521 $ 19.96 Granted 1,267,642 18.78 Vested (1) (901,320) 19.40 Forfeited (171,836) 19.82 Unvested at December 31, 2023 2,075,007 $ 19.49 (1) The number of RSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements. RSUs vest based on the passage of time. Generally, RSUs have a three year vesting schedule and vest one-third on each of the first three anniversaries of the grant date. The fair value of RSUs vested during the year ended December 31, 2023 was $15.8 million. At December 31, 2023, $21.5 million of unrecognized compensation expense related to RSUs is expected to be recognized over a weighted-average period of 1.5 years. PSUs The Company grants PSUs to senior management. In each case, the awards will cliff vest three years following the grant date. PSUs will be settled in shares of the Company's common stock. Depending on the Company's overall performance relative to the applicable measures, the size of the PSU awards are subject to adjustment, up or down, resulting in awards at the end of the performance period that can range from 0% to 225% of target. The Company will ratably recognize the expense over the applicable service period for each grant of PSUs and adjust the expense for the expected achievement of performance conditions as appropriate. The fair value of PSUs is determined by using a Monte Carlo simulation. For the awards granted in February 2023, 2022, and 2021, the number of PSUs that may be earned and vest is based on total shareholder return (“TSR”) relative to the component companies of the Russell 2000 Index over a three-year performance period. The COVID-19 pandemic brought on unique and unprecedented challenges to the Company, particularly in the hearing health and medtech markets. Many of the Company's executive compensation programs were affected, including outstanding PSU awards. Due to the impact of the COVID-19 pandemic on the Company’s overall business performance, effective February 8, 2021, the Company’s Compensation Committee approved certain modifications to PSUs granted in February 2018, 2019, and 2020. For the awards granted in February 2018 (the “2018 PSUs”), the number of PSUs that may be earned and vest was originally based on the Company’s revenues and stock price performance over a three-year performance period. The modified award was based on the Company’s revenues and stock price performance over three separate one-year performance periods to isolate the impact of the COVID-19 pandemic on the Company's fiscal 2020 performance. In addition, the performance periods corresponding to fiscal 2018 and 2019 were weighted at 25% each while the performance period corresponding to fiscal 2020 was weighted at 50%, given the impact of fiscal 2020 performance on shareholders. Service conditions were not modified. The modification of the 2018 PSUs affected nine employees and resulted in total incremental compensation expense of $3.9 million, which was recognized in the first quarter of 2021 as there was no remaining service period. In February 2021, the 2018 PSUs were converted from 329,092 PSUs to 190,544 shares of common stock based on achievement of the modified conditions. For the awards granted in February 2019 (the “2019 PSUs”), the number of PSUs that may be earned and vest was originally based on the Company's revenues and TSR relative to the component companies of the S&P Semiconductor Select Industry Index over a three-year performance period. The modified award was based on the Company’s revenues and TSR relative to the component companies of the S&P Semiconductor Select Industry Index over three separate one-year performance periods to isolate the impact of the COVID-19 pandemic on the Company's fiscal 2020 performance. Each period was weighted equally, as the Company expected to face challenges related to the COVID-19 pandemic in fiscal 2021. Service conditions were not modified. The modification of the 2019 PSUs affected eight employees and resulted in total incremental compensation expense of $2.4 million, which was recognized over the remaining service period. Incremental compensation expense was subject to adjustment for the achievement of the performance condition based on fiscal 2021 revenues. In February 2022, the 2019 PSUs were converted from 227,812 PSUs to 150,811 shares of common stock based on achievement of the modified conditions. For the awards granted in February 2020 (the “2020 PSUs”), the number of PSUs that may be earned and vest was originally based on TSR relative to the component companies of the S&P Semiconductor Select Industry Index over a three-year performance period. The modified award replaces the S&P Semiconductor Select Industry Index with the Russell 2000 Index. The Company is a member of the Russell 2000 Index, which represents a broader, more diversified index that better aligns with the Company's strategy. Service conditions were not modified. The modification of the 2020 PSUs affected eight employees and resulted in total incremental compensation expense of $4.7 million, which will be recognized over the remaining service period. In February 2023, the 2020 PSUs were converted from 261,770 PSUs to 120,677 shares of common stock based on achievement of the modification conditions The following table summarizes the Company's PSU activity for the year ended December 31, 2023: Share units Weighted-average grant date fair value Unvested at December 31, 2022 833,589 $ 25.12 Granted 330,055 29.35 Vested (1) (261,770) 16.14 Forfeited (37,125) 29.20 Unvested at December 31, 2023 864,749 $ 29.28 (1) The number of PSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements. The fair value of PSUs vested during the year ended December 31, 2023 was $2.3 million. At December 31, 2023, $9.9 million of unrecognized compensation expense related to PSUs is expected to be recognized over a weighted-average period of 1.2 years. |
Commitments and Contingent Liab
Commitments and Contingent Liabilities | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingent Liabilities | 15. Commitments and Contingent Liabilities From time to time, the Company is involved in various legal proceedings and claims arising in the ordinary course of its business. The majority of these claims and proceedings relate to commercial, warranty, employment, and intellectual property matters. Although the ultimate outcome of any legal proceeding or claim cannot be predicted with certainty, based on present information, including management’s assessment of the merits of the particular claim, the Company believes that the disposition of these legal proceedings or claims, individually or in the aggregate, after taking into account recorded accruals and the availability and limits of insurance coverage, will not have a material adverse effect on its cash flow, results of operations, or financial condition. The Company owns many patents and other intellectual property pertaining to its products, technology, and manufacturing processes. Some of the Company's patents have been and may continue to be infringed upon or challenged by others. In appropriate cases, the Company has taken and will take steps to protect and defend its patents and other intellectual property, including through the use of legal proceedings in various jurisdictions around the world. Such steps have resulted in and may continue to result in retaliatory legal proceedings, including litigation or other legal proceedings in various jurisdictions and forums around the world alleging infringement by the Company of patents owned by others. The costs of investigations and legal proceedings relating to the enforcement and defense of the Company’s intellectual property may be substantial. Additionally, in multi-forum disputes, the Company may incur adverse judgments with regard to certain claims in certain jurisdictions and forums while still contesting other related claims against the same opposing party in other jurisdictions and forums. Intellectual Property Infringement Claims The Company may, on a limited customer specific basis, provide contractual indemnities for certain losses that arise out of claims that its products infringe on the intellectual property of others. It is not possible to determine the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Historically, the Company has not made significant payments under such indemnity arrangements. The Company’s legal accruals associated with these indemnity arrangements were not significant at December 31, 2023 and 2022. |
Employee Benefit Plans (Notes)
Employee Benefit Plans (Notes) | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | 16. Employee Benefit Plans Knowles sponsors its own defined contribution plans. The Company's expense relating to defined contribution plans was $7.1 million, $6.9 million, and $6.2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Knowles sponsors four defined benefit pension plans to certain non-U.S. employees. The two plans in the U.K. and the plan in Taiwan are closed to new participants; however, all active participants in these plans continue to accrue benefits. The plan in the Philippines is open to new participants. These plans are considered direct obligations of the Company and have been recorded within the accompanying Consolidated Financial Statements. Non-U.S. Defined Benefit Pension Plans Obligations and Funded Status The following tables summarize the balance sheet impact, including the benefit obligations, assets, and funded status associated with the Company's four defined benefit plans for non-U.S. participants at December 31, 2023 and 2022. December 31, (in millions) 2023 2022 Change in benefit obligation: Benefit obligation at beginning of year $ 41.8 $ 69.5 Service cost 0.2 0.3 Interest cost 2.0 1.1 Benefits paid (3.1) (1.9) Actuarial loss gain (1) 0.4 (23.5) Plan amendments — 0.2 Currency translation and other (2) 2.2 (3.9) Benefit obligation at end of year 43.5 41.8 Change in plan assets: Fair value of plan assets at beginning of year 41.3 69.3 Actual return on plan assets 1.8 (20.1) Company contributions 1.0 1.2 Benefits paid (3.1) (1.9) Currency translation and other 2.1 (7.2) Fair value of plan assets at end of year 43.1 41.3 Funded status $ (0.4) $ (0.5) Amounts recognized in the Consolidated Balance Sheets consist of: Other assets and deferred charges $ 3.4 $ 3.4 Other liabilities (3.8) (3.9) Funded status $ (0.4) $ (0.5) Accumulated other comprehensive loss: Net actuarial losses $ 18.1 $ 17.9 Prior service cost 1.2 1.2 Deferred taxes (2.9) (2.7) Total accumulated other comprehensive loss, net of tax 16.4 16.4 Accumulated benefit obligation $ 42.7 $ 41.1 (1) The net actuarial gains during the year ended December 31, 2022 primarily related to changes in the discount rates for the U.K. plans. (2) The Company recorded an increase in liabilities of $3.4 million related to pre-spin-off pension obligations during the year ended December 31, 2022. Pension plans with projected benefit obligations in excess of plan assets consisted of the following at December 31, 2023 and 2022: December 31, (in millions) 2023 2022 Projected benefit obligation $ 25.1 $ 24.5 Fair value of plan assets 21.3 20.6 Pension plans with accumulated benefit obligations in excess of plan assets consisted of the following at December 31, 2023 and 2022: December 31, (in millions) 2023 2022 Accumulated benefit obligation $ 24.9 $ 24.5 Fair value of plan assets 21.3 20.6 Net Periodic Benefit Cost (Income) Components of the net periodic benefit cost (income) were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Service cost $ 0.2 $ 0.3 $ 0.3 Interest cost 2.0 1.1 0.9 Expected return on plan assets (2.1) (2.6) (2.8) Amortization of prior service cost 0.1 — — Amortization of recognized actuarial loss 0.5 0.5 0.8 Other (1) — 3.4 — Total net periodic benefit cost (income) $ 0.7 $ 2.7 $ (0.8) (1) The Company recorded an adjustment of $3.4 million related to pre-spin-off pension obligations during the year ended December 31, 2022. The components of net periodic benefit cost (income) other than service cost are presented in the Other (income) expense, net line on the Consolidated Statements of Earnings. The service cost component is presented within the Cost of goods sold, Research and development expenses, and Selling and administrative expenses lines on the Consolidated Statements of Earnings based on the nature of services performed by the related employees. Assumptions The Company determines actuarial assumptions on an annual basis. The actuarial assumptions used for the Company’s four defined benefit plans for non-U.S. participants will vary depending on the applicable country and as such, the tables below include these assumptions by country, as well as in total. The assumptions used in determining the benefit obligations were as follows: December 31, 2023 2022 Discount rate Philippines 6.20 % 7.50 % Taiwan 1.50 % 1.75 % United Kingdom 4.60 % 4.84 % Weighted-average 4.47 % 4.71 % Average wage increase Philippines 4.00 % 4.00 % Taiwan 4.00 % 4.00 % United Kingdom 4.20 % 4.35 % Weighted-average 4.17 % 4.30 % The assumptions used in determining the net periodic benefit cost (income) were as follows: Years Ended December 31, 2023 2022 2021 Discount rate Philippines 7.50 % 5.25 % 4.00 % Taiwan 1.75 % 0.75 % 0.25 % United Kingdom 4.84 % 1.84 % 1.28 % Weighted-average 4.71 % 1.83 % 1.27 % Average wage increase Philippines 4.00 % 4.00 % 4.00 % Taiwan 4.00 % 4.00 % 4.00 % United Kingdom 4.35 % 4.65 % 4.20 % Weighted-average 4.30 % 4.59 % 4.18 % Expected return on plan assets Philippines 7.50 % 5.90 % * Taiwan 1.75 % 4.00 % 3.50 % United Kingdom 5.17 % 4.15 % 4.34 % Weighted-average 5.00 % 4.15 % 4.32 % * The Philippines plan was unfunded at the beginning of 2021; therefore, no assumption for the expected return on plan assets was made at that time. The Company’s discount rate assumptions are determined by developing yield curves based on high quality corporate bonds with maturities matching the plans’ expected benefit payment streams. The plans’ expected cash flows are then discounted by the resulting year-by-year spot rates. Plan Assets The primary financial objective of the plans is to secure participant retirement benefits. Accordingly, the key objective in the plans’ financial management is to promote stability and, to the extent appropriate, growth in the funded status. Related and supporting financial objectives are established in conjunction with a review of current and projected plan financial requirements. As it relates to the funded defined benefit pension plans, the Company’s funding policy is consistent with the funding requirements of applicable local non-U.S. laws. The Company is responsible for overseeing the management of the investments of the plans’ assets and otherwise ensuring that the plans’ investment programs are in compliance with applicable local law, other relevant legislation, and related plan documents. Where relevant, the Company has retained professional investment managers to manage the plans’ assets and investment process. The investment managers, in executing their investment processes, have the authority and responsibility to select appropriate investments in the asset classes specified by the terms of their applicable prospectus or investment manager agreements with the plans. The assets of the plans are invested to achieve an appropriate return for the plans consistent with a prudent level of risk. The asset return objective is to achieve, as a minimum over time, the passively managed return earned by market index funds, weighted in the proportions outlined by the asset class exposures identified in the plans’ strategic allocation. The expected return on plan assets assumptions are developed through analysis of historical market returns, statistical analysis, current market conditions, and the past experience of plan asset investments. Fair Value Measurements The fair values of plan assets by asset category within the ASC 820 hierarchy were as follows at December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in millions) Level 1 Level 2 Level 3 Total Fair Value Level 1 Level 2 Level 3 Total Fair Value Asset category: Fixed income investments $ 3.5 $ 17.8 $ — $ 21.3 $ 3.3 $ 16.7 $ — $ 20.0 Common stock funds — 6.3 — 6.3 — 6.1 — 6.1 Real estate funds — 4.1 — 4.1 — 4.1 — 4.1 Cash and equivalents 1.7 — — 1.7 1.4 — — 1.4 Other 3.4 6.3 — 9.7 4.1 5.6 — 9.7 Total $ 8.6 $ 34.5 $ — $ 43.1 $ 8.8 $ 32.5 $ — $ 41.3 See Note 11. Hedging Transactions and Derivative Instruments for additional information on the fair value hierarchy. There were no significant transfers between Level 1 and Level 2 assets during the years ended December 31, 2023 and 2022. Fixed income investments include government and municipal securities and corporate bonds, which are valued based on yields currently available on comparable securities of issuers with similar credit ratings. Common stock funds consist of mutual funds and collective trusts. Mutual funds are valued by obtaining quoted prices from nationally recognized securities exchanges. Collective trusts are valued using Net Asset Value (the "NAV") as of the last business day of the year. The NAV is based on the underlying value of the assets owned by the fund minus its liabilities and then divided by the number of shares outstanding. The value of the underlying assets is based on quoted prices in active markets. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. Future Estimates Benefit Payments Estimated future benefit payments to retirees, which reflect expected future service, are as follows: (in millions) 2024 $ 2.2 2025 2.4 2026 2.6 2027 2.9 2028 2.6 2029-2033 13.5 Contributions Generally, annual contributions are made at such times and in such amounts as required by law and agreed with the trustees of the non-U.S. defined benefit plans. The Company estimates it will pay $1.0 million during the year ended December 31, 2024 related to contributions to these plans. This amount may vary based on updated funding agreements with the trustees of these plans. |
Other Comprehensive (Loss) Earn
Other Comprehensive (Loss) Earnings | 12 Months Ended |
Dec. 31, 2023 | |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | |
Other Comprehensive (Loss) Earnings | 17. Other Comprehensive Earnings The amounts recognized in other comprehensive (loss) earnings were as follows: Year Ended December 31, 2023 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (6.1) $ — $ (6.1) Employee benefit plans (0.1) 0.2 0.1 Changes in fair value of cash flow hedges (2.3) 0.6 (1.7) Total other comprehensive loss $ (8.5) $ 0.8 $ (7.7) Year Ended December 31, 2022 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (23.2) $ — $ (23.2) Employee benefit plans 1.4 (0.6) 0.8 Changes in fair value of cash flow hedges 1.1 (0.4) 0.7 Total other comprehensive loss $ (20.7) $ (1.0) $ (21.7) Year Ended December 31, 2021 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (3.6) $ — $ (3.6) Employee benefit plans 6.6 (1.6) 5.0 Changes in fair value of cash flow hedges (1.6) 0.3 (1.3) Total other comprehensive earnings $ 1.4 $ (1.3) $ 0.1 The following table summarizes the changes in balances of each component of accumulated other comprehensive loss, net of tax during the years ended December 31, 2023 and 2022: (in millions) Cash flow hedges Employee benefit plans Cumulative foreign currency translation adjustments Total Balance at January 1, 2022 $ 0.3 $ (17.1) $ (83.6) $ (100.4) Other comprehensive earnings (loss), net of tax 0.7 0.8 (23.2) (21.7) Balance at December 31, 2022 1.0 (16.3) (106.8) (122.1) Other comprehensive (loss) earnings, net of tax (1.7) 0.1 (6.1) (7.7) Balance at December 31, 2023 $ (0.7) $ (16.2) $ (112.9) $ (129.8) The following table summarizes the amounts reclassified from accumulated other comprehensive loss to earnings: Years Ended December 31, (in millions) Statement of Earnings Line 2023 2022 2021 Pension and post-retirement benefit plans: Amortization or settlement of actuarial losses and prior service costs Other expense (income), net $ 0.6 $ 0.6 $ 0.9 Tax (Benefit from) provision for income taxes (0.1) (0.1) (0.2) Net of tax $ 0.5 $ 0.5 $ 0.7 Cash flow hedges: Net losses (gains) reclassified into earnings Cost of goods sold $ 2.7 $ 4.5 $ (2.1) Tax (Benefit from) provision for income taxes (0.5) (1.0) 0.5 Net of tax $ 2.2 $ 3.5 $ (1.6) |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | 18. Segment Information The Company determines its operating segments consistent with the manner in which it manages its operations and evaluates performance for internal review and decision making. These operating segments were determined in accordance with ASC 280, Segment Reporting. The Company’s operating segments engage in business activities from which they earn revenues and incur expenses, have discrete financial information available, and whose financial results are regularly reviewed and used by the chief operating decision maker to evaluate segment performance, allocate resources, and determine management incentive compensation. In November 2022, the Company determined each operating segment represents a single reportable operating segment, as described below: • PD Segment Our PD segment specializes in the design and delivery of high performance capacitor products and RF solutions for technically demanding applications. Our high performance capacitor products are used in applications such as power supplies and medical implants, which sell to a diverse set of customers for mission critical applications across the defense, medtech, industrial, electric vehicle, and communications markets. Our RF solutions solve a broad range of frequency filtering challenges for our customers, who use them in satellite communications and radar systems for defense applications. PD has sales, support, and engineering facilities in North America, Europe, and Asia as well as manufacturing facilities in North America and Asia. • MSA Segment Our MSA segment designs and manufactures innovative audio products, including microphones and balanced armature speakers used in applications that serve the hearing health and premium audio markets. MSA has sales, support, and engineering facilities in North America, Europe, and Asia, as well as manufacturing facilities in Asia. • CMM Segment Our CMM segment designs and manufactures innovative audio products, including MEMS and audio solutions used in applications that serve the mobile, True Wireless Stereo ("TWS"), Internet of Things ("IoT"), and computing markets. CMM has sales, support, and engineering facilities in North America, Europe, and Asia, as well as manufacturing facilities in Asia. Information regarding the Company's reportable segments is as follows: Years Ended December 31, (in millions) 2023 2022 2021 Revenues: Precision Devices $ 221.4 $ 242.9 $ 201.1 MedTech & Specialty Audio 230.0 229.9 231.3 Consumer MEMS Microphones 256.2 291.9 435.7 Total revenues $ 707.6 $ 764.7 $ 868.1 Earnings (loss) from continuing operations before interest and income taxes: Precision Devices $ 25.0 $ 56.1 $ 43.7 MedTech & Specialty Audio 85.2 84.6 77.0 Consumer MEMS Microphones 13.6 (504.5) 60.0 Total segments 123.8 (363.8) 180.7 Corporate expense / other 73.4 50.5 61.9 Interest expense, net 5.4 3.9 14.2 Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Depreciation and amortization: Precision Devices $ 15.8 $ 13.8 $ 13.3 MedTech & Specialty Audio 8.2 8.1 6.3 Consumer MEMS Microphones 20.3 29.5 39.9 Corporate 2.2 2.5 3.0 Total $ 46.5 $ 53.9 $ 62.5 Capital expenditures: Precision Devices $ 7.6 $ 7.4 $ 5.6 MedTech & Specialty Audio 4.6 7.3 11.6 Consumer MEMS Microphones 4.7 17.2 29.2 Corporate — 0.2 2.2 Total $ 16.9 $ 32.1 $ 48.6 Research and development: Precision Devices $ 13.8 $ 12.3 $ 10.5 MedTech & Specialty Audio 18.2 16.9 16.1 Consumer MEMS Microphones 46.1 52.4 65.7 Corporate 0.4 0.1 0.5 Total $ 78.5 $ 81.7 $ 92.8 Information regarding assets of the Company's reportable segments: Total Assets December 31, (in millions) 2023 2022 Precision Devices $ 577.9 $ 275.7 MedTech & Specialty Audio 351.1 358.1 Consumer MEMS Microphones 530.0 547.3 Corporate / eliminations 3.8 2.8 Total $ 1,462.8 $ 1,183.9 The following table details revenues by geographic location. Revenues are attributed to regions based on the location of the Company's direct customer, which in some instances is an intermediary and not necessarily the end user. Long-lived assets are comprised of net property, plant, and equipment and operating lease right-of-use assets. These assets have been classified based on the geographic location of where they reside. The Company's businesses are based primarily in Asia, North America, and Europe. Revenues Long-Lived Assets Years Ended December 31, December 31, (in millions) 2023 2022 2021 2023 2022 Asia $ 426.1 $ 471.3 $ 611.5 $ 91.9 $ 110.5 United States 161.4 174.3 153.2 90.1 60.5 Europe 101.5 104.4 93.5 3.7 2.4 Other Americas 7.1 7.5 5.5 2.8 1.0 Other 11.5 7.2 4.4 — — Total $ 707.6 $ 764.7 $ 868.1 $ 188.5 $ 174.4 The Company's customers that accounted for 10% or more of total revenues were as follows: Revenues Years Ended December 31, 2023 2022 2021 Apple Inc. 16 % 15 % 16 % WS Audiology A/S 10 % * * |
Earnings per Share
Earnings per Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings per Share | 19. Earnings per Share Basic and diluted earnings per share were computed as follows: Years Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Earnings from discontinued operations, net — — 0.2 Net earnings (loss) $ 72.4 $ (430.1) $ 150.4 Basic earnings (loss) per common share: Earnings (loss) from continuing operations $ 0.80 $ (4.69) $ 1.63 Earnings from discontinued operations, net — — — Net earnings (loss) $ 0.80 $ (4.69) $ 1.63 Weighted-average shares outstanding 90.9 91.7 92.3 Diluted earnings (loss) per common share: Earnings (loss) from continuing operations $ 0.79 $ (4.69) $ 1.59 Earnings from discontinued operations, net — — — Net earnings (loss) $ 0.79 $ (4.69) $ 1.59 Diluted weighted-average shares outstanding 91.6 91.7 94.7 For the years ended December 31, 2023, 2022, and 2021, the weighted-average number of anti-dilutive potential common shares for stock-based awards excluded from the calculation of diluted earnings per share above was 1.9 million, 3.4 million, and 0.7 million, respectively. |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2023 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II - Valuation and Qualifying Account | SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Years Ended December 31, 2023, 2022, and 2021 Allowance for Doubtful Accounts (in millions) Balance at Charged to Cost and (1) Accounts Balance at Year Ended December 31, 2023 Allowance for Doubtful Accounts $ 1.1 — (0.9) $ 0.2 Year Ended December 31, 2022 Allowance for Doubtful Accounts $ 0.2 1.0 (0.1) $ 1.1 Year Ended December 31, 2021 Allowance for Doubtful Accounts $ 1.6 (0.2) (1.2) $ 0.2 (1) Net of recoveries on previously reserved or written-off balances. Deferred Tax Valuation Allowance (in millions) Balance at Additions Reductions Balance at Year Ended December 31, 2023 Deferred Tax Valuation Allowance $ 39.7 0.9 (15.1) $ 25.5 Year Ended December 31, 2022 Deferred Tax Valuation Allowance $ 39.1 0.6 — $ 39.7 Year Ended December 31, 2021 Deferred Tax Valuation Allowance $ 98.0 — (58.9) $ 39.1 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net earnings (loss) | $ 72.4 | $ (430.1) | $ 150.4 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Basis of Accounting | Financial Statement Presentation - The Consolidated Financial Statements included in this Annual Report on Form 10-K are presented in conformity with U.S. generally accepted accounting principles ("U.S. GAAP"). | |
Use of Estimates | Use of Estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and disclosures. These estimates may be adjusted due to changes in future economic, industry, or customer financial conditions, as well as changes in technology or demand. Estimates are used in accounting for, among other items, inventory reserves, restructuring reserves, warranty reserves, pension and post-retirement plans, stock-based compensation, useful lives for depreciation and amortization of long-lived assets, future cash flows associated with impairment testing for goodwill, indefinite-lived intangible assets and other long-lived assets, deferred tax assets, uncertain income tax positions, changes in tax laws, and contingencies. Management uses historical experience and all available information to make these estimates. Actual results may ultimately differ from estimates, although management does not believe such differences would materially affect the financial statements in any individual year. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the Consolidated Financial Statements in the period that they are determined. | |
Cash and Cash Equivalents | Cash and Cash Equivalents - Cash and cash equivalents include cash on hand, demand deposits, and temporary cash investments with original maturities less than three months. | |
Allowance for Doubtful Accounts | Allowance for Doubtful Accounts – The Company maintains allowances for estimated losses as a result of customers' inability to make required payments. Management evaluates the aging of the accounts receivable balances, the financial condition of its customers, historical trends, relevant forecasts, and the time outstanding of specific balances to estimate the amount of accounts receivable that may not be collected in the future and records the appropriate provision. | |
Inventories | Inventories – Inventories are stated at the lower of cost or net realizable value, determined on the first-in, first-out ("FIFO") basis. The value of inventory may decline as a result of surplus inventory, price reductions, or technological obsolescence. It is the Company’s policy to carry reserves against the carrying value of inventory when items have no future demand (obsolete inventory) and additionally, where inventory items on hand have demand, yet have insufficient forecasted activity to consume the entire stock within a reasonable period. The Company recognizes reserves against the carrying value of such at-risk inventory items after considering the nature of the risk and any mitigating factors. | |
Property, Plant and Equipment | Property, Plant, and Equipment | |
Lessee, Leases | Leases - The Company determines whether an arrangement is a lease at contract inception. Lease liabilities and right-of-use assets are recognized on the lease commencement date based on the net present value of fixed lease payments over the lease term. The Company includes options to extend or terminate a lease within the lease term when it is reasonably certain the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. Lease liabilities represent an obligation to make lease payments arising from a lease while right-of-use assets represent a right to use an underlying asset during the lease term. Right-of-use assets include prepaid fixed lease payments and exclude lease incentives. As the Company's leases do not have a readily determinable implicit rate, the Company uses its incremental borrowing rate to determine the present value of fixed lease payments based on information available at the lease commencement date. Fixed lease expense for operating leases and right-of-use asset amortization for finance leases are generally recognized on a straight-line basis over the lease term. Variable lease payments, such as payments based on an index rate or usage, are expensed as incurred and excluded from lease liabilities and right-of-use assets. The Company combines lease components and nonlease components such as maintenance into a single lease component, which results in the capitalization of all fixed payments within lease liabilities and right-of-use assets. | |
Derivative Instruments | Derivative Instruments - The Company uses derivative financial instruments to hedge its exposure to foreign currency exchange rate risk. The Company does not enter into derivative financial instruments for speculative purposes and does not have a material portfolio of derivative financial instruments. Derivative financial instruments used for hedging purposes must be designated and effective as a hedge of the identified risk exposure at inception of the contract. The Company recognizes all derivatives as either assets or liabilities on the Consolidated Balance Sheets and measures those instruments at fair value. For derivatives designated as cash flow hedges, the effective portion of changes in the fair value of the derivatives is recorded as a component of other comprehensive earnings and subsequently recognized in net earnings when the hedged items impact earnings. | |
Goodwill and Intangible Assets | Goodwill and Indefinite-Lived Intangible Assets - Goodwill represents the excess of purchase consideration over the fair value of the net assets of businesses acquired. Goodwill and certain other intangible assets deemed to have indefinite lives are not amortized. Instead, goodwill and indefinite-lived intangible assets are tested for impairment at least annually, or more frequently if there are events or circumstances indicating the carrying value of individual reporting units or assets may exceed their respective fair values on a more likely than not basis. The Company performs its annual impairment assessment in the fourth quarter of each year on October 1. Recoverability of goodwill is measured at the reporting unit level. The Company has three reporting units - Precision Devices ("PD"), MedTech & Specialty Audio ("MSA"), and Consumer MEMS Microphones ("CMM.") The goodwill balances associated with PD, MSA, and CMM were $132.8 million, $137.7 million, and $270.2 million, respectively, as of December 31, 2023. As discussed in Note 18. Segment Information, in the fourth quarter of 2022, the Company determined that each of its three operating segments represents a single reportable segment (compared to the two reportable segments disclosed previously). The Company had no change in its reporting units as a result of the change in its reportable segments. The impairment assessment compares the fair value of each reporting unit to its carrying value. Impairment is measured as the amount by which the carrying value of a reporting unit exceeds its fair value. Fair value is estimated using a discounted cash flow model that includes the Company’s market participant assumptions, forecasted future cash flows based on historical performance and future estimated results, determinations of appropriate discount rates, and other assumptions which are considered reasonable and inherent in the discounted cash flow analysis. Significant assumptions used in the model included forecasted revenue and terminal growth rates, profit margins, income tax rates, capital expenditures, working capital requirements, and the Company's weighted average cost of capital. These assumptions require significant judgment and actual results may differ from estimated amounts. For the impairment testing conducted as of October 1, 2023, the fair value of the PD and MSA reporting units exceeded their carrying values by at least 180% and the fair value of the CMM reporting unit exceeded its carrying value by approximately 7%. The CMM reporting unit recorded goodwill impairment charges totaling $470.9 million for the year ended December 31, 2022 (see Note 4. Impairment Charges). No goodwill impairment charges were recorded for any reporting unit for the years ended December 31, 2023 or 2021. Potential circumstances that could have a negative effect on the fair value of our reporting units include, but are not limited to, lower than forecasted revenue and terminal growth rates, decreased profit margins, higher income taxes, increased capital expenditures, higher working capital requirements, and changes in the weighted average cost of capital. A reduction in the estimated fair value of the reporting units including due to the potential sale or restructuring of the CMM business, could trigger an impairment in the future. The Company cannot predict the occurrence of certain events or changes in circumstances that might adversely affect the carrying value of goodwill and intangible assets. In testing its indefinite-lived trademarks for impairment, the Company uses a relief from royalty method to calculate and compare the fair value of the intangible asset to its carrying value. This method estimates the fair value of trademarks by calculating the present value of royalty income that could hypothetically be earned by licensing the trademark to a third party. Any excess of carrying value over the estimated fair value is recognized as an impairment loss. No impairment of indefinite-lived trademarks was indicated for the years ended December 31, 2023, 2022, or 2021. See Note 7. Goodwill and Other Intangible Assets for additional information on goodwill and indefinite-lived intangible assets. Other Intangible and Long-Lived Assets - Other intangible assets with determinable lives consist primarily of customer relationships, developed technology, and trademarks, which are amortized over estimated useful lives typically ranging from 5 to 15 years. Long-lived assets and intangible assets with determinable lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an indicator of impairment exists for any grouping of assets, an estimate of undiscounted future cash flows is produced and compared to its carrying value. If an asset is determined to be impaired, the loss is measured by the excess of the carrying amount of the asset over its fair value as determined by an estimate of discounted future cash flows. The Company recorded impairment charges for its long-lived assets of $4.0 million during the year ended December 31, 2021. There were no impairments of long-lived assets recorded during the years ended December 31, 2023 and 2022. See Note 4. Impairment Charges for additional details. | |
Deferred Charges, Policy | Other Assets and Deferred Charges - Investments in mutual funds of $6.2 million and $5.0 million are included in Other assets and deferred charges as of December 31, 2023 and 2022, respectively. These investments are carried at fair value based on quoted prices for identical assets in active markets, resulting in classification within Level 1 of the fair value hierarchy. Gains and losses related to the investments are recorded within the Consolidated Statements of Earnings as a component of Other (income) expense, net. Other assets and deferred charges also include non-current deferred tax assets. | |
Foreign Currency | Foreign Currency - Assets and liabilities of non-U.S. subsidiaries, where the functional currency is not the U.S. dollar, are translated into U.S. dollars at year-end exchange rates. Revenue and expense items are translated using weighted-average exchange rates. Foreign currency translation gains and losses are included as a component of Accumulated other comprehensive loss. Assets and liabilities of an entity that are denominated in currencies other than an entity’s functional currency are re-measured into the functional currency using end of period exchange rates or historical rates where applicable to certain balances. Gains and losses related to these re-measurements are recorded within the Consolidated Statements of Earnings as a component of Other (income) expense, net. | |
Revenue Recognition | Revenue Recognition - Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The majority of the Company’s revenue is generated through the manufacture and sale of a broad range of specialized products and components. For product and component sales, each good sold to a customer typically represents a distinct performance obligation. The Company’s performance obligation to provide goods to a customer is typically satisfied at a point in time upon completion of the shipping process as indicated by the terms of the contract, at which point control is transferred to the customer and revenue is recognized. The Company has no significant arrangements with multiple performance obligations. Remaining performance obligations consist of the aggregate amount of the total transaction price that is unsatisfied or partially satisfied. As of December 31, 2023 and 2022, our total remaining performance obligations were immaterial. The Company recognizes sales-based royalty revenue under third-party license agreements as the related sales are made by licensees. The terms of a contract or historical business practice can give rise to variable consideration, including customer discounts, rebates, and returns. The Company estimates variable consideration using either the expected value or most likely amount method. We include amounts in the transaction price to the extent it is probable that a significant reversal of revenue will not occur in a subsequent reporting period. Our estimates of variable consideration are based on all reasonably available information (historical, current, and forecasted). Rebates are recognized over the contract period based on expected revenue levels. Sales discounts and rebates totaled $4.8 million, $4.4 million, and $5.0 million for the years ended December 31, 2023, 2022, and 2021, respectively. Returns and allowances totaled $4.3 million, $7.1 million, and $4.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. The Company accounts for shipping and handling activities that occur after control of the related good transfers to the customer as fulfillment activities rather than evaluating such activities as performance obligations. As a result, all shipping and handling costs related to contracts with customers are recognized in the Cost of goods sold line on the Consolidated Statements of Earnings. Additionally, the Company applies the practical expedient allowing incremental costs of obtaining a contract to be expensed as incurred if the amortization period of the resulting asset would have been less than one year. These costs primarily consist of sales commissions and the Company has no such significant costs exceeding the one year limit for applying the practical expedient. Receivables, net from contracts with customers were $129.2 million and $125.7 million as of December 31, 2023 and 2022, respectively. See Note 18. Segment Information for disclosures regarding the disaggregation of revenues. | |
Stock-Based Compensation | Stock-Based Compensation – The principal awards issued under the stock-based compensation plans include stock options, restricted stock units ("RSUs"), and performance share units ("PSUs"). The cost for such awards is measured at the grant date based on the fair value of the award. The value of the portion of the award that is expected to ultimately vest is generally recognized as expense on a straight-line basis, generally over the explicit service period and is included in Cost of goods sold, Research and development expenses, and Selling and administrative expenses in the Consolidated Statements of Earnings, depending on the functional area of the underlying employees. At the time of grant, the Company estimates forfeitures, based on historical experience, in order to estimate the portion of the award that will ultimately vest. The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted to employees. The fair value of each RSU granted is equal to the share price at the date of the grant. The fair value of each PSU is determined using a Monte Carlo simulation. The cost related to PSUs with performance conditions is recognized based on the expected attainment of performance targets. Changes in estimates for performance conditions that impact the number of shares expected to vest are recognized prospectively through cumulative adjustments. The cost for PSUs is recognized regardless of the expected attainment of market conditions as the grant date fair value considers the range of possible stock price and total shareholder return outcomes. See Note 14. Equity Incentive Program for additional information related to the Company’s stock-based compensation. | |
Income Taxes | Income Taxes - The Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset and liability method. Under this method, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. The Company offsets and presents deferred tax liabilities and assets, as well as any related valuation allowance, as a single non-current amount on the Consolidated Balance Sheets on a jurisdictional basis. The Company's policy is to release income tax effects from accumulated other comprehensive loss in the period the underlying item expires. The Company establishes valuation allowances for its deferred tax assets if, based on all available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such assessments, significant weight is given to evidence that can be objectively verified. The assessment of the need for a valuation allowance requires considerable judgment on the part of management with respect to the benefits that could be realized from future taxable income, as well as other positive and negative factors. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. The Company recognizes tax benefits from uncertain tax positions only if it believes that it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. Adjustments are made to these reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on the Company's financial condition and operating results. The provision for income taxes includes the effects of any reserves that are believed to be appropriate, as well as the related net interest and penalties. | |
Research and development expense | Research and Development Costs – Research and development costs, including qualifying engineering costs, are expensed when incurred. |
Leases (Policies)
Leases (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Lessee, Leases | Leases - The Company determines whether an arrangement is a lease at contract inception. Lease liabilities and right-of-use assets are recognized on the lease commencement date based on the net present value of fixed lease payments over the lease term. The Company includes options to extend or terminate a lease within the lease term when it is reasonably certain the option will be exercised. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. Lease liabilities represent an obligation to make lease payments arising from a lease while right-of-use assets represent a right to use an underlying asset during the lease term. Right-of-use assets include prepaid fixed lease payments and exclude lease incentives. As the Company's leases do not have a readily determinable implicit rate, the Company uses its incremental borrowing rate to determine the present value of fixed lease payments based on information available at the lease commencement date. Fixed lease expense for operating leases and right-of-use asset amortization for finance leases are generally recognized on a straight-line basis over the lease term. Variable lease payments, such as payments based on an index rate or usage, are expensed as incurred and excluded from lease liabilities and right-of-use assets. The Company combines lease components and nonlease components such as maintenance into a single lease component, which results in the capitalization of all fixed payments within lease liabilities and right-of-use assets. |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Inventory, Net [Abstract] | |
Components of Inventory | The following table details the major components of inventories, net: (in millions) December 31, 2023 December 31, 2022 Raw materials $ 140.3 $ 116.1 Work in progress 36.7 28.3 Finished goods 63.0 62.8 Subtotal 240.0 207.2 Less reserves (43.6) (37.7) Total $ 196.4 $ 169.5 |
Property, Plant and Equipment_2
Property, Plant and Equipment, net (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Components of property, plant and equipment, net | (in millions) December 31, 2023 December 31, 2022 Land $ 14.3 $ 12.5 Buildings and improvements 122.5 114.6 Machinery, equipment, and other 518.2 531.2 Subtotal 655.0 658.3 Less accumulated depreciation (479.6) (496.5) Total $ 175.4 $ 161.8 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | The changes in the carrying value of goodwill by reportable segment for the years ended December 31, 2023 and 2022 are as follows: (in millions) Precision Devices MedTech & Specialty Audio Consumer MEMS Microphones Total Balance at January 1, 2022 $ 62.5 $ 137.7 $ 741.1 $ 941.3 Impairment charges (1) — — (470.9) (470.9) Purchase price adjustment 0.7 — — 0.7 Foreign currency translation — — (0.1) (0.1) Balance at December 31, 2022 63.2 137.7 270.1 471.0 Acquisition 69.6 — — 69.6 Foreign currency translation — — 0.1 0.1 Balance at December 31, 2023 $ 132.8 $ 137.7 $ 270.2 $ 540.7 (1) During the year ended December 31, 2022 the Company recorded total goodwill impairment charges of $470.9 million. See Note 4. Impairment Charges for more information. |
Schedule of Future Amortization Expense | Amortization expense for the next five years and thereafter, based on current definite-lived intangible balances, is estimated to be as follows: (in millions) 2024 $ 23.1 2025 22.5 2026 16.6 2027 16.6 2028 15.8 2029 and thereafter 62.8 Total $ 157.4 |
Schedule Of Carrying Values Of Finite And Indefinite Lived Intangible Assets | The gross carrying value and accumulated amortization for each major class of intangible assets are as follows: December 31, 2023 December 31, 2022 (in millions) Gross Carrying Accumulated Gross Carrying Accumulated Amortized intangible assets: Trademarks $ 16.0 $ 1.2 $ 2.0 $ 0.8 Customer relationships 121.1 16.0 36.4 10.3 Developed technology 64.5 27.4 45.4 20.1 Other 2.4 2.0 2.4 1.9 Total 204.0 46.6 86.2 33.1 Unamortized intangible assets: Trademarks 32.0 32.0 Total intangible assets, net $ 189.4 $ 85.1 In connection with the acquisition of CD in 2023, the Company recognized customer relationships of $82.7 million, developed technology of $19.1 million, and trademarks of $14.0 million. See also Note 3. Acquisitions. The Company completed an asset acquisition in 2023. In connection with this acquisition, the Company recognized customer relationships with a fair value of approximately $2.0 million, reflecting cash paid of $0.3 million and contingent consideration with an estimated fair value of $1.7 million. These customer relationships have an estimated useful life of 7 years. |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Lease, Cost [Table Text Block] | The following table details the components of lease cost: Years Ended December 31, (in millions) 2023 2022 2021 Operating lease cost (1) $ 7.9 $ 8.2 $ 9.9 Finance lease cost: Amortization of right-of-use assets 2.3 2.3 2.3 Interest on lease liabilities 0.2 0.3 0.4 Sublease income (3.3) (3.5) (3.0) Total lease cost $ 7.1 $ 7.3 $ 9.6 (1) Includes short-term and variable lease costs, which were immaterial. |
Schedule of Lease Assets and Liabilities [Table Text Block] | The following table presents supplemental balance sheet information related to finance leases: (in millions) Balance Sheet Line December 31, 2023 December 31, 2022 Finance lease right-of-use assets Property, plant, and equipment, net $ 3.4 $ 5.3 Current finance lease liabilities Other accrued expenses $ 1.6 $ 2.5 Long-term finance lease liabilities Other liabilities 0.6 1.4 Total finance lease liabilities $ 2.2 $ 3.9 |
Schedule of Lease Payments [Table Text Block] | The following table presents supplemental cash flow information related to leases: Years Ended December 31, (in millions) 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.1 $ 12.4 $ 10.2 Operating cash flows from finance leases 0.2 0.3 0.4 Financing cash flows from finance leases 2.5 4.8 2.3 Lease liabilities arising from obtaining right-of-use assets: (2) Operating leases $ 2.6 $ 2.0 $ 6.5 Finance leases 0.7 0.4 0.3 |
Finance Lease, Liability, Maturity [Table Text Block] | The following table details weighted-average remaining lease terms and discount rates: December 31, 2023 December 31, 2022 Weighted-average remaining lease term (in years): Operating leases 3.3 2.5 Finance leases 2.5 2.2 Weighted-average discount rate: Operating leases 5.0 % 3.4 % Finance leases 5.6 % 5.3 % |
Schedule of Maturities of Lease liabilities [Table Text Block] | The following table details maturities of lease liabilities as of December 31, 2023: (in millions) Operating Leases Finance Leases 2024 $ 5.5 $ 1.6 2025 3.3 0.4 2026 2.4 0.2 2027 2.1 0.1 2028 1.0 — 2029 and thereafter 0.2 — Total lease payments 14.5 2.3 Less interest (1.2) (0.1) Present value of lease liabilities $ 13.3 $ 2.2 |
Accrued Expenses and Other Li_2
Accrued Expenses and Other Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accrued Liabilities and Other Liabilities [Abstract] | |
Schedule of Accrued Expenses | The following table details the major components of other accrued expenses: (in millions) December 31, 2023 December 31, 2022 Restructuring and exit costs $ 8.5 $ 4.0 Sales volume rebates 3.6 4.0 Accrued taxes other than income taxes 2.4 1.8 Accrued insurance 2.0 1.6 Current finance lease liabilities 1.6 2.5 Current hedging liability 0.7 0.8 Warranty 0.7 0.4 Other 5.5 4.8 Total $ 25.0 $ 19.9 |
Schedule of Other Noncurrent Liabilities | The following table details the major components of other liabilities: (in millions) December 31, 2023 December 31, 2022 Deferred compensation, including defined benefit plans $ 13.6 $ 12.9 Restructuring and exit costs 10.7 18.7 Unrecognized tax benefits 2.3 2.5 Unearned/deferred revenue 1.7 2.5 Long-term finance lease liabilities 0.6 1.4 Long-term hedging liability 0.4 — Other 1.8 0.8 Total $ 31.1 $ 38.8 |
Schedule of Product Warranty Liability | The changes in the carrying amount of product warranties were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Beginning balance, January 1 $ 0.4 $ 0.5 $ 0.4 Provision for warranties 0.5 0.6 1.0 Settlements made (0.4) (0.5) (0.9) Other adjustments, including currency translation (1) 0.2 (0.2) — Ending balance, December 31 $ 0.7 $ 0.4 $ 0.5 |
Restructuring and Related Act_2
Restructuring and Related Activities (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring and Related Costs | The following table details restructuring charges incurred by reportable segment for the periods presented: Years Ended December 31, (in millions) 2023 2022 2021 Precision Devices $ 2.5 $ — $ 0.1 MedTech & Specialty Audio — — 0.1 Consumer MEMS Microphones (1.1) 41.2 0.3 Corporate 0.8 0.6 — Total $ 2.2 $ 41.8 $ 0.5 |
Schedule of Restructuring Reserve by Type of Cost | The following table details the Company’s severance and other restructuring accrual activity: (in millions) Severance Pay and Benefits Contract Termination and Other Costs Total Balance at January 1, 2021 $ 1.9 $ 0.7 $ 2.6 Restructuring charges 0.5 — 0.5 Payments (2.0) (0.7) (2.7) Balance at December 31, 2021 0.4 — 0.4 Restructuring charges 6.6 35.2 41.8 Payments (6.2) (1.6) (7.8) Other, including foreign currency (1) 0.1 (11.8) (11.7) Balance at December 31, 2022 0.9 21.8 22.7 Restructuring charges 4.7 (2.5) 2.2 Payments (4.3) (3.1) (7.4) Other, including foreign currency (2) 1.1 0.6 1.7 Balance at December 31, 2023 $ 2.4 $ 16.8 $ 19.2 (1) Other activity during 2022 includes the non-cash disposal of fixed assets of $13.5 million within the MEMS microphones product line. (2) Other activity during 2023 includes $1.1 million of reserves assumed by the Company with the acquisition of CD within the PD segment. |
Schedule of Restructuring Reserve by Balance Sheet Location | The severance and restructuring accruals are recorded in the following line items on the Consolidated Balance Sheets: (in millions) December 31, 2023 December 31, 2022 Other accrued expenses $ 8.5 $ 4.0 Other liabilities 10.7 18.7 Total $ 19.2 $ 22.7 |
Hedging Transactions and Deri_2
Hedging Transactions and Derivative Instruments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Fair Value of Derivative Instruments | The fair values of derivative instruments held by the Company are as follows (in millions): Derivative Assets (Liabilities) Hedge Type Contract Type Balance Sheet Line December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments Cash flow hedges Foreign exchange contracts Prepaid and other current assets $ 0.4 $ 1.1 Cash flow hedges Foreign exchange contracts Other assets and deferred charges — 1.3 Cash flow hedges Foreign exchange contracts Other accrued expenses (0.7) (0.8) Cash flow hedges Foreign exchange contracts Other liabilities (0.4) — Derivatives not designated as hedging instruments Economic hedges Foreign exchange contracts Prepaid and other current assets 0.1 0.6 Economic hedges Foreign exchange contracts Other accrued expenses (0.1) — |
Derivative Instruments, Gain (Loss) | The pre-tax amount of unrealized (loss) gain recognized in accumulated other comprehensive loss on derivatives designated as hedging instruments is as follows (in millions): Years Ended December 31, Hedge Type Contract Type 2023 2022 2021 Cash flow hedges Foreign exchange contracts $ (5.0) $ (3.4) $ 0.5 The table above excludes a tax benefit of $1.1 million and $0.6 million for the years ended December 31, 2023 and 2022, respectively, and tax expense of $0.2 million for the year ended December 31, 2021. The pre-tax impact of derivatives on the Consolidated Statements of Earnings is as follows (in millions): Years Ended December 31, 2023 2022 2021 Hedge Type Contract Type Cost of goods sold Other expense (income), net Cost of goods sold Other expense (income), net Cost of goods sold Other expense (income), net Total amounts per Consolidated Statements of Earnings $ 435.5 $ 0.7 $ 455.7 $ (0.5) $ 508.6 $ (3.0) Effect of derivatives designated as hedging instruments Amount of loss (gain) reclassified from accumulated other comprehensive loss into earnings: Cash flow hedges Foreign exchange contracts 2.7 — 4.5 — (2.1) — Effect of derivatives not designated as hedging instruments Amount of loss (gain) recognized in earnings: Economic hedges Foreign exchange contracts — 3.3 — 1.0 — (1.4) |
Borrowings and Lines of Credit
Borrowings and Lines of Credit (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Term Loan and Revolving Credit Facilities | Revolving Credit Facility On February 8, 2023, the Company entered into an Amended and Restated Credit Agreement (the "A&R Credit Agreement") that amends and restates the prior Credit Agreement, dated September 4, 2020, and provides for a senior secured revolving credit facility with borrowings in an aggregate principal amount at any time outstanding not to exceed $400.0 million (the "Credit Facility"). The A&R Credit Agreement, among other things, extends the maturity date of the Credit Facility from January 2, 2024 to February 8, 2028, replaces the London Inter-Bank Offered Rate (“LIBOR”) with the Term Secured Overnight Financing Rate (“Term SOFR”) as a reference rate available for borrowings, amends the minimum Interest Coverage Ratio, and amends certain other financial covenants with which the Company must comply, as described below. On September 25, 2023, the Company amended its A&R Credit Agreement to, among other things, (a) permit the Company in connection with the acquisition of CD, to incur senior priority seller financing indebtedness (the “Seller Note”) in an aggregate principal amount of $122.9 million secured by certain assets (including equity interests) acquired in connection with such acquisition and the capital stock of Cornell Dubilier, LLC (the “Acquisition Assets”), which shall mature two years after the effective date of such Seller Note (the “Seller Note Maturity Date”), (b) extends the requirement to pledge the Acquisition Assets that would otherwise constitute collateral under the Credit Agreement to the date that is 90 days after the Seller Note Maturity Date, and (c) restricts, until the Seller Note Maturity Date, the amount of dispositions and investments from the Company and certain of its subsidiaries into Cornell Dubilier, LLC and the acquired subsidiaries that constitute Acquisition Assets from exceeding $80.0 million in the aggregate. All other terms remain the same as the A&R Credit Agreement dated February 8, 2023. Up to $100.0 million of the Credit Facility will be available in Euro, Pounds Sterling, and other currencies requested by the Company and up to $50.0 million of the Credit Facility will be made available in the form of letters of credit. Undrawn amounts under the Credit Facility accrue a commitment fee at a per annum rate of 0.225% to 0.350%, based on a leverage ratio grid. At any time during the term of the Credit Facility, the Company will be permitted to increase the commitments under the Credit Facility or to establish one or more incremental term loan facilities under the Credit Facility in an aggregate principal amount not to exceed the sum of $200.0 million, plus additional amounts, so long as the senior secured leverage ratio does not exceed 2.00 to 1.00. The A&R Credit Agreement includes requirements, to be tested quarterly, that the Company maintains (i) a minimum ratio of Consolidated EBITDA to consolidated cash interest expense of 3.00 to 1.00, (the "Interest Coverage Ratio"), (ii) a ratio of total indebtedness, minus netted cash in an aggregate amount not to exceed $50.0 million, to Consolidated EBITDA of 3.75 to 1.00 (the "Total Net Leverage Ratio"), and (iii) a maximum ratio of senior net secured indebtedness to Consolidated EBITDA of 3.25 to 1.00 (the "Senior Secured Net Leverage Ratio"). For these ratios, Consolidated EBITDA and consolidated interest expense are calculated using the most recent four consecutive fiscal quarters in a manner defined in the A&R Credit Agreement. At December 31, 2023, the Company was in compliance with these covenants and it expects to remain in compliance with all of its debt covenants over the next twelve months. The interest rates under the A&R Credit Facility will be, at the Borrowers' option (1) (A) in the case of borrowings denominated in U.S. dollars Term SOFR, (B) in the case of borrowings denominated in Sterling, Daily Simple Sonia, or (C) for borrowings denominated in Euro, EURIBOR, in each case, plus the rates per annum determined from time to time based on the total net leverage ratio of the Company as of the end of and for the most recent period of four fiscal quarters for which financial statements have been delivered (the "Applicable Margin"); or (2) in the case of borrowings denominated in U.S. dollars, alternate base rate ("ABR") (as defined in the A&R Credit Agreement) plus the Applicable Margin. The Applicable Margin for Term SOFR, Daily Simple Sonia, or EURIBOR could range from 1.50% to 2.50% while the Applicable Margin for ABR could range from 0.50% to 1.50%. The weighted-average interest rate on the Company's borrowings under the Credit Facility and the 2020 Credit Facility was 6.55%, 3.21%, and 2.25% for the years ended December 31, 2023, 2022, and 2021, respectively. The weighted-average commitment fee on the revolving lines of credit was 0.23% for the years ended December 31, 2023 and 2022 and 0.26% for the years ended December 31, 2021. Seller Note On November 1, 2023, the Company completed the acquisition of CD for a total purchase price of $246.8 million. This acquisition was funded by borrowings on the Revolving Credit Facility and an interest-free note from the seller with aggregate principal payments of $122.9 million (the "Seller Note"). The Seller Note is due and payable in cash with $50.0 million maturing on November 1, 2024 and $72.9 million maturing on November 1, 2025. On the acquisition date, the Company recorded the Seller Note at its present value of $109.9 million by discounting the future principal payments using an imputed rate of interest of approximately 7.1% in accordance with accounting guidance in ASC 835, Interest. The Company recognized imputed interest expense on the Seller Note of approximately $1.3 million for the year ended December 31, 2023. The Seller Note is secured by certain assets (including equity interest) acquired in connection with the acquisition. The Seller Note includes Knowles Capital Holdings, Inc. and Knowles Intermediate PD Holdings, LLC as borrowers, which jointly and severally agree to pay James P. Kaplan, as representative of the sellers of Cornell Dubilier, the principal amount of $122.9 million as described above. The Seller Note is not interest-bearing except at such time as an event of default has occurred, upon which and during the continuance of an event of default, all overdue principal will accrue interest at 2.0% per annum plus the SOFR-based rate otherwise applicable under the Company’s existing credit facility. The Seller Note is subject to customary conditions and events of default and the secured nature of the Seller Note is supported by a Security Agreement. |
Schedule of Interest Expense and Interest Income | Interest expense and interest income for the years ended December 31, 2023, 2022, and 2021 were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Interest expense $ 7.4 $ 4.3 $ 14.4 Interest income (2.0) (0.4) (0.2) Interest expense, net $ 5.4 $ 3.9 $ 14.2 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Income Tax, Domestic and Foreign | The components of earnings (loss) before income taxes and discontinued operations were: Years Ended December 31, (in millions) 2023 2022 2021 Domestic $ (120.4) $ (410.1) $ 15.5 Foreign 165.4 (8.1) 89.1 Total earnings (loss) before income taxes and discontinued operations $ 45.0 $ (418.2) $ 104.6 |
Schedule of Components of Income Tax Expense (Benefit) | Income tax (benefit) expense for the years ended December 31, 2023, 2022, and 2021 is comprised of the following: Years Ended December 31, (in millions) 2023 2022 2021 Current: U.S. Federal $ 1.8 $ 1.2 $ 0.4 State and local 0.3 0.6 0.3 Foreign 12.1 5.5 14.8 Total current tax expense $ 14.2 $ 7.3 $ 15.5 Deferred: U.S. Federal $ (39.9) $ 3.0 $ (57.1) State and local (2.5) (0.3) (2.6) Foreign 0.8 1.9 (1.4) Total deferred tax (benefit) expense (41.6) 4.6 (61.1) Total income tax (benefit) expense $ (27.4) $ 11.9 $ (45.6) |
Schedule of Effective Income Tax Rate Reconciliation | The reconciliation of income tax (benefit) expense at the U.S. Federal income tax rate to the Company’s actual income tax (benefit) expense was as follows: Years Ended December 31, 2023 2022 2021 Income tax expense (benefit) at U.S. federal statutory income tax rate $ 9.4 $ (87.8) $ 22.0 State and local taxes, net of Federal income tax benefit (2.1) 0.6 0.3 Foreign operations tax effect 4.2 6.4 3.5 Research and experimentation tax credits (2.9) (3.4) (4.0) Valuation allowance (14.4) 0.8 (59.7) Tax incentives (1.7) (1.3) (1.2) Tax contingencies (0.2) (1.1) 0.6 Tax holiday (0.8) (0.4) (10.6) Foreign taxes 0.2 1.1 1.0 Non-deductible and non-taxable interest (1.5) 0.2 (0.2) Stock-based compensation 3.7 1.8 5.1 Impact of intangible property transfers (26.6) — — Other, principally non-tax deductible items 1.6 2.5 1.3 Goodwill impairment — 90.6 — Global low tax and foreign derived intangible income 4.3 0.1 (2.5) Foreign currency adjustments — — (0.7) Prior period items (0.6) 1.8 (0.5) Total income tax (benefit) expense $ (27.4) $ 11.9 $ (45.6) |
Schedule of Deferred Tax Assets and Liabilities | The components of the Company’s deferred tax assets and liabilities included the following: (in millions) December 31, 2023 December 31, 2022 Deferred tax assets: Accrued compensation, principally post-retirement, and other employee benefits $ 13.2 $ 11.0 Accrued expenses 5.2 4.4 Accrued interest 0.4 1.5 Net operating loss and other carryforwards 67.4 68.0 Inventories, principally due to reserves for financial reporting purposes and capitalization for tax purposes 8.2 8.2 Unremitted earnings of non-U.S. subsidiaries 0.7 2.0 Intangible assets, principally due to different tax and financial reporting bases 23.3 6.9 Plant and equipment, principally due to differences in depreciation 10.0 13.8 Total gross deferred tax assets 128.4 115.8 Valuation allowance (25.5) (39.7) Total deferred tax assets $ 102.9 $ 76.1 Deferred tax liabilities: Other liabilities $ (4.0) $ (2.2) Total gross deferred tax liabilities (4.0) (2.2) Net deferred tax asset $ 98.9 $ 73.9 Classified as follows in the Consolidated Balance Sheets: Other assets and deferred charges (non-current deferred tax assets) $ 99.6 $ 74.8 Deferred income taxes (non-current deferred tax liabilities) (0.7) (0.9) Net deferred tax asset $ 98.9 $ 73.9 |
Schedule of Unrecognized Tax Benefits Roll Forward | Unrecognized tax benefits at January 1, 2021 $ 10.2 Reductions for tax positions of prior years (0.3) Settlements (0.4) Unrecognized tax benefits at December 31, 2021 $ 9.5 Reductions as a result of a lapse in statute of limitations (1.3) Foreign exchange fluctuations (0.1) Unrecognized tax benefits at December 31, 2022 $ 8.1 Reductions as a result of a lapse in statute of limitations (0.3) Foreign exchange fluctuations 0.2 Unrecognized tax benefits at December 31, 2023 $ 8.0 |
Equity Incentive Program (Table
Equity Incentive Program (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Share-Based Compensation Recognized Period Costs | The following table summarizes the stock-based compensation expense recognized by the Company for the periods presented: Years Ended December 31, (in millions) 2023 2022 2021 Pre-tax stock-based compensation expense Cost of goods sold $ 2.1 $ 1.6 $ 1.6 Research and development expenses 5.9 5.6 5.5 Selling and administrative expenses 21.0 21.4 25.0 Total pre-tax stock-based compensation expense 29.0 28.6 32.1 Tax benefit 3.3 4.4 5.1 Total stock-based compensation expense, net of tax $ 25.7 $ 24.2 $ 27.0 |
Schedule of Black-Scholes Option-Pricing Assumptions | The fair value of stock options granted by the Company was estimated on the date of grant using a Black-Scholes option-pricing model based on the assumptions shown in the table below. No stock options were granted during the year ended December 31, 2023. Years Ended December 31, 2022 2021 Risk-free interest rate 0.85% 0.06% Dividend yield —% —% Expected life (years) 4.5 4.5 Volatility 34.3% 36.0% Fair value at date of grant $6.29 $6.14 to $6.31 |
Schedule of SSAR and Stock Options Activity | The following table summarizes the Company's stock-settled stock appreciation right ("SSAR") and stock option activity for the year ended December 31, 2023. SSARs Stock Options Number of Shares Weighted-Average Exercise Price Aggregate Intrinsic Value Weighted-Average Remaining Contractual Term (Years) Number of Shares Weighted-Average Exercise Price Aggregate Intrinsic Value Weighted-Average Remaining Contractual Term (Years) (in millions, except share and per share amounts) Outstanding at December 31, 2022 223,564 $ 23.92 2,703,424 $ 16.28 Exercised — — (536,771) 12.47 Forfeited — — (12,684) 20.97 Expired (223,564) 23.92 (49,613) 19.49 Outstanding at December 31, 2023 — $ — $ — 0.0 2,104,356 $ 17.15 $ 3.3 2.3 Exercisable at December 31, 2023 — $ — $ — 0.0 1,947,845 $ 16.84 $ 3.3 2.0 |
Schedule of Other Share-based Compensation, Activity | Other information regarding the exercise of SSARs and stock options is listed below: Years Ended December 31, (in millions) 2023 2022 2021 SSARs Aggregate intrinsic value of SSARs exercised $ — $ 0.1 $ 0.1 Stock Options Cash received by Knowles for exercise of stock options $ 1.6 $ 7.5 $ 25.6 Aggregate intrinsic value of stock options exercised 2.9 6.0 6.6 Tax benefit from stock options exercised 0.6 1.2 1.2 |
Schedule of Restricted Stock Units Award Activity | The following table summarizes the Company's RSU activity for the year ended December 31, 2023: Share units Weighted-average grant date fair value Unvested at December 31, 2022 1,880,521 $ 19.96 Granted 1,267,642 18.78 Vested (1) (901,320) 19.40 Forfeited (171,836) 19.82 Unvested at December 31, 2023 2,075,007 $ 19.49 |
Schedule of Nonvested Performance-Based Units Activity | The following table summarizes the Company's PSU activity for the year ended December 31, 2023: Share units Weighted-average grant date fair value Unvested at December 31, 2022 833,589 $ 25.12 Granted 330,055 29.35 Vested (1) (261,770) 16.14 Forfeited (37,125) 29.20 Unvested at December 31, 2023 864,749 $ 29.28 (1) The number of PSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements. |
Share-Based Payment Arrangement, Performance Shares, Activity | PSUs The Company grants PSUs to senior management. In each case, the awards will cliff vest three years following the grant date. PSUs will be settled in shares of the Company's common stock. Depending on the Company's overall performance relative to the applicable measures, the size of the PSU awards are subject to adjustment, up or down, resulting in awards at the end of the performance period that can range from 0% to 225% of target. The Company will ratably recognize the expense over the applicable service period for each grant of PSUs and adjust the expense for the expected achievement of performance conditions as appropriate. The fair value of PSUs is determined by using a Monte Carlo simulation. For the awards granted in February 2023, 2022, and 2021, the number of PSUs that may be earned and vest is based on total shareholder return (“TSR”) relative to the component companies of the Russell 2000 Index over a three-year performance period. The COVID-19 pandemic brought on unique and unprecedented challenges to the Company, particularly in the hearing health and medtech markets. Many of the Company's executive compensation programs were affected, including outstanding PSU awards. Due to the impact of the COVID-19 pandemic on the Company’s overall business performance, effective February 8, 2021, the Company’s Compensation Committee approved certain modifications to PSUs granted in February 2018, 2019, and 2020. For the awards granted in February 2018 (the “2018 PSUs”), the number of PSUs that may be earned and vest was originally based on the Company’s revenues and stock price performance over a three-year performance period. The modified award was based on the Company’s revenues and stock price performance over three separate one-year performance periods to isolate the impact of the COVID-19 pandemic on the Company's fiscal 2020 performance. In addition, the performance periods corresponding to fiscal 2018 and 2019 were weighted at 25% each while the performance period corresponding to fiscal 2020 was weighted at 50%, given the impact of fiscal 2020 performance on shareholders. Service conditions were not modified. The modification of the 2018 PSUs affected nine employees and resulted in total incremental compensation expense of $3.9 million, which was recognized in the first quarter of 2021 as there was no remaining service period. In February 2021, the 2018 PSUs were converted from 329,092 PSUs to 190,544 shares of common stock based on achievement of the modified conditions. For the awards granted in February 2019 (the “2019 PSUs”), the number of PSUs that may be earned and vest was originally based on the Company's revenues and TSR relative to the component companies of the S&P Semiconductor Select Industry Index over a three-year performance period. The modified award was based on the Company’s revenues and TSR relative to the component companies of the S&P Semiconductor Select Industry Index over three separate one-year performance periods to isolate the impact of the COVID-19 pandemic on the Company's fiscal 2020 performance. Each period was weighted equally, as the Company expected to face challenges related to the COVID-19 pandemic in fiscal 2021. Service conditions were not modified. The modification of the 2019 PSUs affected eight employees and resulted in total incremental compensation expense of $2.4 million, which was recognized over the remaining service period. Incremental compensation expense was subject to adjustment for the achievement of the performance condition based on fiscal 2021 revenues. In February 2022, the 2019 PSUs were converted from 227,812 PSUs to 150,811 shares of common stock based on achievement of the modified conditions. For the awards granted in February 2020 (the “2020 PSUs”), the number of PSUs that may be earned and vest was originally based on TSR relative to the component companies of the S&P Semiconductor Select Industry Index over a three-year performance period. The modified award replaces the S&P Semiconductor Select Industry Index with the Russell 2000 Index. The Company is a member of the Russell 2000 Index, which represents a broader, more diversified index that better aligns with the Company's strategy. Service conditions were not modified. The modification of the 2020 PSUs affected eight employees and resulted in total incremental compensation expense of $4.7 million, which will be recognized over the remaining service period. In February 2023, the 2020 PSUs were converted from 261,770 PSUs to 120,677 shares of common stock based on achievement of the modification conditions The following table summarizes the Company's PSU activity for the year ended December 31, 2023: Share units Weighted-average grant date fair value Unvested at December 31, 2022 833,589 $ 25.12 Granted 330,055 29.35 Vested (1) (261,770) 16.14 Forfeited (37,125) 29.20 Unvested at December 31, 2023 864,749 $ 29.28 (1) The number of PSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements. The fair value of PSUs vested during the year ended December 31, 2023 was $2.3 million. At December 31, 2023, $9.9 million of unrecognized compensation expense related to PSUs is expected to be recognized over a weighted-average period of 1.2 years. |
Employee Benefit Plans (Tables)
Employee Benefit Plans (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Defined Benefit Plan Disclosure [Line Items] | |
Schedule of Plan Obligations and Funded Status | The following tables summarize the balance sheet impact, including the benefit obligations, assets, and funded status associated with the Company's four defined benefit plans for non-U.S. participants at December 31, 2023 and 2022. December 31, (in millions) 2023 2022 Change in benefit obligation: Benefit obligation at beginning of year $ 41.8 $ 69.5 Service cost 0.2 0.3 Interest cost 2.0 1.1 Benefits paid (3.1) (1.9) Actuarial loss gain (1) 0.4 (23.5) Plan amendments — 0.2 Currency translation and other (2) 2.2 (3.9) Benefit obligation at end of year 43.5 41.8 Change in plan assets: Fair value of plan assets at beginning of year 41.3 69.3 Actual return on plan assets 1.8 (20.1) Company contributions 1.0 1.2 Benefits paid (3.1) (1.9) Currency translation and other 2.1 (7.2) Fair value of plan assets at end of year 43.1 41.3 Funded status $ (0.4) $ (0.5) Amounts recognized in the Consolidated Balance Sheets consist of: Other assets and deferred charges $ 3.4 $ 3.4 Other liabilities (3.8) (3.9) Funded status $ (0.4) $ (0.5) Accumulated other comprehensive loss: Net actuarial losses $ 18.1 $ 17.9 Prior service cost 1.2 1.2 Deferred taxes (2.9) (2.7) Total accumulated other comprehensive loss, net of tax 16.4 16.4 Accumulated benefit obligation $ 42.7 $ 41.1 |
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets | Pension plans with projected benefit obligations in excess of plan assets consisted of the following at December 31, 2023 and 2022: December 31, (in millions) 2023 2022 Projected benefit obligation $ 25.1 $ 24.5 Fair value of plan assets 21.3 20.6 |
Schedule of Accumulated Benefit Obligations in Excess of Plan Assets | Pension plans with accumulated benefit obligations in excess of plan assets consisted of the following at December 31, 2023 and 2022: December 31, (in millions) 2023 2022 Accumulated benefit obligation $ 24.9 $ 24.5 Fair value of plan assets 21.3 20.6 |
Schedule of Net Periodic Benefit Costs | Components of the net periodic benefit cost (income) were as follows: Years Ended December 31, (in millions) 2023 2022 2021 Service cost $ 0.2 $ 0.3 $ 0.3 Interest cost 2.0 1.1 0.9 Expected return on plan assets (2.1) (2.6) (2.8) Amortization of prior service cost 0.1 — — Amortization of recognized actuarial loss 0.5 0.5 0.8 Other (1) — 3.4 — Total net periodic benefit cost (income) $ 0.7 $ 2.7 $ (0.8) |
Schedule of Assumptions Used | The assumptions used in determining the benefit obligations were as follows: December 31, 2023 2022 Discount rate Philippines 6.20 % 7.50 % Taiwan 1.50 % 1.75 % United Kingdom 4.60 % 4.84 % Weighted-average 4.47 % 4.71 % Average wage increase Philippines 4.00 % 4.00 % Taiwan 4.00 % 4.00 % United Kingdom 4.20 % 4.35 % Weighted-average 4.17 % 4.30 % The assumptions used in determining the net periodic benefit cost (income) were as follows: Years Ended December 31, 2023 2022 2021 Discount rate Philippines 7.50 % 5.25 % 4.00 % Taiwan 1.75 % 0.75 % 0.25 % United Kingdom 4.84 % 1.84 % 1.28 % Weighted-average 4.71 % 1.83 % 1.27 % Average wage increase Philippines 4.00 % 4.00 % 4.00 % Taiwan 4.00 % 4.00 % 4.00 % United Kingdom 4.35 % 4.65 % 4.20 % Weighted-average 4.30 % 4.59 % 4.18 % Expected return on plan assets Philippines 7.50 % 5.90 % * Taiwan 1.75 % 4.00 % 3.50 % United Kingdom 5.17 % 4.15 % 4.34 % Weighted-average 5.00 % 4.15 % 4.32 % |
Fair Value of Plan Assets by Asset Category | The fair values of plan assets by asset category within the ASC 820 hierarchy were as follows at December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in millions) Level 1 Level 2 Level 3 Total Fair Value Level 1 Level 2 Level 3 Total Fair Value Asset category: Fixed income investments $ 3.5 $ 17.8 $ — $ 21.3 $ 3.3 $ 16.7 $ — $ 20.0 Common stock funds — 6.3 — 6.3 — 6.1 — 6.1 Real estate funds — 4.1 — 4.1 — 4.1 — 4.1 Cash and equivalents 1.7 — — 1.7 1.4 — — 1.4 Other 3.4 6.3 — 9.7 4.1 5.6 — 9.7 Total $ 8.6 $ 34.5 $ — $ 43.1 $ 8.8 $ 32.5 $ — $ 41.3 |
Schedule of Expected Benefit Payments | Estimated future benefit payments to retirees, which reflect expected future service, are as follows: (in millions) 2024 $ 2.2 2025 2.4 2026 2.6 2027 2.9 2028 2.6 2029-2033 13.5 |
Other Comprehensive (Loss) Ea_2
Other Comprehensive (Loss) Earnings (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | |
Schedule of Amounts Recognized in Other Comprehensive Income | The amounts recognized in other comprehensive (loss) earnings were as follows: Year Ended December 31, 2023 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (6.1) $ — $ (6.1) Employee benefit plans (0.1) 0.2 0.1 Changes in fair value of cash flow hedges (2.3) 0.6 (1.7) Total other comprehensive loss $ (8.5) $ 0.8 $ (7.7) Year Ended December 31, 2022 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (23.2) $ — $ (23.2) Employee benefit plans 1.4 (0.6) 0.8 Changes in fair value of cash flow hedges 1.1 (0.4) 0.7 Total other comprehensive loss $ (20.7) $ (1.0) $ (21.7) Year Ended December 31, 2021 (in millions) Pre-tax Tax Net of tax Foreign currency translation $ (3.6) $ — $ (3.6) Employee benefit plans 6.6 (1.6) 5.0 Changes in fair value of cash flow hedges (1.6) 0.3 (1.3) Total other comprehensive earnings $ 1.4 $ (1.3) $ 0.1 |
Schedule of Components of Accumulated Other Comprehensive Income (Loss) | The following table summarizes the changes in balances of each component of accumulated other comprehensive loss, net of tax during the years ended December 31, 2023 and 2022: (in millions) Cash flow hedges Employee benefit plans Cumulative foreign currency translation adjustments Total Balance at January 1, 2022 $ 0.3 $ (17.1) $ (83.6) $ (100.4) Other comprehensive earnings (loss), net of tax 0.7 0.8 (23.2) (21.7) Balance at December 31, 2022 1.0 (16.3) (106.8) (122.1) Other comprehensive (loss) earnings, net of tax (1.7) 0.1 (6.1) (7.7) Balance at December 31, 2023 $ (0.7) $ (16.2) $ (112.9) $ (129.8) The following table summarizes the amounts reclassified from accumulated other comprehensive loss to earnings: Years Ended December 31, (in millions) Statement of Earnings Line 2023 2022 2021 Pension and post-retirement benefit plans: Amortization or settlement of actuarial losses and prior service costs Other expense (income), net $ 0.6 $ 0.6 $ 0.9 Tax (Benefit from) provision for income taxes (0.1) (0.1) (0.2) Net of tax $ 0.5 $ 0.5 $ 0.7 Cash flow hedges: Net losses (gains) reclassified into earnings Cost of goods sold $ 2.7 $ 4.5 $ (2.1) Tax (Benefit from) provision for income taxes (0.5) (1.0) 0.5 Net of tax $ 2.2 $ 3.5 $ (1.6) |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Revenue and Earnings from continuing operations by market segment | Information regarding the Company's reportable segments is as follows: Years Ended December 31, (in millions) 2023 2022 2021 Revenues: Precision Devices $ 221.4 $ 242.9 $ 201.1 MedTech & Specialty Audio 230.0 229.9 231.3 Consumer MEMS Microphones 256.2 291.9 435.7 Total revenues $ 707.6 $ 764.7 $ 868.1 Earnings (loss) from continuing operations before interest and income taxes: Precision Devices $ 25.0 $ 56.1 $ 43.7 MedTech & Specialty Audio 85.2 84.6 77.0 Consumer MEMS Microphones 13.6 (504.5) 60.0 Total segments 123.8 (363.8) 180.7 Corporate expense / other 73.4 50.5 61.9 Interest expense, net 5.4 3.9 14.2 Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Depreciation and amortization: Precision Devices $ 15.8 $ 13.8 $ 13.3 MedTech & Specialty Audio 8.2 8.1 6.3 Consumer MEMS Microphones 20.3 29.5 39.9 Corporate 2.2 2.5 3.0 Total $ 46.5 $ 53.9 $ 62.5 Capital expenditures: Precision Devices $ 7.6 $ 7.4 $ 5.6 MedTech & Specialty Audio 4.6 7.3 11.6 Consumer MEMS Microphones 4.7 17.2 29.2 Corporate — 0.2 2.2 Total $ 16.9 $ 32.1 $ 48.6 Research and development: Precision Devices $ 13.8 $ 12.3 $ 10.5 MedTech & Specialty Audio 18.2 16.9 16.1 Consumer MEMS Microphones 46.1 52.4 65.7 Corporate 0.4 0.1 0.5 Total $ 78.5 $ 81.7 $ 92.8 |
Revenue from External Customers by Geographic Areas | The following table details revenues by geographic location. Revenues are attributed to regions based on the location of the Company's direct customer, which in some instances is an intermediary and not necessarily the end user. Long-lived assets are comprised of net property, plant, and equipment and operating lease right-of-use assets. These assets have been classified based on the geographic location of where they reside. The Company's businesses are based primarily in Asia, North America, and Europe. Revenues Long-Lived Assets Years Ended December 31, December 31, (in millions) 2023 2022 2021 2023 2022 Asia $ 426.1 $ 471.3 $ 611.5 $ 91.9 $ 110.5 United States 161.4 174.3 153.2 90.1 60.5 Europe 101.5 104.4 93.5 3.7 2.4 Other Americas 7.1 7.5 5.5 2.8 1.0 Other 11.5 7.2 4.4 — — Total $ 707.6 $ 764.7 $ 868.1 $ 188.5 $ 174.4 |
Schedules of Concentration of Risk, by Risk Factor | The Company's customers that accounted for 10% or more of total revenues were as follows: Revenues Years Ended December 31, 2023 2022 2021 Apple Inc. 16 % 15 % 16 % WS Audiology A/S 10 % * * |
Reconciliation of Assets from Segment to Consolidated | Information regarding assets of the Company's reportable segments: Total Assets December 31, (in millions) 2023 2022 Precision Devices $ 577.9 $ 275.7 MedTech & Specialty Audio 351.1 358.1 Consumer MEMS Microphones 530.0 547.3 Corporate / eliminations 3.8 2.8 Total $ 1,462.8 $ 1,183.9 |
Earnings per Share (Tables)
Earnings per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Reconciliation of information used in computing basic and diluted earnings per share | Basic and diluted earnings per share were computed as follows: Years Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Earnings from discontinued operations, net — — 0.2 Net earnings (loss) $ 72.4 $ (430.1) $ 150.4 Basic earnings (loss) per common share: Earnings (loss) from continuing operations $ 0.80 $ (4.69) $ 1.63 Earnings from discontinued operations, net — — — Net earnings (loss) $ 0.80 $ (4.69) $ 1.63 Weighted-average shares outstanding 90.9 91.7 92.3 Diluted earnings (loss) per common share: Earnings (loss) from continuing operations $ 0.79 $ (4.69) $ 1.59 Earnings from discontinued operations, net — — — Net earnings (loss) $ 0.79 $ (4.69) $ 1.59 Diluted weighted-average shares outstanding 91.6 91.7 94.7 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details) $ in Millions | 3 Months Ended | 12 Months Ended | |||||
Dec. 31, 2023 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) reporting_unit shares | Dec. 31, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Apr. 28, 2022 USD ($) | Feb. 24, 2020 USD ($) | |
Accounting Policies [Line Items] | |||||||
Revenue Recognition, Sales Discounts and Rebates | $ 4.8 | $ 4.4 | $ 5 | ||||
Operating Lease, Liability | $ 13.3 | 13.3 | |||||
Operating Lease, Right-of-Use Asset | 13.1 | $ 13.1 | 12.6 | ||||
Goodwill and Intangible Assets [Abstract] | |||||||
Number of Reporting Units | reporting_unit | 3 | ||||||
Goodwill | 540.7 | $ 540.7 | 471 | 941.3 | |||
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | 0 | 0 | 0 | ||||
Property, Plant and Equipment [Abstract] | |||||||
Total impairment charges | 231.1 | $ 239.8 | $ 0 | 470.9 | 4 | ||
Document Fiscal Year Focus | 2023 | ||||||
Revenue Recognition, Sales Returns, Reserve for Sales Returns | $ 4.3 | 7.1 | 4.3 | ||||
Increase (Decrease) in Contract Receivables, Net | 129.2 | 125.7 | |||||
Investments | 6.2 | 6.2 | 5 | ||||
Stock Repurchase Program, Authorized Amount | $ 150 | $ 100 | |||||
Goodwill, Impairment Loss | 0 | 0 | |||||
Tangible Asset Impairment Charges | 0 | 0 | |||||
Purchases of property and equipment included in accounts payable | 1.1 | 1.1 | 5.4 | ||||
Noncash Investing and Financing Items [Abstract] | |||||||
Purchases of property and equipment included in accounts payable | 1.1 | $ 1.1 | $ 5.4 | ||||
Immaterial Asset Acquisition | Customer relationships | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Finite-Lived Customer Relationships, Gross | 2 | 2 | |||||
Asset Acquisition, Contingent Consideration, Liability, Noncurrent | $ 1.7 | $ 1.7 | |||||
Treasury Stock, Common | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Stock Repurchased During Period, Shares | shares | 2,851,604 | 2,339,045 | 2,139,413 | ||||
Maximum | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Finite-Lived Intangible Asset, Useful Life | 15 years | 15 years | |||||
Minimum | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Finite-Lived Intangible Asset, Useful Life | 5 years | 5 years | |||||
Buildings and improvements | Maximum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 31 years 6 months | 31 years 6 months | |||||
Buildings and improvements | Minimum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 5 years | 5 years | |||||
Machinery and equipment | Maximum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 7 years | 7 years | |||||
Machinery and equipment | Minimum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 1 year 6 months | 1 year 6 months | |||||
Furniture and fixtures | Maximum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 5 years | 5 years | |||||
Furniture and fixtures | Minimum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 2 years | 2 years | |||||
Vehicles | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 3 years | 3 years | |||||
Software and software development costs | Maximum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 5 years | 5 years | |||||
Software and software development costs | Minimum | |||||||
Property, Plant and Equipment [Abstract] | |||||||
Property, plant and equipment, useful life | 3 years | 3 years | |||||
Precision Devices | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | $ 132.8 | $ 132.8 | $ 63.2 | $ 62.5 | |||
Property, Plant and Equipment [Abstract] | |||||||
Total impairment charges | 0 | ||||||
Precision Devices | Minimum | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Percentage of fair value in excess of carrying amount | 180% | 180% | |||||
MedTech & Specialty Audio | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | $ 137.7 | $ 137.7 | 137.7 | 137.7 | |||
Property, Plant and Equipment [Abstract] | |||||||
Total impairment charges | 0 | ||||||
MedTech & Specialty Audio | Minimum | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Percentage of fair value in excess of carrying amount | 180% | 180% | |||||
Consumer MEMS Microphones | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | $ 270.2 | $ 270.2 | 270.1 | $ 741.1 | |||
Property, Plant and Equipment [Abstract] | |||||||
Total impairment charges | $ 470.9 | ||||||
Consumer MEMS Microphones | Minimum | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Percentage of fair value in excess of carrying amount | 7% | 7% | |||||
Precision Devices | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | $ 132.8 | $ 132.8 | |||||
MedTech & Specialty Audio | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | 137.7 | 137.7 | |||||
Consumer MEMS Microphones | |||||||
Goodwill and Intangible Assets [Abstract] | |||||||
Goodwill | $ 270.2 | $ 270.2 |
Disposed and Discontinued Ope_2
Disposed and Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale [Member] - Speaker and Receiver Product Line - USD ($) $ in Millions | 12 Months Ended | |
Jul. 07, 2016 | Dec. 31, 2021 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Discontinued Operation, Tax Effect of Discontinued Operation | $ (0.2) | |
Disposal Group, Including Discontinued Operation, Consideration | $ 45 | |
Proceeds from the sale of business | $ 40.6 |
Disposed and Discontinued Ope_3
Disposed and Discontinued Operations (Details) $ in Millions | Jul. 07, 2016 USD ($) |
Speaker and Receiver Product Line | Discontinued Operations, Disposed of by Sale [Member] | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |
Disposal Group, Including Discontinued Operation, Consideration | $ 45 |
Acquisition Acquisition (Detail
Acquisition Acquisition (Details) - USD ($) $ in Millions | 12 Months Ended | ||||
Nov. 01, 2023 | May 03, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Business Combinations [Abstract] | |||||
Business Acquisition, Integration, Restructuring and Other Related Costs | 3. Acquisitions Cornell Dubilier On November 1, 2023, the Company acquired (i) all the issued and outstanding shares of Kaplan Electronics, Inc. and (ii) certain assets of Cornell Dubilier Electronics, Inc. and CD Aero, LLC (collectively, "Cornell Dubilier" or "CD") for aggregate consideration of $259.8 million, which equated to a total fair value of consideration transferred of $246.8 million. This purchase price of $246.8 million consisted of $136.9 million in cash payments and an interest-free seller note (the “Seller Note”) with a fair value of $109.9 million. The Seller Note consists of aggregate principal amounts of $122.9 million with $50.0 million maturing on November 1, 2024 and $72.9 million maturing on November 1, 2025 and is secured by certain assets (including equity interests) acquired in connection with the acquisition (see also Note 12. Borrowings). During the year ended December 31, 2023, the Company incurred costs related to this transaction totaling $7.8 million, which are reflected within "Selling and administrative expenses" in the Consolidated Statement of Earnings. CD is a manufacturer of film, electrolytic, and mica capacitors used in medtech, defense, and industrial electrification applications. The transaction was accounted for as a business combination under Accounting Standards Codification 805. The Company has substantially completed the purchase price allocation for the acquisition of CD. As additional information is obtained about the net assets acquired within the measurement period (not to exceed one year from the date of acquisition), including finalization of asset appraisals, the Company will refine its estimates of the purchase price allocation. The table below represents a preliminary allocation of the purchase price to net assets acquired as of November 1, 2023: (in millions) Receivables $ 13.4 Inventories 41.6 Property, plant, and equipment 31.8 Customer relationships 82.7 Developed technology 19.1 Trademarks 14.0 Operating lease right-of-use assets 3.4 Other assets and deferred charges 1.0 Goodwill 69.6 Current liabilities assumed (11.3) Deferred income taxes (15.8) Long-term operating lease liabilities (2.7) Total purchase price $ 246.8 The fair value for customer relationships was determined using the multi-period excess earnings method under the income approach. This method reflects the present value of expected future cash flows less charges representing the contribution of other assets to those cash flows. The fair value for developed technology and trademarks was determined using the relief from royalty method under the income approach. The fair value measurements of the intangible assets are based on significant unobservable inputs, and thus represent Level 3 inputs. Significant assumptions used in assessing the fair values of customer relationships, developed technology, and trademarks include forecasted revenue and terminal growth rates, profit margins, customer attrition rates, royalty rates, and discount rates. The weighted-average discount rates applied to expected future cash flows to reflect the risks related to intangible assets identified in connection with the CD acquisition were as follows: Customer relationships 22.8 % Developed technology 20.2 % Trademarks 20.1 % The customer relationships, developed technology, and trademarks identified will be amortized on a straight-line basis over their estimated useful lives. The weighted-average useful lives assigned to these assets were as follows: Customer relationships 10 years Developed technology 9 years Trademarks 14 years The excess of the total purchase price over the total fair value of the identifiable assets and liabilities was recorded as goodwill. The goodwill recognized is primarily attributable to synergies expected to be realized on this transaction and the assembled workforce. Of the total goodwill of $69.6 million recognized for this transaction, approximately $26.8 million is tax deductible. All goodwill related to CD has been allocated to the PD segment, which is the segment expected to benefit from the acquisition. The Company believes the fair values assigned to intangible assets are based on reasonable assumptions and estimates that approximate the amounts a market participant would pay for these intangible assets as of the acquisition date. Actual results could differ materially from these estimates. Impact of CD Acquisition and Pro-Forma Summary Included in the Consolidated Statements of Earnings are CD’s revenues and loss before income taxes of $20.2 million and $1.1 million, respectively, from the date of acquisition through December 31, 2023. The $1.1 million loss before income taxes includes employee retention and intangible asset amortization expense of $1.0 million and $1.6 million, respectively. The following unaudited pro-forma summary presents consolidated financial information as if CD had been acquired on January 1, 2022. The unaudited pro-forma financial information is based on historical results of operations and financial positions of the Company and CD. The pro-forma earnings are adjusted to reflect the comparable impact of depreciation and amortization expense resulting from the fair value measurement of tangible and intangible assets, nonrecurring deal-related costs, employee retention, inventory step-up charges, and interest expense on borrowings to fund the acquisition. The unaudited pro-forma financial information does not necessarily represent the results that would have occurred had the acquisition occurred on January 1, 2022. In addition, the unaudited pro-forma information should not be deemed to be indicative of future results. Years Ended December 31, (in millions) 2023 2022 Revenues: As reported $ 707.6 $ 764.7 Pro-forma 815.9 915.8 Earnings from continuing operations: As reported $ 72.4 $ (430.1) Pro-forma 69.8 (445.8) Basic earnings per share from continuing operations: As reported $ 0.80 $ (4.69) Pro-forma 0.77 (4.86) Diluted earnings per share from continuing operations: As reported $ 0.79 $ (4.69) Pro-forma 0.76 (4.86) Integrated Microwave Corporation On May 3, 2021, the Company acquired all of the outstanding shares of common stock of Integrated Microwave Corporation ("IMC") for $81.4 million. During the first quarter of 2022, the Company recorded a purchase price adjustment of $0.7 million that was paid during the second quarter of 2022. The adjustment, which did not impact the Consolidated Statements of Earnings, resulted in an increase to goodwill of $0.7 million. The acquired business provides RF filters to the defense, industrial, and communications markets. The transaction was accounted for under the acquisition method of accounting and the results of operations are included in the Consolidated Financial Statements from the date of acquisition in the Precision Devices ("PD") segment. Included in the Consolidated Statements of Earnings are IMC’s revenues and loss before income taxes of $11.2 million and $0.3 million, respectively, from the date of acquisition through December 31, 2021. The table below represents the allocation of the purchase price to net assets acquired as of May 3, 2021: (in millions) Cash $ 2.2 Receivables 3.0 Inventories 2.6 Property, plant, and equipment 8.3 Customer relationships 27.7 Developed technology 5.2 Trademarks and other amortized intangible assets 1.6 Goodwill 32.0 Assumed current liabilities (1.2) Total purchase price $ 81.4 The fair value for customer relationships was determined using the multi-period excess earnings method under the income approach. This method reflects the present value of expected future cash flows less charges representing the contribution of other assets to those cash flows. The fair value for developed technology was determined using the relief from royalty method under the income approach. The fair value measurements of intangible assets are based on significant unobservable inputs, and thus represent Level 3 inputs. Significant assumptions used in assessing the fair values of customer relationships and developed technology include forecasted revenue growth rates, profit margins, customer attrition rates, royalty rates, and discount rates. Discount rates of 13.0% and 14.0% were applied to the expected future cash flows to reflect the risk related to customer relationships and developed technology, respectively. Customer relationships and developed technology will be amortized on a straight-line basis over estimated useful lives of 8 years and 10 years, respectively. The excess of the total purchase price over the total fair value of the identifiable assets and liabilities was recorded as goodwill. The goodwill recognized is primarily attributable to synergies and the assembled workforce. All of the goodwill resulting from this acquisition is tax deductible. Goodwill has been allocated to the PD segment, which is the segment expected to benefit from the acquisition. The Company believes the fair values assigned to intangible assets are based on reasonable assumptions and estimates that approximate the amounts a market participant would pay for these intangible assets as of the acquisition date. Actual results could differ materially from these estimates. Pro-forma financial information has not been provided as the acquisition did not have a material impact on the Consolidated Statements of Earnings. | ||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | The table below represents the allocation of the purchase price to net assets acquired as of May 3, 2021: (in millions) Cash $ 2.2 Receivables 3.0 Inventories 2.6 Property, plant, and equipment 8.3 Customer relationships 27.7 Developed technology 5.2 Trademarks and other amortized intangible assets 1.6 Goodwill 32.0 Assumed current liabilities (1.2) Total purchase price $ 81.4 | ||||
Business Acquisition [Line Items] | |||||
Goodwill | $ 540.7 | $ 471 | $ 941.3 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years 10 months 24 days | ||||
Cornell Dubilier | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 246.8 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | 13.4 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory | 41.6 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 31.8 | ||||
Business Combination, Recognized Identifiable Assets [Line Items] | 3.4 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 1 | ||||
Goodwill | 69.6 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities | (11.3) | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | (15.8) | ||||
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation | (2.7) | ||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 26.8 | ||||
Integrated Microwave Corporation | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 81.4 | ||||
Payments to Acquire Businesses, Gross | 81.4 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables | 3 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory | 2.6 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 8.3 | ||||
Goodwill | 32 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (1.2) | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | 2.2 | ||||
Customer relationships | |||||
Business Acquisition [Line Items] | |||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 9 years 1 month 6 days | ||||
Customer relationships | Cornell Dubilier | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 82.7 | ||||
Acquired Intangible Assets, Weighted Average Discount Rate Percent | 22.80% | ||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 10 years | ||||
Customer relationships | Integrated Microwave Corporation | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 27.7 | ||||
Finite-Lived Intangible Asset, Useful Life | 8 years | ||||
Developed technology | |||||
Business Acquisition [Line Items] | |||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years 6 months | ||||
Developed technology | Cornell Dubilier | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 19.1 | ||||
Acquired Intangible Assets, Weighted Average Discount Rate Percent | 20.20% | ||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 9 years | ||||
Developed technology | Integrated Microwave Corporation | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 5.2 | ||||
Finite-Lived Intangible Asset, Useful Life | 10 years | ||||
Trademarks [Member] | |||||
Business Acquisition [Line Items] | |||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years 9 months 18 days | ||||
Trademarks [Member] | Cornell Dubilier | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 14 | ||||
Acquired Intangible Assets, Weighted Average Discount Rate Percent | 20.10% | ||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 14 years | ||||
Trademarks [Member] | Integrated Microwave Corporation | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 1.6 | ||||
Precision Devices | |||||
Business Acquisition [Line Items] | |||||
Goodwill | $ 132.8 | $ 63.2 | $ 62.5 | ||
Precision Devices | Cornell Dubilier | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Consideration Transferred | $ 259.8 | ||||
Payments to Acquire Businesses, Gross | 136.9 | ||||
Business Combination, Consideration Transferred, Liabilities Incurred | 109.9 | ||||
Business Acquisition, Transaction Costs | $ 7.8 | ||||
Precision Devices | Cornell Dubilier | Seller Note | |||||
Business Acquisition [Line Items] | |||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 122.9 |
Acquisition Acquisition - Selec
Acquisition Acquisition - Selected Unaudited Pro-forma Combined Statement of Earnings (Details) - USD ($) $ / shares in Units, $ in Millions | 2 Months Ended | 8 Months Ended | 12 Months Ended | |||
May 03, 2021 | Dec. 31, 2023 | Dec. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Business Acquisition [Line Items] | ||||||
Revenues | $ 707.6 | $ 764.7 | $ 868.1 | |||
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $ 72.4 | $ (430.1) | $ 150.2 | |||
Income (Loss) from Continuing Operations, Per Basic Share | $ 0.80 | $ (4.69) | $ 1.63 | |||
Income (Loss) from Continuing Operations, Per Diluted Share | $ 0.79 | $ (4.69) | $ 1.59 | |||
Cornell Dubilier | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | $ 20.2 | |||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | 1.1 | |||||
Retention Payable | 1 | $ 1 | ||||
Amortization Expense | $ 1.6 | |||||
Revenues | 707.6 | $ 764.7 | ||||
Business Acquisition, Pro Forma Revenue | 815.9 | 915.8 | ||||
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | 72.4 | (430.1) | ||||
Business Acquisition, Pro Forma Net Income (Loss) | $ 69.8 | $ (445.8) | ||||
Income (Loss) from Continuing Operations, Per Basic Share | $ 0.80 | $ (4.69) | ||||
Business Acquisition, Pro Forma Earnings Per Share, Basic | 0.77 | (4.86) | ||||
Income (Loss) from Continuing Operations, Per Diluted Share | 0.79 | (4.69) | ||||
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ 0.76 | $ (4.86) | ||||
Integrated Microwave Corporation | ||||||
Business Acquisition [Line Items] | ||||||
Payments to Acquire Businesses, Gross | $ 81.4 | |||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | $ 11.2 | |||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ 0.3 |
Impairments (Details)
Impairments (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Dec. 31, 2023 | Jun. 30, 2023 | Sep. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | |
Asset Impairment Charges [Abstract] | |||||||
Asset Impairment Charges | 4. Impairment Charges Goodwill Impairment The Company tests goodwill for impairment at least annually as of October 1, or more frequently if there are events or circumstances indicating the carrying value of individual reporting units may exceed their respective fair values on a more likely than not basis. During the second quarter of 2022, the Company identified a triggering event requiring an interim impairment assessment for the CMM reporting unit, which resulted in a goodwill impairment charge of $239.8 million The triggering event occurred due to the identification of a rapid decline in current demand and a reduction in the expected future growth rate for global consumer electronics, which resulted in reductions to forecasted revenue and terminal growth rates and profit margins. Additionally, during the fourth quarter of 2022, the Company identified another triggering event requiring an impairment assessment of the CMM reporting unit, which resulted in a goodwill impairment charge of $231.1 million. This triggering event occurred due to the identification of further declines in forecasted demand for global consumer electronics, resulting in reductions to forecasted revenue and profit margins. In addition, the Company’s assumptions for weighted average cost of capital and income tax rates increased as a result of rising interest rates and not satisfying certain tax holiday conditions. The goodwill impairment charges are presented within Impairment charges in Operating expenses on the Consolidated Statements of Earnings. No goodwill impairment charges were recorded during the years ended December 31, 2023 or 2021. Fair value was estimated using a discounted cash flow model that included the Company's market participant assumptions, forecasted future cash flows based on historical performance and future estimated results, determinations of appropriate discount rates, and other assumptions which were considered reasonable and inherent in the discounted cash flow analysis. The fair value estimate was based on known or knowable information at the assessment date. Significant assumptions used in the model included forecasted revenue and terminal growth rates, profit margins, income tax rates, capital expenditures, working capital requirements, and the Company's weighted average cost of capital. The fair value measurements for reporting units are based on significant unobservable inputs, and thus represent Level 3 inputs. Fair value measurements require considerable judgment and are sensitive to changes in underlying assumptions. As a result, there can be no assurance that estimates and assumptions made for purposes of the impairment assessment will prove to be an accurate prediction of the future. Potential circumstances that could have a negative effect on the fair value of our reporting units include, but are not limited to, lower than forecasted revenue and terminal growth rates, decreased profit margins, higher income taxes, increased capital expenditures, higher working capital requirements, and changes in the weighted average cost of capital. A reduction in the estimated fair value of the reporting units, including as a result of our strategic alternative review, could trigger an impairment in the future. Long-Lived Asset Impairment The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company vacated its leased facility in Mountain View, California, resulting in its classification as a separate asset group. This facility was previously used by the Intelligent Audio product line, which is included within the CMM segment. Based on an assessment of market conditions, in particular the impact of the COVID-19 pandemic, the Company determined that the carrying amount of the asset group was not recoverable through undiscounted future cash flows, which included estimated sublease proceeds. The fair value of the operating lease right-of-use asset was determined by an estimate of discounted future cash flows that included estimated sublease proceeds and the determination of an appropriate discount rate based on market participant assumptions. The fair value measurements of operating lease right-of-use assets are based on significant unobservable inputs, and thus represent Level 3 inputs. During the third quarter of 2021, the Company determined that the remaining carrying amount of the asset group was not recoverable through undiscounted future cash flows, which included estimated sublease proceeds, due to the prolonged impact of the COVID-19 pandemic on market conditions. Based on the excess of the carrying amount of the asset group over its fair value, the Company recorded an impairment loss of $3.2 million within Impairment charges in Operating expenses during the year ended December 31, 2021. The Company entered into an operating lease for a research and development facility in Santa Clara, California during the first quarter of 2020 that did not commence until the second quarter of 2021. Upon commencement, the Company recognized operating lease liabilities of $4.0 million and right-of-use assets of $2.4 million. During the third quarter of 2021, the Company determined that the remaining carrying amount of the operating lease right-of-use asset was not recoverable through undiscounted future cash flows, which included estimated sublease proceeds, due to the prolonged impact of the COVID-19 pandemic on market conditions. Based on the excess of the carrying amount of the operating lease right-of-use asset over its fair value, the Company recorded an impairment loss of $0.8 million within Impairment charges in Operating expenses during the year ended December 31, 2021. If actual results differ from estimated amounts, additional impairment charges may be recorded in the future. | ||||||
Total impairment charges | $ 231.1 | $ 239.8 | $ 0 | $ 470.9 | $ 4 | ||
Operating Lease, Liability | 13.3 | 13.3 | |||||
Operating Lease, Right-of-Use Asset | 13.1 | 13.1 | 12.6 | ||||
Total impairment charges | 231.1 | $ 239.8 | 0 | 470.9 | 4 | ||
Operating Lease, Right-of-Use Asset | 13.1 | 13.1 | 12.6 | ||||
Operating Lease, Liability | $ 13.3 | $ 13.3 | |||||
Mountain View California | |||||||
Asset Impairment Charges [Abstract] | |||||||
Total impairment charges | 3.2 | ||||||
Total impairment charges | $ 3.2 | ||||||
Santa Clara California | |||||||
Asset Impairment Charges [Abstract] | |||||||
Total impairment charges | $ 0.8 | ||||||
Operating Lease, Liability | $ 4 | ||||||
Operating Lease, Right-of-Use Asset | 2.4 | ||||||
Total impairment charges | $ 0.8 | ||||||
Operating Lease, Right-of-Use Asset | 2.4 | ||||||
Operating Lease, Liability | $ 4 | ||||||
Precision Devices | |||||||
Asset Impairment Charges [Abstract] | |||||||
Total impairment charges | 0 | ||||||
Total impairment charges | $ 0 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Inventory, Net [Abstract] | ||
Raw materials | $ 140.3 | $ 116.1 |
Work in progress | 36.7 | 28.3 |
Finished goods | 63 | 62.8 |
Subtotal | 240 | 207.2 |
Less reserves | (43.6) | (37.7) |
Total | $ 196.4 | $ 169.5 |
Property, Plant and Equipment_3
Property, Plant and Equipment, net (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||||
Property plant and equipment, gross | $ 655 | $ 655 | $ 658.3 | |
Less Accumulated depreciation | (479.6) | (479.6) | (496.5) | |
Property, plant and equipment, net | 175.4 | 175.4 | 161.8 | |
Gain (Loss) on Disposition of Property Plant Equipment | (10) | 0.5 | $ 0 | |
Proceeds from the sale of property, plant, and equipment | 12.5 | 0.1 | 0.6 | |
Proceeds from the sale of fixed assets, fair value of control transferred | 11.2 | |||
Depreciation | 33 | 41.7 | $ 46.6 | |
Consumer MEMS Microphones | ||||
Property, Plant and Equipment [Line Items] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | (11) | |||
Deferred Revenue | 0.2 | 0.2 | ||
Proceeds from the sale of property, plant, and equipment | 11.4 | |||
Land | ||||
Property, Plant and Equipment [Line Items] | ||||
Property plant and equipment, gross | 14.3 | 14.3 | 12.5 | |
Buildings and improvements | ||||
Property, Plant and Equipment [Line Items] | ||||
Property plant and equipment, gross | 122.5 | 122.5 | 114.6 | |
Machinery, equipment, and other | ||||
Property, Plant and Equipment [Line Items] | ||||
Property plant and equipment, gross | $ 518.2 | 518.2 | $ 531.2 | |
Gain on sale of fixed assets | ||||
Property, Plant and Equipment [Line Items] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | (10) | |||
Cost of Goods Sold, Restructuring Charges [Member] | ||||
Property, Plant and Equipment [Line Items] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | (1) | |||
Cost of Goods Sold, Restructuring Charges [Member] | Consumer MEMS Microphones | ||||
Property, Plant and Equipment [Line Items] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | $ (1) |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets - Goodwill (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Goodwill [Roll Forward] | |||||
Beginning balance | $ 471 | $ 941.3 | |||
Acquisitions | 69.6 | ||||
Total impairment charges | $ (231.1) | $ (239.8) | 0 | (470.9) | $ (4) |
Goodwill, Foreign Currency Translation Gain (Loss) | 0.1 | (0.1) | |||
Ending balance | 540.7 | 540.7 | 471 | 941.3 | |
Goodwill, Purchase Accounting Adjustments | 0.7 | ||||
Payments to Acquire Assets, Investing Activities | 0.3 | 0 | 0 | ||
Precision Devices | |||||
Goodwill [Roll Forward] | |||||
Beginning balance | 63.2 | 62.5 | |||
Acquisitions | 69.6 | ||||
Total impairment charges | 0 | ||||
Goodwill, Foreign Currency Translation Gain (Loss) | 0 | 0 | |||
Ending balance | 132.8 | 132.8 | 63.2 | 62.5 | |
Precision Devices | Integrated Microwave Corporation | |||||
Goodwill [Roll Forward] | |||||
Goodwill, Purchase Accounting Adjustments | 0.7 | ||||
MedTech & Specialty Audio | |||||
Goodwill [Roll Forward] | |||||
Beginning balance | 137.7 | 137.7 | |||
Acquisitions | 0 | ||||
Total impairment charges | 0 | ||||
Goodwill, Foreign Currency Translation Gain (Loss) | 0 | 0 | |||
Ending balance | 137.7 | 137.7 | 137.7 | 137.7 | |
Goodwill, Purchase Accounting Adjustments | 0 | ||||
Consumer MEMS Microphones | |||||
Goodwill [Roll Forward] | |||||
Beginning balance | 270.1 | 741.1 | |||
Acquisitions | 0 | ||||
Total impairment charges | (470.9) | ||||
Goodwill, Foreign Currency Translation Gain (Loss) | 0.1 | (0.1) | |||
Ending balance | $ 270.2 | $ 270.2 | 270.1 | $ 741.1 | |
Goodwill, Purchase Accounting Adjustments | $ 0 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets - Intangible Assets and Amortization Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Gross | $ 204 | $ 86.2 | |
Accumulated Amortization | 46.6 | 33.1 | |
Intangible Assets, Net | 189.4 | 85.1 | |
Payments to Acquire Assets, Investing Activities | $ 0.3 | 0 | $ 0 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 8 years 10 months 24 days | ||
Selling and Administrative Expenses | |||
Finite-Lived Intangible Assets [Line Items] | |||
Amortization Expense | $ 13.5 | 12.2 | $ 15.9 |
Trademarks | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Gross | 16 | 2 | |
Accumulated Amortization | $ 1.2 | 0.8 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years 9 months 18 days | ||
Customer relationships | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Gross | $ 121.1 | 36.4 | |
Accumulated Amortization | $ 16 | 10.3 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 9 years 1 month 6 days | ||
Customer relationships | Immaterial Asset Acquisition | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Customer Relationships, Gross | $ 2 | ||
Payments to Acquire Assets, Investing Activities | 0.3 | ||
Asset Acquisition, Contingent Consideration, Liability, Noncurrent | $ 1.7 | ||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 7 years | ||
Developed technology | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Gross | $ 64.5 | 45.4 | |
Accumulated Amortization | $ 27.4 | 20.1 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years 6 months | ||
Other | |||
Finite-Lived Intangible Assets [Line Items] | |||
Finite-Lived Intangible Assets, Gross | $ 2.4 | 2.4 | |
Accumulated Amortization | $ 2 | 1.9 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 7 years 3 months 18 days | ||
Trademarks | |||
Finite-Lived Intangible Assets [Line Items] | |||
Indefinite-lived Intangible Assets (Excluding Goodwill) | $ 32 | $ 32 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets - Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Trademarks | ||
Unamortized intangible assets: | ||
Gross Carrying Amount | $ 32 | $ 32 |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets - Future Amortization Expense (Details) $ in Millions | Dec. 31, 2023 USD ($) |
Future Amortization Expense [Abstract] | |
2023 | $ 23.1 |
2024 | 22.5 |
2025 | 16.6 |
2026 | 16.6 |
2027 | 15.8 |
Finite-Lived Intangible Asset, Expected Amortization, after Year Five | 62.8 |
Finite-Lived Intangible Assets, Net | $ 157.4 |
Leases (Details)
Leases (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 01, 2023 | |
Finance Lease, Right-of-Use Asset | $ 3.4 | $ 5.3 | ||
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property, Plant and Equipment, Net | Property, Plant and Equipment, Net | ||
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Other accrued expenses | Other accrued expenses | ||
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Long-term operating lease liabilities | Long-term operating lease liabilities | ||
Finance Lease, Liability, Noncurrent | $ 0.6 | $ 1.4 | ||
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year | 5.5 | |||
Finance Lease, Liability, Payments, Remainder of Fiscal Year | $ 1.6 | |||
Operating Lease, Weighted Average Remaining Lease Term | 3 years 3 months 18 days | 2 years 6 months | ||
Operating Lease, Payments | $ 9.1 | $ 12.4 | $ 10.2 | |
Finance Lease, Right-of-Use Asset | 3.4 | 5.3 | ||
Operating Lease, Cost | 7.9 | 8.2 | 9.9 | |
Finance Lease, Right-of-Use Asset, Amortization | 2.3 | 2.3 | 2.3 | |
Finance Lease, Interest Expense | 0.2 | 0.3 | 0.4 | |
Sublease Income | (3.3) | (3.5) | (3) | |
Lease, Cost | 7.1 | 7.3 | 9.6 | |
Finance Lease, Liability | 2.2 | 3.9 | ||
Finance Lease, Interest Payment on Liability | 0.2 | 0.3 | 0.4 | |
Finance Lease, Principal Payments | 2.5 | 4.8 | 2.3 | |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 2.6 | 2 | 6.5 | |
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | $ 0.7 | $ 0.4 | $ 0.3 | |
Finance Lease, Weighted Average Remaining Lease Term | 2 years 6 months | 2 years 2 months 12 days | ||
Operating Lease, Weighted Average Discount Rate, Percent | 5% | 3.40% | ||
Finance Lease, Weighted Average Discount Rate, Percent | 5.60% | 5.30% | ||
Lessee, Operating Lease, Liability, Payments, Due Year Two | $ 3.3 | |||
Finance Lease, Liability, Payments, Due Year Two | 0.4 | |||
Lessee, Operating Lease, Liability, Payments, Due Year Three | 2.4 | |||
Finance Lease, Liability, Payments, Due Year Three | 0.2 | |||
Lessee, Operating Lease, Liability, Payments, Due Year Four | 2.1 | |||
Finance Lease, Liability, Payments, Due Year Four | 0.1 | |||
Lessee, Operating Lease, Liability, Payments, Due Year Five | 1 | |||
Finance Lease, Liability, Payments, Due Year Five | 0 | |||
Lessee, Operating Lease, Liability, Payments, Due after Year Five | 0.2 | |||
Finance Lease, Liability, Payments, Due after Year Five | 0 | |||
Lessee, Operating Lease, Liability, Payments, Due | 14.5 | |||
Finance Lease, Liability, Payment, Due | 2.3 | |||
Lessee, Operating Lease, Liability, Undiscounted Excess Amount | (1.2) | |||
Finance Lease, Liability, Undiscounted Excess Amount | (0.1) | |||
Operating Lease, Liability | $ 13.3 | |||
Cornell Dubilier | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities | $ 3.4 | |||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities | $ 0.1 | |||
Maximum [Member] | ||||
Lessee, Operating Lease, Term of Contract | 7 years | |||
Lessor, Operating Lease, Renewal Term | 6 years | |||
Minimum [Member] | ||||
Lessee, Operating Lease, Term of Contract | 1 year | |||
Lessee Operating and Finance Leases Options to Terminate Leases Term | 1 year |
Accrued Expenses and Other Li_3
Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Accrued Liabilities and Other Liabilities [Abstract] | ||
Restructuring and exit costs | $ 8.5 | $ 4 |
Sales volume rebates | 3.6 | 4 |
Accrued taxes other than income taxes | 2.4 | 1.8 |
Accrued Insurance | 2 | 1.6 |
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | 1.6 | 2.5 |
Derivative Liability, Current | 0.7 | 0.8 |
Warranty | 0.7 | 0.4 |
Other | 5.5 | 4.8 |
Other accrued expenses | $ 25 | $ 19.9 |
Accrued Expenses and Other Li_4
Accrued Expenses and Other Liabilities - Schedule of Other Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Accrued Liabilities and Other Liabilities [Abstract] | ||
Finance Lease, Liability, Noncurrent | $ 0.6 | $ 1.4 |
Total | $ 31.1 | $ 38.8 |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Total | Total |
Finance Lease, Liability, Noncurrent | $ 0.6 | $ 1.4 |
Derivative Liability, Noncurrent | $ 0.4 | $ 0 |
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Total | Total |
Other liabilities | ||
Accrued Liabilities and Other Liabilities [Abstract] | ||
Restructuring and exit costs | $ 10.7 | $ 18.7 |
Deferred compensation, including defined benefit plans | 13.6 | 12.9 |
Unrecognized tax benefits | 2.3 | 2.5 |
Other Sundry Liabilities, Noncurrent | 1.8 | 0.8 |
Deferred compensation, including defined benefit plans | 13.6 | 12.9 |
Restructuring and exit costs | 10.7 | 18.7 |
Unrecognized tax benefits | 2.3 | 2.5 |
Deferred Revenue, Revenue Recognized | 1.7 | 2.5 |
Other Sundry Liabilities, Noncurrent | $ 1.8 | $ 0.8 |
Accrued Expenses and Other Li_5
Accrued Expenses and Other Liabilities Accrued Expenses and Other Liabilities - Product Warrant Accrual Rollforward (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 01, 2023 | |
Warranty Accrual [Roll Forward] | ||||
Beginning balance, January 1 | $ 0.4 | $ 0.5 | $ 0.4 | |
Provision for warranties | 0.5 | 0.6 | 1 | |
Settlements made | (0.4) | (0.5) | (0.9) | |
Standard Product Warranty Accrual, Additions from Business Acquisition | (0.2) | (0.2) | 0 | |
Ending balance, December 31 | 0.7 | 0.4 | 0.5 | |
Standard and Extended Product Warranty Accrual | $ 0.7 | $ 0.4 | $ 0.5 | |
Cornell Dubilier | ||||
Standard and Extended Product Warranty Accrual | $ 0.3 |
Restructuring and Related Act_3
Restructuring and Related Activities - Costs Recognized and Remaining Costs (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring Cost and Reserve [Line Items] | |||
Gain (Loss) on Disposition of Property Plant Equipment | $ 10 | $ (0.5) | $ 0 |
Restructuring Charges | 2.2 | 41.8 | 0.5 |
Restructuring Charges | 2.2 | 41.8 | 0.5 |
Consumer MEMS Microphones | |||
Restructuring Cost and Reserve [Line Items] | |||
Gain (Loss) on Disposition of Property Plant Equipment | 11 | ||
Restructuring Charges | 1.1 | 41.2 | 0.3 |
Restructuring Charges | 1.1 | 41.2 | $ 0.3 |
Cost of Goods Sold, Restructuring Charges [Member] | |||
Restructuring Cost and Reserve [Line Items] | |||
Gain (Loss) on Disposition of Property Plant Equipment | 1 | ||
Restructuring Charges | 21.1 | ||
Restructuring Charges | 21.1 | ||
Cost of Goods Sold, Restructuring Charges [Member] | Consumer MEMS Microphones | |||
Restructuring Cost and Reserve [Line Items] | |||
Gain (Loss) on Disposition of Property Plant Equipment | 1 | ||
Severance Pay and Benefits | Cost of Goods Sold, Restructuring Charges [Member] | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring Charges | 4.4 | ||
Restructuring Charges | $ 4.4 | ||
Contract Termination | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring Charges | (1.5) | ||
Restructuring Charges | $ (1.5) |
Restructuring and Related Act_4
Restructuring and Related Activities - Restructuring Activities (Details) - USD ($) $ in Millions | 2 Months Ended | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | $ (2.2) | $ (41.8) | $ (0.5) | |
Document Fiscal Year Focus | 2023 | |||
Restructuring Reserve [Roll Forward] | ||||
Beginning balance | $ 22.7 | 0.4 | 2.6 | |
Restructuring charges | (2.2) | (41.8) | (0.5) | |
Payments | (7.4) | (7.8) | (2.7) | |
Other, including foreign currency | (1.7) | 11.7 | ||
Ending balance | $ 19.2 | $ 19.2 | 22.7 | 0.4 |
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] | Cost of goods sold, Restructuring charges | |||
Restructuring charges | $ 3.5 | 9.6 | 0.5 | |
Restructuring charges - cost of goods sold | (1.3) | 32.2 | 0 | |
Gain (Loss) on Disposition of Property Plant Equipment | 10 | (0.5) | 0 | |
Cornell Dubilier | ||||
Restructuring Reserve [Roll Forward] | ||||
Restructuring charges | (1.1) | |||
Intelligent Audio | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (39) | |||
Severance Pay and Benefits | ||||
Restructuring Reserve [Roll Forward] | ||||
Beginning balance | 0.9 | 0.4 | 1.9 | |
Restructuring charges | (4.7) | (6.6) | (0.5) | |
Payments | (4.3) | (6.2) | (2) | |
Other, including foreign currency | (1.1) | (0.1) | ||
Ending balance | 2.4 | 2.4 | 0.9 | 0.4 |
Facility Closing [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Beginning balance | 21.8 | 0 | 0.7 | |
Restructuring charges | (2.5) | (35.2) | 0 | |
Payments | (3.1) | (1.6) | (0.7) | |
Other, including foreign currency | 0.6 | 11.8 | ||
Ending balance | $ 16.8 | 16.8 | 21.8 | 0 |
Contract Termination | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | 1.5 | |||
Corporate, Non-Segment [Member] | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (0.8) | (0.6) | 0 | |
Precision Devices | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (2.5) | 0 | (0.1) | |
MedTech & Specialty Audio | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | 0 | 0 | (0.1) | |
Consumer MEMS Microphones | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (1.1) | (41.2) | $ (0.3) | |
Restructuring Reserve [Roll Forward] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | 11 | |||
Restructuring Charges [Member] | Severance Pay and Benefits | Consumer MEMS Microphones | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (1.4) | |||
Restructuring Charges [Member] | Precision Devices | Severance Pay and Benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (2.5) | |||
Restructuring Charges [Member] | Consumer MEMS Microphones | ||||
Restructuring Reserve [Roll Forward] | ||||
Restructuring charges | 9.6 | |||
Restructuring Charges [Member] | Consumer MEMS Microphones | Other Restructuring | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (0.6) | |||
Restructuring Charges [Member] | Corporate Segment | Other Restructuring | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (0.8) | |||
Cost of Goods Sold, Restructuring Charges [Member] | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (21.1) | |||
Restructuring Reserve [Roll Forward] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | 1 | |||
Cost of Goods Sold, Restructuring Charges [Member] | Severance Pay and Benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (4.4) | |||
Cost of Goods Sold, Restructuring Charges [Member] | Facility Closing [Member] | Intelligent Audio | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | (13.5) | |||
Cost of Goods Sold, Restructuring Charges [Member] | Consumer MEMS Microphones | ||||
Restructuring Reserve [Roll Forward] | ||||
Gain (Loss) on Disposition of Property Plant Equipment | $ 1 | |||
Cost of Goods Sold, Restructuring Charges [Member] | Consumer MEMS Microphones | Severance Pay and Benefits | Intelligent Audio | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Charges | $ (2.2) |
Restructuring and Related Act_5
Restructuring and Related Activities - Balance Sheet Location (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Reserve | $ 19.2 | $ 22.7 | $ 0.4 | $ 2.6 |
Other, including foreign currency | (1.7) | 11.7 | ||
Facility Closing [Member] | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Reserve | 16.8 | 21.8 | $ 0 | $ 0.7 |
Other, including foreign currency | 0.6 | 11.8 | ||
Other accrued expenses | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Reserve | 8.5 | 4 | ||
Other liabilities | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring Reserve | $ 10.7 | $ 18.7 |
Hedging Transactions and Deri_3
Hedging Transactions and Derivative Instruments - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Derivative [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax | $ 1.1 | $ 0.6 | $ (0.2) |
Foreign Currency Gain (Loss) [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | Not Designated as Hedging Instrument | |||
Derivative [Line Items] | |||
Derivative, Notional Amount | 111.7 | 86.3 | |
Foreign Exchange Forward [Member] | Cash Flow Hedging | Designated as Hedging Instrument | |||
Derivative [Line Items] | |||
Derivative, Notional Amount | 49.2 | 68 | |
Foreign Exchange Contract [Member] | Cash flow hedges | |||
Derivative [Line Items] | |||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax | (5) | (3.4) | 0.5 |
Foreign Exchange Contract [Member] | Cash Flow Hedging | Designated as Hedging Instrument | Other expense (income), net | |||
Derivative [Line Items] | |||
Gain (loss) on derivatives | $ 0 | $ 0 | $ 0 |
Hedging Transactions and Deri_4
Hedging Transactions and Derivative Instruments - Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Derivatives, Fair Value [Line Items] | |||
Cost of goods sold | $ 435.5 | $ 455.7 | $ 508.6 |
Interest Revenue (Expense), Net | (5.4) | (3.9) | (14.2) |
Other Nonoperating Income (Expense) | $ (0.7) | $ 0.5 | 3 |
Document Fiscal Year Focus | 2023 | ||
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other Assets, Noncurrent | Other Assets, Noncurrent | |
Derivative Liability, Statement of Financial Position [Extensible Enumeration] | Other accrued expenses | Other accrued expenses | |
Derivative Liability, Current | $ 0.7 | $ 0.8 | |
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other accrued expenses | Other accrued expenses | |
Derivative Liability, Noncurrent | $ (0.4) | $ 0 | |
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Long-term operating lease liabilities | Long-term operating lease liabilities | |
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration] | Prepaid and other current assets | Prepaid and other current assets | |
Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Forward [Member] | |||
Derivatives, Fair Value [Line Items] | |||
Derivative, Notional Amount | $ 49.2 | $ 68 | |
Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Contract [Member] | |||
Derivatives, Fair Value [Line Items] | |||
Derivative Asset, Current | 0.4 | 1.1 | |
Derivative Asset, Noncurrent | 0 | 1.3 | |
Derivative Liability, Current | (0.7) | (0.8) | |
Derivative Liability, Noncurrent | (0.4) | 0 | |
Not Designated as Hedging Instrument, Economic Hedge [Member] | Not Designated as Hedging Instrument | Foreign Currency Gain (Loss) [Member] | |||
Derivatives, Fair Value [Line Items] | |||
Derivative, Notional Amount | 111.7 | 86.3 | |
Not Designated as Hedging Instrument, Economic Hedge [Member] | Not Designated as Hedging Instrument | Foreign Currency Economic Hedge | |||
Derivatives, Fair Value [Line Items] | |||
Derivative Asset, Current | 0.1 | 0.6 | |
Derivative Liability, Current | 0.1 | 0 | |
Cost of Sales | Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Contract [Member] | |||
Derivatives, Fair Value [Line Items] | |||
Gain (loss) on derivatives | (2.7) | (4.5) | 2.1 |
Cost of Sales | Not Designated as Hedging Instrument, Economic Hedge [Member] | Not Designated as Hedging Instrument | Foreign Currency Economic Hedge | |||
Derivatives, Fair Value [Line Items] | |||
Gain (loss) on derivatives | 0 | 0 | 0 |
Other expense (income), net | Cash Flow Hedging | Designated as Hedging Instrument | Foreign Exchange Contract [Member] | |||
Derivatives, Fair Value [Line Items] | |||
Gain (loss) on derivatives | 0 | 0 | 0 |
Other expense (income), net | Not Designated as Hedging Instrument, Economic Hedge [Member] | Not Designated as Hedging Instrument | Foreign Currency Economic Hedge | |||
Derivatives, Fair Value [Line Items] | |||
Gain (loss) on derivatives | $ 3.3 | $ 1 | $ (1.4) |
Hedging Transaction and Derivat
Hedging Transaction and Derivative Instruments - Fair Value of Derivatives Qualifying as Hedging Instrument (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Foreign Exchange Contract [Member] | Designated as Hedging Instrument | Cash Flow Hedging | Other expense (income), net | |||
Derivative Instruments, Gain (Loss) [Line Items] | |||
Gain (loss) on derivatives | $ 0 | $ 0 | $ 0 |
Foreign Exchange Contract [Member] | Designated as Hedging Instrument | Cash Flow Hedging | Cost of Sales | |||
Derivative Instruments, Gain (Loss) [Line Items] | |||
Gain (loss) on derivatives | (2.7) | (4.5) | 2.1 |
Foreign Currency Economic Hedge | Not Designated as Hedging Instrument | Not Designated as Hedging Instrument, Economic Hedge [Member] | Other expense (income), net | |||
Derivative Instruments, Gain (Loss) [Line Items] | |||
Gain (loss) on derivatives | 3.3 | 1 | (1.4) |
Foreign Currency Economic Hedge | Not Designated as Hedging Instrument | Not Designated as Hedging Instrument, Economic Hedge [Member] | Cost of Sales | |||
Derivative Instruments, Gain (Loss) [Line Items] | |||
Gain (loss) on derivatives | $ 0 | $ 0 | $ 0 |
Borrowings and Lines of Credi_2
Borrowings and Lines of Credit - Schedule of Long-term Debt Instruments (Details) - USD ($) | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Sep. 25, 2023 | |
Debt Instrument [Line Items] | ||||
Document Fiscal Year Focus | 2023 | |||
Long-term borrowings [Abstract] | ||||
Line of Credit Facility, Commitment Fee Percentage | 0.50% | |||
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year | $ 50,000,000 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Two | 72,900,000 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Three | 0 | |||
Long-term Debt, Maturities, Repayments of Principal in Year Four | 0 | |||
Long-term debt (noncurrent) | 224,100,000 | $ 45,000,000 | ||
Long-term Debt, Current Maturities | 47,100,000 | 0 | ||
Long-term Line of Credit | 160,000,000 | 45,000,000 | ||
Long-term debt | 271,200,000 | 45,000,000 | ||
Long-term Debt, Maturities, Repayments of Principal in Year Five | $ 160,000,000 | |||
Debt instrument, Convenant, Senior Secured Leverage Ratio Under Accordion Feature, Maximum | 2 | |||
Debt covenant, EBITDA to interest ratio | 3 | |||
Debt Instrument, Covenant, Debt to EBITDA, Maximum | 3.75 | |||
Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum | 3.25 | |||
Repayments of Short-Term Debt | $ 50,000,000 | |||
Credit Facility due February 8, 2028 | ||||
Long-term borrowings [Abstract] | ||||
Line of credit facility, maximum borrowing capacity | 400,000,000 | |||
Line of credit facility, accordion feature, increase limit | 200,000,000 | |||
Credit Facility due February 8, 2028 | Euro Member Countries, Euro | ||||
Long-term borrowings [Abstract] | ||||
Line of credit facility, maximum borrowing capacity | 100,000,000 | |||
September 25, 2023 Credit Facility Amendment | ||||
Long-term borrowings [Abstract] | ||||
Line of credit facility, maximum borrowing capacity | 80,000,000 | |||
Secured Long-Term Debt, Noncurrent | $ 122,900,000 | |||
Seller Note | ||||
Long-term borrowings [Abstract] | ||||
Other Notes Payable | 111,200,000 | $ 0 | ||
Letter of Credit | Credit Facility due February 8, 2028 | ||||
Long-term borrowings [Abstract] | ||||
Line of credit facility, maximum borrowing capacity | $ 50,000,000 | |||
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Credit Facilities [Member] | ||||
Long-term borrowings [Abstract] | ||||
Long-term Debt, Weighted Average Interest Rate, at Point in Time | 6.55% | 3.21% | 2.25% | |
Weighted Average [Member] | ||||
Long-term borrowings [Abstract] | ||||
Line of Credit Facility, Commitment Fee Percentage | 0.23% | 0.23% | 0.26% | |
Minimum | Credit Facility due February 8, 2028 | ||||
Long-term borrowings [Abstract] | ||||
Line of Credit Facility, Commitment Fee Percentage | 0.225% | |||
Maximum | Credit Facility due February 8, 2028 | ||||
Long-term borrowings [Abstract] | ||||
Line of Credit Facility, Commitment Fee Percentage | 0.35% |
Borrowings and Lines of Credi_3
Borrowings and Lines of Credit - Schedule of Interest Expense and Interest Income (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Maturities of Long-term Debt [Abstract] | |||
Long-term Debt, Maturities, Repayments of Principal in Year Two | $ 72.9 | ||
Long-term Debt, Maturities, Repayments of Principal in Year Three | 0 | ||
Long-term Debt, Maturities, Repayments of Principal in Year Four | 0 | ||
Long-term Debt, Maturities, Repayments of Principal in Year Five | $ 160 | ||
Document Fiscal Year Focus | 2023 | ||
Interest Expense, Borrowings | $ 7.4 | $ 4.3 | $ 14.4 |
Interest Income, Operating | (2) | (0.4) | (0.2) |
Interest Income (Expense), Net | 5.4 | 3.9 | 14.2 |
Interest Revenue (Expense), Net | $ 5.4 | $ 3.9 | $ 14.2 |
Borrowings and Lines of Credi_4
Borrowings and Lines of Credit Borrowings and Lines of Credit - Narrative (Details) $ / shares in Units, $ in Millions | 2 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Nov. 01, 2023 USD ($) Rate | Dec. 31, 2023 USD ($) | Jun. 30, 2022 shares | Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | May 04, 2016 $ / shares | |
Debt Instrument [Line Items] | ||||||||
Long-term Debt, Current Maturities | $ 47.1 | $ 47.1 | $ 0 | |||||
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share | $ / shares | $ 0 | $ 0 | $ 0 | |||||
Debt covenant, EBITDA to interest ratio | 3 | |||||||
Debt Instrument, Covenant, Debt to EBITDA, Maximum | 3.75 | |||||||
Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum | 3.25 | |||||||
Long-term debt | 224.1 | $ 224.1 | $ 45 | |||||
Net deferred tax asset | 98.9 | $ 98.9 | 73.9 | |||||
Document Fiscal Year Focus | 2023 | |||||||
Line of Credit Facility, Commitment Fee Percentage | 0.50% | |||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 0 | |||||||
Long-term Debt, Maturities, Repayments of Principal in Year Five | 160 | $ 160 | ||||||
Restructuring Charges | 2.2 | 41.8 | 0.5 | |||||
Restructuring charges | 2.2 | 41.8 | 0.5 | |||||
Shares Issued During Period, Value, Exercise of Warrants | $ 3.1 | 0 | ||||||
Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | 2.5 | 0 | 0.1 | |||||
Cornell Dubilier | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring charges | 1.1 | |||||||
Cornell Dubilier | Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Interest Expense, Debt | $ 1.3 | |||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 109.9 | |||||||
Cornell Dubilier | Seller Note | Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 50 | |||||||
Imputed Interest Rate on Future Payments | Rate | 7.10% | |||||||
Severance Pay and Benefits | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring charges | 4.7 | 6.6 | 0.5 | |||||
Facility Closing [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring charges | 2.5 | 35.2 | $ 0 | |||||
Cost of Goods Sold, Restructuring Charges [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | 21.1 | |||||||
Cost of Goods Sold, Restructuring Charges [Member] | Severance Pay and Benefits | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | 4.4 | |||||||
Restructuring Charges [Member] | Severance Pay and Benefits | Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | $ 2.5 | |||||||
Intelligent Audio | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | 39 | |||||||
Intelligent Audio | Cost of Goods Sold, Restructuring Charges [Member] | Facility Closing [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Restructuring Charges | $ 13.5 | |||||||
Seller Note | Cornell Dubilier | Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 122.9 | |||||||
Treasury Stock, Common | ||||||||
Debt Instrument [Line Items] | ||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 363,579 | |||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ (5.9) | |||||||
Shares Issued During Period, Shares, Exercise of Warrants | shares | 200,000 | 203,615 | ||||||
Shares Issued During Period, Value, Exercise of Warrants | $ 3.1 | |||||||
Convertible Debt | Convertible Notes Due Twenty Twenty One [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 21.1050 | |||||||
Proceeds from issuance of warrants | $ 39.1 | |||||||
Seller Note | Cornell Dubilier | Precision Devices | ||||||||
Debt Instrument [Line Items] | ||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 72.9 | |||||||
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Credit Facilities | ||||||||
Debt Instrument [Line Items] | ||||||||
Long-term Debt, Weighted Average Interest Rate, at Point in Time | 6.55% | 6.55% | 3.21% | 2.25% | ||||
Minimum | Credit Facility due January 2, 2024 [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of Credit Facility, Commitment Fee Percentage | 0.50% | |||||||
Minimum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Credit Facility due January 2, 2024 [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Basis Spread on Variable Rate | 1.50% | |||||||
Maximum | Credit Facility due January 2, 2024 [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of Credit Facility, Commitment Fee Percentage | 1.50% | |||||||
Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Credit Facility due January 2, 2024 [Member] | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Basis Spread on Variable Rate | 2.50% | |||||||
Weighted Average | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of Credit Facility, Commitment Fee Percentage | 0.23% | 0.23% | 0.26% |
Income Taxes - Income before Ta
Income Taxes - Income before Tax, Domestic and Foreign (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Income Tax Disclosure [Abstract] | ||||
Document Fiscal Year Focus | 2023 | |||
Components of Earnings before Income Tax [Abstract] | ||||
Domestic | $ (120.4) | $ (410.1) | $ 15.5 | |
Foreign | 165.4 | (8.1) | 89.1 | |
(Loss) earnings before income taxes | [1] | 45 | (418.2) | 104.6 |
Unrecognized Tax Benefits, Income Tax Penalties Accrued | 0 | $ 0.1 | $ 0.3 | |
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | 2.3 | |||
Income Tax Holiday [Line Items] | ||||
Undistributed earnings of foreign subsidiaries | $ 1,400 | |||
Foreign Tax Authority | ||||
Income Tax Holiday [Line Items] | ||||
Income Tax Holiday, Income Tax Benefits Per Share | $ 0.01 | $ 0.01 | $ 0.12 | |
[1] Years Ended December 31, (in millions) 2023 2022 2021 Revenues: Precision Devices $ 221.4 $ 242.9 $ 201.1 MedTech & Specialty Audio 230.0 229.9 231.3 Consumer MEMS Microphones 256.2 291.9 435.7 Total revenues $ 707.6 $ 764.7 $ 868.1 Earnings (loss) from continuing operations before interest and income taxes: Precision Devices $ 25.0 $ 56.1 $ 43.7 MedTech & Specialty Audio 85.2 84.6 77.0 Consumer MEMS Microphones 13.6 (504.5) 60.0 Total segments 123.8 (363.8) 180.7 Corporate expense / other 73.4 50.5 61.9 Interest expense, net 5.4 3.9 14.2 Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Depreciation and amortization: Precision Devices $ 15.8 $ 13.8 $ 13.3 MedTech & Specialty Audio 8.2 8.1 6.3 Consumer MEMS Microphones 20.3 29.5 39.9 Corporate 2.2 2.5 3.0 Total $ 46.5 $ 53.9 $ 62.5 Capital expenditures: Precision Devices $ 7.6 $ 7.4 $ 5.6 MedTech & Specialty Audio 4.6 7.3 11.6 Consumer MEMS Microphones 4.7 17.2 29.2 Corporate — 0.2 2.2 Total $ 16.9 $ 32.1 $ 48.6 Research and development: Precision Devices $ 13.8 $ 12.3 $ 10.5 MedTech & Specialty Audio 18.2 16.9 16.1 Consumer MEMS Microphones 46.1 52.4 65.7 Corporate 0.4 0.1 0.5 Total $ 78.5 $ 81.7 $ 92.8 |
Income Taxes - Components of In
Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Document Fiscal Year Focus | 2023 | ||
Current: | |||
U.S. Federal | $ 1.8 | $ 1.2 | $ 0.4 |
State and local | 0.3 | 0.6 | 0.3 |
Foreign | 12.1 | 5.5 | 14.8 |
Total current tax expense | 14.2 | 7.3 | 15.5 |
Deferred: | |||
U.S. Federal | (39.9) | 3 | (57.1) |
State and local | (2.5) | (0.3) | (2.6) |
Foreign | 0.8 | 1.9 | (1.4) |
Total deferred tax (benefit) expense | (41.6) | 4.6 | (61.1) |
Total income tax (benefit) expense | $ (27.4) | $ 11.9 | $ (45.6) |
Income Taxes - Effective Income
Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Holiday [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Effective Income Tax Rate Reconciliation [Abstract] | |||
Income tax expense (benefit) at U.S. federal statutory income tax rate | $ 9.4 | $ (87.8) | $ 22 |
State and local taxes, net of Federal income tax benefit | (2.1) | 0.6 | 0.3 |
Foreign operations tax effect | 4.2 | 6.4 | 3.5 |
Research and experimentation tax credits | (2.9) | (3.4) | (4) |
Valuation allowance | (14.4) | 0.8 | (59.7) |
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | (1.7) | (1.3) | (1.2) |
Tax contingencies | (0.2) | (1.1) | 0.6 |
Effective Income Tax Rate Reconciliation, Tax Holiday, Percent | (0.8) | (0.4) | (10.6) |
Foreign taxes | 0.2 | 1.1 | 1 |
Other, principally non-tax deductible items | (1.5) | 0.2 | (0.2) |
Stock-based compensation | 3.7 | 1.8 | 5.1 |
Effective Income Tax Reconciliation, Intellectual Property Transfer Impact | 26.6 | 0 | 0 |
Other, principally non-tax deductible items | 1.6 | 2.5 | 1.3 |
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount | 0 | 90.6 | 0 |
Prior period items | (0.6) | 1.8 | (0.5) |
Total income tax (benefit) expense | (27.4) | 11.9 | (45.6) |
Effective Income Tax Rate Reconciliation, Foreign Currency Adjustments, Percent | 0 | 0 | (0.7) |
Foreign statutory income tax rate | 4.3 | 0.1 | (2.5) |
Valuation allowance | (25.5) | (39.7) | (39.1) |
Foreign Tax Authority | |||
Effective Income Tax Rate Reconciliation [Abstract] | |||
Effective income tax rate reconciliation, tax holiday | $ 1.1 | $ 0.8 | $ 10.7 |
Income tax holiday benefit (usd per share) | $ 0.01 | $ 0.01 | $ 0.12 |
Income Taxes - Deferred Tax Ass
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Valuation Allowance [Line Items] | |||
Deferred Income Taxes and Other Assets, Noncurrent | $ 99.6 | $ 74.8 | |
Deferred Tax Assets, Goodwill and Intangible Assets | 23.3 | 6.9 | |
Deferred Tax Assets, Undistributed Foreign Earnings | 0.7 | 2 | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 15.1 | ||
Deferred tax assets: | |||
Accrued compensation, principally post-retirement, and other employee benefits | 13.2 | 11 | |
Accrued expenses | 5.2 | 4.4 | |
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | 0.4 | 1.5 | |
Net operating loss and other carryforwards | 67.4 | 68 | |
Inventories, principally due to reserves for financial reporting purposes and capitalization for tax purposes | 8.2 | 8.2 | |
Plant and equipment, principally due to differences in depreciation | 10 | 13.8 | |
Total gross deferred tax assets | 128.4 | 115.8 | |
Valuation allowance | (25.5) | (39.7) | $ (39.1) |
Total deferred tax assets | 102.9 | 76.1 | |
Deferred tax liabilities: | |||
Other liabilities | (4) | (2.2) | |
Total gross deferred tax liabilities | (4) | (2.2) | |
Deferred Tax Liabilities, Net, Classification [Abstract] (Deprecated 2022) | |||
Net deferred tax asset | 98.9 | 73.9 | |
Deferred Income Tax Liabilities, Net | $ (0.7) | $ (0.9) |
Income Taxes - Net Operating Lo
Income Taxes - Net Operating Loss and Tax Credit Carryforwards (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Loss Carryforwards [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Income Tax Credits [Abstract] | |||
Undistributed earnings of foreign subsidiaries | $ 1,400 | ||
Undistributed Earnings of Foreign Subsidiaries, not Permanently Reivested | 300 | ||
Undistributed Earnings of Foreign Subsidiaries, Permanently Reivested | 1,100 | ||
Capital Loss Carryforwards, Not Subject to Expiration | 0.1 | ||
State and Local Jurisdiction | |||
Net Operating Loss Carryforwards [Abstract] | |||
Operating loss carryforwards, subject to expiration | 3.2 | ||
Foreign Tax Authority | |||
Operating Loss Carryforwards [Line Items] | |||
Income Tax Holiday, Aggregate Dollar Amount | 1.1 | $ 0.8 | $ 10.7 |
Net Operating Loss Carryforwards [Abstract] | |||
Operating loss carryforwards | 5.2 | ||
Operating Loss Carryforwards, Subject to Expiration in 10-20 years | 4.1 | ||
Operating Loss Carryforwards, Not Subject to Expiration | $ 0.7 | ||
Income Tax Credits [Abstract] | |||
Income Tax Holiday, Income Tax Benefits Per Share | $ 0.01 | $ 0.01 | $ 0.12 |
Operating Loss Carryforwards, Subject to Expiration in up to 5 years | $ 0.3 | ||
Domestic Tax Authority | |||
Net Operating Loss Carryforwards [Abstract] | |||
Operating loss carryforwards | 3.8 | ||
Operating Loss Carryforwards, Subject to Expiration in 5-10 years | 2.1 | ||
Operating Loss Carryforwards, Subject to Expiration in 10-20 years | 1.7 | ||
Research Tax Credit Carryforward | |||
Income Tax Credits [Abstract] | |||
Tax credit carryforward amount | 24.3 | ||
Foreign Tax Credit Carryforward | |||
Income Tax Credits [Abstract] | |||
Tax credit carryforward amount | 15.1 | ||
State Tax Credit Carryforward | |||
Income Tax Credits [Abstract] | |||
Tax credit carryforward amount | 15.7 | ||
Tax Year 2022 Through Tax Year 2036 | State Tax Credit Carryforward | |||
Income Tax Credits [Abstract] | |||
Tax credit carryforward amount | 2 | ||
After Tax Year 2036 | State Tax Credit Carryforward | |||
Income Tax Credits [Abstract] | |||
Tax credit carryforward amount | $ 13.7 |
Income Taxes - Unrecognized Tax
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Total accrued liabilities | $ 0 | $ 0.1 | $ 0.3 |
Potential benefit on the effective tax rate | 2.3 | ||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Unrecognized tax benefits beginning balance | 8.1 | 9.5 | 10.2 |
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | (0.3) | ||
Settlements | (0.4) | ||
Reductions as a result of a lapse in statute of limitations | (0.3) | (1.3) | |
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation | 0.2 | 0.1 | |
Unrecognized tax benefits ending balance | $ 8 | $ 8.1 | $ 9.5 |
Equity Incentive Program - Shar
Equity Incentive Program - Share Based Compensation Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Document Fiscal Year Focus | 2023 | |||
Pre-tax compensation expense | $ 29 | $ 28.6 | $ 32.1 | |
Tax benefit | 3.3 | 4.4 | 5.1 | |
Total stock-based compensation expense, net of tax | $ 25.7 | 24.2 | 27 | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 7,100,000 | |||
Selling and Administrative Expenses | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Pre-tax compensation expense | $ 21 | 21.4 | 25 | |
Research and Development Expense | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Pre-tax compensation expense | 5.9 | 5.6 | 5.5 | |
Cost of Sales | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Pre-tax compensation expense | 2.1 | $ 1.6 | $ 1.6 | |
Share-based Payment Arrangement, Option [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 34.30% | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 0.4 | |||
Weighted average period for compensation expense to be recognized | 9 months 18 days | |||
Performance Shares [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 9.9 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | 261,770 | |||
Weighted average period for compensation expense to be recognized | 1 year 2 months 12 days | |||
Performance Shares [Member] | 2019 | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | 150,811 |
Equity Incentive Program - Stoc
Equity Incentive Program - Stock Options and SSARs (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SSARs, Number of Shares (in shares): | |||
Forfeited | 0 | ||
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | |||
Dividend yield | 0% | ||
Expected life (years) | 4 years 6 months | ||
Volatility | 34.30% | ||
Stock Options, Number of Shares (in share): | |||
Beginning balance | 2,703,424 | ||
Exercised | (536,771) | ||
Forfeited | (12,684) | ||
Expired | (49,613) | ||
Ending balance | 2,104,356 | 2,703,424 | |
Exercisable | 1,947,845 | ||
Stock Options, Weighted Average Exercise Price (in dollars per share): | |||
Beginning balance | $ 16.28 | ||
Exercised | 12.47 | ||
Forfeited | 20.97 | ||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | 19.49 | ||
Ending balance | 17.15 | $ 16.28 | |
Exercisable | $ 16.84 | ||
SARS and Options, Additional Disclosures | |||
Options, aggregate intrinsic value, outstanding | $ 3.3 | ||
Options, aggregate intrinsic value, exercisable | $ 3.3 | ||
Options, weighted average remaining contractual term, outstanding | 2 years 3 months 18 days | ||
Options, weighted average remaining contractual term, exercisable | 2 years | ||
Unrecognized compensation expense | $ 0.4 | ||
Weighted average period for compensation expense to be recognized | 9 months 18 days | ||
Award expiration period | 7 years | ||
SSARs and Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | |||
Dividend yield | 0% | ||
SSARs | |||
SSARs, Number of Shares (in shares): | |||
Beginning balance | 223,564 | ||
Exercised | 0 | ||
Expired | (223,564) | ||
Ending balance | 0 | 223,564 | |
Exercisable | 0 | ||
SSARs, Weighted-average grant date fair value (in dollars per share): | |||
Beginning balance | $ 23.92 | ||
Exercised | 0 | ||
Forfeited | 0 | ||
Expired | 23.92 | ||
Ending balance | 0 | $ 23.92 | |
Exercisable | $ 0 | ||
SARS and Options, Additional Disclosures | |||
SSARs, aggregate intrinsic value, outstanding | $ 0 | ||
SSARs, aggregate intrinsic value, exercisable | $ 0 | ||
SSARs, weighted average remaining contractual terms, outstanding | 0 years | ||
SSARs, weighted average remaining contractual term, exercisable | 0 years | ||
Unrecognized compensation expense | $ 0 | ||
Minimum | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | |||
Risk-free interest rate | 0.85% | 0.06% | |
Expected life (years) | 4 years 6 months | ||
Volatility | 36% | ||
Fair value at date of grant | $ 6.29 | $ 6.14 | |
Maximum | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | |||
Fair value at date of grant | $ 6.31 |
Equity Incentive Program - RSUs
Equity Incentive Program - RSUs (Details) $ / shares in Units, $ in Millions | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Stock Options | |
Weighted Average Grant Date Fair Value (in dollars per share): | |
Unrecognized compensation expense | $ | $ 0.4 |
Weighted average period for compensation expense to be recognized | 9 months 18 days |
Restricted Stock Units (RSUs) | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Fair value of SSARs that are exercisable | $ | $ 15.8 |
Number of Shares (in shares): | |
Beginning balance | shares | 1,880,521 |
Granted | shares | 1,267,642 |
Vested (1) | shares | (901,320) |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | (171,836) |
Ending balance | shares | 2,075,007 |
Weighted Average Grant Date Fair Value (in dollars per share): | |
Beginning balance | $ / shares | $ 19.96 |
Granted | $ / shares | 18.78 |
Vested (1) | $ / shares | 19.40 |
Forfeited | $ / shares | 19.82 |
Ending balance | $ / shares | $ 19.49 |
Unrecognized compensation expense | $ | $ 21.5 |
Weighted average period for compensation expense to be recognized | 1 year 6 months |
Equity Incentive Program - Addi
Equity Incentive Program - Additional Information (Details) shares in Millions | 12 Months Ended |
Dec. 31, 2023 shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 16.1 |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 7.1 |
Stock Options | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Award expiration period | 7 years |
Equity Incentive Program Equity
Equity Incentive Program Equity Incentive Program - Other Information Regarding SSARs and Stock Options (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Cash received by Knowles for exercise of stock options | $ 1.6 | $ 7.5 | $ 25.6 |
Share-based Payment Arrangement, Exercise of Option, Tax Benefit | 0.6 | 1.2 | 1.2 |
SSARs | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate intrinsic value of SSARs exercised | 0 | 0.1 | 0.1 |
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Cash received by Knowles for exercise of stock options | 1.6 | 7.5 | 25.6 |
Aggregate intrinsic value of stock options exercised | $ 2.9 | $ 6 | $ 6.6 |
Equity Incentive Program Equi_2
Equity Incentive Program Equity Incentive Program - PSUs (Details) - Performance Shares [Member] $ in Millions | 3 Months Ended | 12 Months Ended | ||||
Mar. 31, 2023 USD ($) | Mar. 31, 2023 shares | Mar. 31, 2023 numberOfGrantees | Mar. 31, 2022 shares | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 $ / shares shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | 864,749 | 833,589 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 330,055 | |||||
Vested (1) | (261,770) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | (37,125) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | $ / shares | $ 29.28 | $ 25.12 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | 29.35 | |||||
Vested (1) | $ / shares | 16.14 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares | $ 29.20 | |||||
Unrecognized compensation expense | $ | $ 9.9 | |||||
Weighted average period for compensation expense to be recognized | 1 year 2 months 12 days | |||||
Fair value of SSARs that are exercisable | $ | $ 2.3 | |||||
Minimum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Incremental Increase of Initial Grant Value, Percentage | 0% | |||||
Maximum | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Incremental Increase of Initial Grant Value, Percentage | 225% | |||||
2018 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 329,092 | |||||
Vested (1) | (190,544) | |||||
Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected | 3.9 | 9 | ||||
2019 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 227,812 | 261,770 | ||||
Vested (1) | (150,811) | |||||
Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected | 2.4 | 8 | ||||
2020 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Vested (1) | (120,677) | |||||
Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected | 4.7 | 8 |
Employee Benefit Plans - Additi
Employee Benefit Plans - Additional Information (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 USD ($) pension_plan | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Defined Benefit Plan Disclosure [Line Items] | |||
Defined contribution plan expense | $ 7.1 | $ 6.9 | $ 6.2 |
Document Fiscal Year Focus | 2023 | ||
Number of defined benefit pension plans | pension_plan | 4 | ||
Actuarial losses arising during period, net of tax | $ 0.4 | (0.3) | (4.3) |
Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Amortization of recognized actuarial loss | $ 0.5 | $ 0.5 | $ 0.8 |
Employee Benefit Plans - Change
Employee Benefit Plans - Change in Benefit Obligation and Funded Status (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Document Fiscal Year Focus | 2023 | |||
Accumulated Other Comprehensive Loss (Earnings) [Abstract] | ||||
Increase (Decrease) in Obligation, Pension Benefits | $ 3.4 | |||
Foreign Plan [Member] | ||||
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] | ||||
Benefit obligation at beginning of year | $ 41.8 | $ 69.5 | ||
Service cost | 0.2 | 0.3 | $ 0.3 | |
Interest cost | 2 | 1.1 | 0.9 | |
Defined Benefit Plan, Benefit Obligation, Benefits Paid | 3.1 | 1.9 | ||
Actuarial loss gain (1) | 0.4 | 23.5 | ||
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment | 0 | 0.2 | ||
Currency translation and other (2) | 2.2 | (3.9) | ||
Benefit obligation at end of year | 43.5 | 41.8 | 69.5 | |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ||||
Fair value of plan assets at beginning of year | 41.3 | 69.3 | ||
Actual return on plan assets | 1.8 | (20.1) | ||
Company contributions | 1 | 1.2 | ||
Defined Benefit Plan, Plan Assets, Benefits Paid | 3.1 | 1.9 | ||
Currency translation and other | 2.1 | (7.2) | ||
Fair value of plan assets at end of year | 43.1 | 41.3 | $ 69.3 | |
Funded status | (0.4) | (0.5) | ||
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] | ||||
Other assets and deferred charges | 3.4 | 3.4 | ||
Other liabilities | (3.8) | (3.9) | ||
Funded status | (0.4) | (0.5) | ||
Accumulated Other Comprehensive Loss (Earnings) [Abstract] | ||||
Net actuarial losses | 18.1 | 17.9 | ||
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax | 1.2 | 1.2 | ||
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), Tax | (2.9) | (2.7) | ||
Total accumulated other comprehensive loss, net of tax | 16.4 | 16.4 | ||
Accumulated benefit obligation | $ 42.7 | $ 41.1 |
Employee Benefit Plans - Accumu
Employee Benefit Plans - Accumulated Benefit Obligations in Excess of Plan Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Defined Benefit Plan Disclosure [Line Items] | ||
Document Fiscal Year Focus | 2023 | |
Foreign Plan [Member] | ||
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets [Abstract] | ||
Projected benefit obligation | $ 25.1 | $ 24.5 |
Accumulated benefit obligation | 24.9 | 24.5 |
Fair value of plan assets | 21.3 | 20.6 |
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets | $ 21.3 | $ 20.6 |
Employee Benefit Plans - Compon
Employee Benefit Plans - Components of the Net Periodic Benefit Cost (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Foreign Plan [Member] | |||
Components of Net Periodic Benefit Cost [Abstract] | |||
Service cost | $ 0.2 | $ 0.3 | $ 0.3 |
Interest cost | 2 | 1.1 | 0.9 |
Expected return on plan assets | (2.1) | (2.6) | (2.8) |
Defined Benefit Plan, Amortization of Prior Service Cost (Credit) | 0.1 | 0 | 0 |
Amortization of recognized actuarial loss | 0.5 | 0.5 | 0.8 |
Defined Benefit Plan, Other Cost (Credit) | 0 | 3.4 | 0 |
Total net periodic benefit cost (income) | $ 0.7 | $ 2.7 | $ (0.8) |
Employee Benefit Plans - Actuar
Employee Benefit Plans - Actuarial Assumptions (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Foreign Plan [Member] | |||
Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | |||
Discount rate | 4.47% | 4.71% | |
Average wage increase | 4.17% | 4.30% | |
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | |||
Discount rate | 4.71% | 1.83% | 1.27% |
Average wage increase | 4.30% | 4.59% | 4.18% |
Expected return on plan assets | 5% | 4.15% | 4.32% |
Foreign Plan [Member] | Philippines | |||
Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | |||
Discount rate | 6.20% | 7.50% | |
Average wage increase | 4% | 4% | |
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | |||
Discount rate | 7.50% | 5.25% | 4% |
Average wage increase | 4% | 4% | 4% |
Foreign Plan [Member] | Taiwan | |||
Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | |||
Discount rate | 1.50% | 1.75% | |
Average wage increase | 4% | 4% | |
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | |||
Discount rate | 1.75% | 0.75% | 0.25% |
Average wage increase | 4% | 4% | 4% |
Expected return on plan assets | 1.75% | 4% | 3.50% |
Foreign Plan [Member] | United Kingdom | |||
Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | |||
Discount rate | 4.60% | 4.84% | |
Average wage increase | 4.20% | 4.35% | |
Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | |||
Discount rate | 4.84% | 1.84% | 1.28% |
Average wage increase | 4.35% | 4.65% | 4.20% |
Expected return on plan assets | 5.17% | 4.15% | 4.34% |
Employee Benefit Plans - Fair V
Employee Benefit Plans - Fair Value of Plan Assets by Category (Details) - Foreign Plan [Member] - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase | 4.17% | 4.30% | |
Fair value of plan assets | $ 43.1 | $ 41.3 | $ 69.3 |
Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 8.6 | 8.8 | |
Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 34.5 | 32.5 | |
Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Fixed income investments | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 21.3 | 20 | |
Fixed income investments | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 3.5 | 3.3 | |
Fixed income investments | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 17.8 | 16.7 | |
Fixed income investments | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Common stock funds | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 6.3 | 6.1 | |
Common stock funds | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Common stock funds | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 6.3 | 6.1 | |
Common stock funds | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Real Estate Funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 4.1 | 4.1 | |
Real Estate Funds [Member] | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Real Estate Funds [Member] | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 4.1 | 4.1 | |
Real Estate Funds [Member] | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Cash and equivalents | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 1.7 | 1.4 | |
Cash and equivalents | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 1.7 | 1.4 | |
Cash and equivalents | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Cash and equivalents | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 0 | 0 | |
Other | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 9.7 | 9.7 | |
Other | Level 1 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 3.4 | 4.1 | |
Other | Level 2 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | 6.3 | 5.6 | |
Other | Level 3 | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets | $ 0 | $ 0 |
Employee Benefit Plans - Future
Employee Benefit Plans - Future Estimates (Details) - Foreign Plan [Member] $ in Millions | Dec. 31, 2023 USD ($) |
Expected Future Benefit Payments [Abstract] | |
2023 | $ 2.2 |
2024 | 2.4 |
2025 | 2.6 |
2026 | 2.9 |
2027 | 2.6 |
2028 - 2032 | 13.5 |
Estimated Future Employer Contributions [Abstract] | |
Estimated 2023 employer contribution | $ 1 |
Employee Benefit Plans - Supple
Employee Benefit Plans - Supplemental Retirement Plan (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax | $ (0.4) | $ 0.3 | $ 4.3 |
Foreign Plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | $ 16.4 | $ 16.4 |
Other Comprehensive (Loss) Ea_3
Other Comprehensive (Loss) Earnings - Amounts Recognized in OCI (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Foreign currency translation: | |||
Foreign currency translation, before tax | $ (6.1) | $ (23.2) | $ (3.6) |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent | 0 | 0 | 0 |
Foreign currency translation, net of tax | (6.1) | (23.2) | (3.6) |
Employee benefit plans: | |||
Employee benefit plans, before Tax | (0.1) | 1.4 | 6.6 |
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent | 0.2 | (0.6) | (1.6) |
Net change in employee benefit plans | 0.1 | 0.8 | 5 |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax | (2.3) | 1.1 | (1.6) |
Changes in fair value of cash flow hedges: | |||
Change in fair value of cash flow hedges, tax | 0.6 | (0.4) | 0.3 |
Total cash flow hedges | (1.7) | 0.7 | (1.3) |
Total: | |||
Other Comprehensive Income (Loss), before tax | (8.5) | (20.7) | 1.4 |
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Total | (0.8) | 1 | 1.3 |
Other comprehensive (loss) earnings, net of tax | $ (7.7) | $ (21.7) | $ 0.1 |
Other Comprehensive (Loss) Ea_4
Other Comprehensive (Loss) Earnings - Components of AOCI (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Components of AOCI [Abstract] | |||
Beginning balance | $ (122.1) | $ (100.4) | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (7.7) | (21.7) | $ 0.1 |
Ending balance | (129.8) | (122.1) | (100.4) |
Cash flow hedges | |||
Components of AOCI [Abstract] | |||
Beginning balance | 1 | 0.3 | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (1.7) | 0.7 | |
Ending balance | (0.7) | 1 | 0.3 |
Employee benefit plans | |||
Components of AOCI [Abstract] | |||
Beginning balance | (16.3) | (17.1) | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | 0.1 | 0.8 | |
Ending balance | (16.2) | (16.3) | (17.1) |
Cumulative foreign currency translation adjustments | |||
Components of AOCI [Abstract] | |||
Beginning balance | (106.8) | (83.6) | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (6.1) | (23.2) | |
Ending balance | $ (112.9) | $ (106.8) | $ (83.6) |
Other Comprehensive (Loss) Ea_5
Other Comprehensive (Loss) Earnings - Changes in Components of AOCI (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pension and Postretirement Benefit Plans [Abstract] | |||
Amortization or settlement of actuarial losses and prior service costs | $ 0.6 | $ 0.6 | $ 0.9 |
Tax | (0.1) | (0.1) | (0.2) |
Net of tax | 0.5 | 0.5 | 0.7 |
Cash Flow Hedges [Abstract] | |||
Net losses (gains) reclassified into earnings | 2.7 | 4.5 | (2.1) |
Other Comprehensive Income (Loss) before Reclassifications, Tax | (1) | ||
Tax | (0.5) | 0.5 | |
Net of tax | $ 2.2 | $ 3.5 | $ (1.6) |
Segment Information - Informati
Segment Information - Information on Reportable Segments (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Segment Reporting Information [Line Items] | ||||
Document Fiscal Year Focus | 2023 | |||
Reconciliation from Segment Totals to Consolidated [Abstract] | ||||
Revenues | $ 707.6 | $ 764.7 | $ 868.1 | |
Reconciliation of Net Earnings from Segments [Abstract] | ||||
Interest expense, net | 5.4 | 3.9 | 14.2 | |
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | [1] | 45 | (418.2) | 104.6 |
(Benefit from) provision for income taxes | (27.4) | 11.9 | (45.6) | |
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | 72.4 | (430.1) | 150.2 | |
Reconciliation of Depreciation and Amortization [Abstract] | ||||
Depreciation and amortization | 46.5 | 53.9 | 62.5 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | (78.5) | (81.7) | (92.8) | |
Operating segments | ||||
Reconciliation of Net Earnings from Segments [Abstract] | ||||
(Loss) earnings before interest and income taxes | [1] | 123.8 | (363.8) | 180.7 |
Reconciliation of Capital Expenditures [Abstract] | ||||
Capital expenditures | 16.9 | 32.1 | 48.6 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | (78.5) | (81.7) | (92.8) | |
Operating segments | Precision Devices | ||||
Reconciliation from Segment Totals to Consolidated [Abstract] | ||||
Revenues | 221.4 | 242.9 | 201.1 | |
Reconciliation of Net Earnings from Segments [Abstract] | ||||
(Loss) earnings before interest and income taxes | 25 | 56.1 | 43.7 | |
Reconciliation of Depreciation and Amortization [Abstract] | ||||
Depreciation and amortization | 15.8 | 13.8 | 13.3 | |
Reconciliation of Capital Expenditures [Abstract] | ||||
Capital expenditures | 7.6 | 7.4 | 5.6 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | (13.8) | (12.3) | (10.5) | |
Operating segments | Consumer MEMS Microphones | ||||
Reconciliation from Segment Totals to Consolidated [Abstract] | ||||
Revenues | 256.2 | 291.9 | 435.7 | |
Reconciliation of Net Earnings from Segments [Abstract] | ||||
(Loss) earnings before interest and income taxes | 13.6 | (504.5) | 60 | |
Reconciliation of Depreciation and Amortization [Abstract] | ||||
Depreciation and amortization | 20.3 | 29.5 | 39.9 | |
Reconciliation of Capital Expenditures [Abstract] | ||||
Capital expenditures | 4.7 | 17.2 | 29.2 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | (46.1) | (52.4) | (65.7) | |
Operating segments | MedTech & Specialty Audio | ||||
Reconciliation from Segment Totals to Consolidated [Abstract] | ||||
Revenues | 230 | 229.9 | 231.3 | |
Reconciliation of Net Earnings from Segments [Abstract] | ||||
(Loss) earnings before interest and income taxes | 85.2 | 84.6 | 77 | |
Reconciliation of Depreciation and Amortization [Abstract] | ||||
Depreciation and amortization | 8.2 | 8.1 | 6.3 | |
Reconciliation of Capital Expenditures [Abstract] | ||||
Capital expenditures | 4.6 | 7.3 | 11.6 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | (18.2) | (16.9) | (16.1) | |
Corporate, Non-Segment [Member] | ||||
Reconciliation of Net Earnings from Segments [Abstract] | ||||
Corporate Expense and Other | 73.4 | 50.5 | 61.9 | |
Reconciliation of Depreciation and Amortization [Abstract] | ||||
Depreciation and amortization | 2.2 | 2.5 | 3 | |
Reconciliation of Capital Expenditures [Abstract] | ||||
Capital expenditures | 0 | 0.2 | 2.2 | |
Reconciliation of Research and Development Expense [Abstract] | ||||
Research and development expenses | $ 0.4 | $ 0.1 | $ 0.5 | |
[1] Years Ended December 31, (in millions) 2023 2022 2021 Revenues: Precision Devices $ 221.4 $ 242.9 $ 201.1 MedTech & Specialty Audio 230.0 229.9 231.3 Consumer MEMS Microphones 256.2 291.9 435.7 Total revenues $ 707.6 $ 764.7 $ 868.1 Earnings (loss) from continuing operations before interest and income taxes: Precision Devices $ 25.0 $ 56.1 $ 43.7 MedTech & Specialty Audio 85.2 84.6 77.0 Consumer MEMS Microphones 13.6 (504.5) 60.0 Total segments 123.8 (363.8) 180.7 Corporate expense / other 73.4 50.5 61.9 Interest expense, net 5.4 3.9 14.2 Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations $ 72.4 $ (430.1) $ 150.2 Depreciation and amortization: Precision Devices $ 15.8 $ 13.8 $ 13.3 MedTech & Specialty Audio 8.2 8.1 6.3 Consumer MEMS Microphones 20.3 29.5 39.9 Corporate 2.2 2.5 3.0 Total $ 46.5 $ 53.9 $ 62.5 Capital expenditures: Precision Devices $ 7.6 $ 7.4 $ 5.6 MedTech & Specialty Audio 4.6 7.3 11.6 Consumer MEMS Microphones 4.7 17.2 29.2 Corporate — 0.2 2.2 Total $ 16.9 $ 32.1 $ 48.6 Research and development: Precision Devices $ 13.8 $ 12.3 $ 10.5 MedTech & Specialty Audio 18.2 16.9 16.1 Consumer MEMS Microphones 46.1 52.4 65.7 Corporate 0.4 0.1 0.5 Total $ 78.5 $ 81.7 $ 92.8 |
Segment Information - Reportabl
Segment Information - Reportable Segments Adjusted Working Capital and Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Segment Reporting Information [Line Items] | ||
Document Fiscal Year Focus | 2023 | |
Total assets | $ 1,462.8 | $ 1,183.9 |
Operating segments | Precision Devices | ||
Segment Reporting Information [Line Items] | ||
Total assets | 577.9 | 275.7 |
Operating segments | MedTech & Specialty Audio | ||
Segment Reporting Information [Line Items] | ||
Total assets | 351.1 | 358.1 |
Operating segments | Consumer MEMS Microphones | ||
Segment Reporting Information [Line Items] | ||
Total assets | 530 | 547.3 |
Corporate, Non-Segment [Member] | ||
Segment Reporting Information [Line Items] | ||
Total assets | $ 3.8 | $ 2.8 |
Segment Information - Revenue b
Segment Information - Revenue by Geographic Location (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Revenues | $ 707.6 | $ 764.7 | $ 868.1 |
Long-Lived Assets | 188.5 | 174.4 | |
Asia | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Revenues | 426.1 | 471.3 | 611.5 |
Long-Lived Assets | 91.9 | 110.5 | |
United States | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Revenues | 161.4 | 174.3 | 153.2 |
Long-Lived Assets | 90.1 | 60.5 | |
Europe | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Revenues | 101.5 | 104.4 | 93.5 |
Long-Lived Assets | 3.7 | 2.4 | |
Other Americas | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Revenues | 7.1 | 7.5 | 5.5 |
Long-Lived Assets | 2.8 | 1 | |
Other | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Revenues | 11.5 | 7.2 | $ 4.4 |
Long-Lived Assets | $ 0 | $ 0 |
Segment Information Segment Inf
Segment Information Segment Information - Concentration of Credit Risk (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Concentration Risk [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Customer A | |||
Concentration Risk [Line Items] | |||
Concentration Risk, Percentage | 16% | 15% | 16% |
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Customer | |||
Concentration Risk [Line Items] | |||
Concentration Risk, Percentage | 10% |
Earnings per Share (Details)
Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Reconciliation of information used in computing basic and diluted earnings per share [Abstract] | ||||
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $ 72.4 | $ (430.1) | $ 150.2 | |
Earnings (loss) from discontinued operations, net | 0 | 0 | 0.2 | |
Net earnings (loss) | $ 72.4 | $ (430.1) | $ 150.4 | |
Basic earnings (loss) per common share: | ||||
Income (Loss) from Continuing Operations, Per Basic Share | $ 0.80 | $ (4.69) | $ 1.63 | |
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share | 0 | 0 | 0 | |
Earnings Per Share, Basic | $ 0.80 | $ (4.69) | $ 1.63 | |
Basic weighted average shares outstanding (in shares) | [1] | 90,900,000 | 91,700,000 | 92,300,000 |
Diluted earnings (loss) per common share: | ||||
Income (Loss) from Continuing Operations, Per Diluted Share | $ 0.79 | $ (4.69) | $ 1.59 | |
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share | 0 | 0 | 0 | |
Earnings Per Share, Diluted | $ 0.79 | $ (4.69) | $ 1.59 | |
Dilutive weighted average shares outstanding (in shares) | [1] | 91,600,000 | 91,700,000 | 94,700,000 |
Weighted average number of anti-dilutive shares excluded from the calculation (in shares) | 1,900,000 | 3,400,000 | 700,000 | |
[1] Years Ended December 31, 2023 2022 2021 Revenues $ 707.6 $ 764.7 $ 868.1 Cost of goods sold 435.5 455.7 508.6 (Gain) loss on sale of fixed assets (10.0) 0.5 — Restructuring charges - cost of goods sold (1.3) 32.2 — Gross profit 283.4 276.3 359.5 Research and development expenses 78.5 81.7 92.8 Selling and administrative expenses 150.3 128.9 146.4 Impairment charges — 470.9 4.0 Restructuring charges 3.5 9.6 0.5 Operating expenses 232.3 691.1 243.7 Operating earnings (loss) 51.1 (414.8) 115.8 Interest expense, net 5.4 3.9 14.2 Other expense (income), net 0.7 (0.5) (3.0) Earnings (loss) before income taxes and discontinued operations 45.0 (418.2) 104.6 (Benefit from) provision for income taxes (27.4) 11.9 (45.6) Earnings (loss) from continuing operations 72.4 (430.1) 150.2 Earnings from discontinued operations, net — — 0.2 Net earnings (loss) $ 72.4 $ (430.1) $ 150.4 Earnings (loss) per share from continuing operations: Basic $ 0.80 $ (4.69) $ 1.63 Diluted $ 0.79 $ (4.69) $ 1.59 Earnings per share from discontinued operations: Basic $ — $ — $ — Diluted $ — $ — $ — Net earnings (loss) per share: Basic $ 0.80 $ (4.69) $ 1.63 Diluted $ 0.79 $ (4.69) $ 1.59 Weighted-average common shares outstanding: Basic 90.9 91.7 92.3 Diluted 91.6 91.7 94.7 |
Schedule II - Valuation and Q_2
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Document Fiscal Year Focus | 2023 | ||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Valuation allowance | $ 25.5 | $ 39.7 | $ 39.1 |
Allowance for doubtful accounts receivable | 0.2 | 1.1 | 0.2 |
Allowance for Doubtful Accounts | |||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) | 0 | ||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at Beginning of Year | 1.1 | 0.2 | 1.6 |
Charged to Cost and Expense | 1 | 0.2 | |
Accounts Written off / Reductions | (0.9) | (0.1) | (1.2) |
Balance at End of Year | 1.1 | 0.2 | |
Deferred Tax Valuation Allowance | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at Beginning of Year | 39.7 | 39.1 | 98 |
Additions | 0.9 | 0.6 | 0 |
Accounts Written off / Reductions | $ (15.1) | 0 | (58.9) |
Balance at End of Year | $ 39.7 | $ 39.1 |
Uncategorized Items - kn-202312
Label | Element | Value |
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | $ 147,800,000 |